                         SEQUENCE LISTING

<110>  IMMUNOMIC THERAPEUTICS, INC.
 
<120>  ANTI-HVEM ANTIBODIES

<130>  01305-0019-00PCT

<150>  US 63/131,829
<151>  2020-12-30

<160>  1449  

<170>  PatentIn version 3.5

<210>  1
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S14-12AH as 
       described in Table 3.

<400>  1

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Asn Ile Phe Thr Asn Ser 
            20                  25                  30          


Trp Leu Gly Trp Ile Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Val Tyr Pro Gly Gly Gly Tyr Asn Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ile Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Arg Leu Thr Ser Glu Asp Ser Gly Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  2
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S14-13AH as 
       described in Table 3.

<400>  2

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Asn Ser 
            20                  25                  30          


Trp Leu Gly Trp Ile Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Val Tyr Pro Gly Gly Gly Tyr Asn Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ile Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Arg Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  3
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S14-14AH as 
       described in Table 3.

<400>  3

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Asn Tyr 
            20                  25                  30          


Trp Leu Gly Trp Ile Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Val Tyr Pro Gly Gly Gly Tyr Asn Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Arg Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  4
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S14-19AH as 
       described in Table 3.

<400>  4

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Ser 
            20                  25                  30          


Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Asn Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Met Asp Ser Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  5
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-31AH as 
       described in Table 3.

<400>  5

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Ser 
            20                  25                  30          


Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Asn Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Leu Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  6
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-35AH as 
       described in Table 3.

<400>  6

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Ser 
            20                  25                  30          


Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Asn Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Gly Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  7
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-23AH as 
       described in Table 3.

<400>  7

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Leu Ile Asn Ser 
            20                  25                  30          


Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Asn Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Ile Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  8
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-24AH as 
       described in Table 3.

<400>  8

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Ile Ile Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Val Asp Ser Ser Ala Thr Thr Ala Tyr 
65                  70                  75                  80  


Ile Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Met Asp His Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  9
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-28AH as 
       described in Table 3.

<400>  9

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Val Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Gln Ile Ser Cys Lys Ala Ser Gly Phe Thr Leu Thr Asn Tyr 
            20                  25                  30          


Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Thr Asn Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Gly Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Met Asp Lys Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  10
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-28BH as 
       described in Table 3.

<400>  10

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Val Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Phe Thr Leu Thr Asn Tyr 
            20                  25                  30          


Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Thr Asn Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Gly Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Met Asp Lys Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  11
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-30AH as 
       described in Table 3.

<400>  11

Gln Val Gln Leu Gln Gln Ser Gly Thr Glu Val Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Phe Thr Leu Thr Asn Tyr 
            20                  25                  30          


Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Ala Asn Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Gly Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Met Asp Lys Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  12
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-32AH as 
       described in Table 3.

<400>  12

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Trp Leu Gly Trp Val Lys Gln Trp Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Asn Ile Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  13
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-32BH as 
       described in Table 3.

<400>  13

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Asn Ile Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  14
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-32CH as 
       described in Table 3.

<400>  14

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Asn Ile Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ile Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  15
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-33AH as 
       described in Table 3.

<400>  15

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Arg Ile Ser Cys Lys Ala Ser Gly Tyr Thr Leu Thr Asn Ser 
            20                  25                  30          


Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Thr Lys Tyr Asn Glu Asn Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Arg Leu Thr Ser Glu Asp Ser Gly Val Tyr Phe Cys 
                85                  90                  95      


Val Gly Ala Val Ala Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  16
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-35AH as 
       described in Table 3.

<400>  16

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Asn Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  17
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-36AH as 
       described in Table 3.

<400>  17

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Ser 
            20                  25                  30          


Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Ile Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  18
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-38AH as 
       described in Table 3.

<400>  18

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Arg Ile Ser Cys Lys Ala Ser Gly Tyr Thr Leu Thr Asn Ser 
            20                  25                  30          


Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Thr Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Val Ala Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  19
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-3BH as described
       in Table 3.

<400>  19

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Ser 
            20                  25                  30          


Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Asn Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Arg Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  20
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-3CH as described
       in Table 3.

<400>  20

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Ser 
            20                  25                  30          


Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Asn Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  21
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-41AH as 
       described in Table 3.

<400>  21

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Arg Phe Thr Asn Tyr 
            20                  25                  30          


Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Asn Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  22
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-41BH as 
       described in Table 3.

<400>  22

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Arg Phe Thr Asn Tyr 
            20                  25                  30          


Trp Leu Gly Trp Ile Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Asn Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Ile Val Ser 
            100                 105                 110         


Ser 
    


<210>  23
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-43AH as 
       described in Table 3.

<400>  23

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Met Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Ile Ile Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Val Asp Ser Ser Ala Thr Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  24
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-48AH as 
       described in Table 3.

<400>  24

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Arg Ile Ser Cys Lys Ala Ser Gly Tyr Thr Leu Thr Asn Ser 
            20                  25                  30          


Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Asn Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Val Ala Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  25
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-50AH as 
       described in Table 3.

<400>  25

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Arg Phe Thr Asn Ser 
            20                  25                  30          


Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Asn Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Leu Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  26
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-54AH as 
       described in Table 3.

<400>  26

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Val Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Phe Thr Leu Thr Asn Tyr 
            20                  25                  30          


Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Thr Asn Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Gly Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Met Asp Asn Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  27
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-57AH as 
       described in Table 3.

<400>  27

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Ser 
            20                  25                  30          


Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Asn Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ile Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  28
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-60AH as 
       described in Table 3.

<400>  28

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Arg Ile Ser Cys Lys Ala Ser Gly Tyr Thr Leu Thr Asn Ser 
            20                  25                  30          


Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Thr Lys Tyr Asn Glu Asn Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Ser Ala Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Gly Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Met Ala Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  29
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-62AH as 
       described in Table 3.

<400>  29

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asn Tyr 
            20                  25                  30          


Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Asn Met Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  30
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-7AH as described
       in Table 3.

<400>  30

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Arg Phe Thr Asn Ser 
            20                  25                  30          


Trp Leu Gly Trp Ile Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Asn Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Arg Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Met Asp Ser Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  31
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-7BH as described
       in Table 3.

<400>  31

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ile Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Arg Phe Thr Asn Ser 
            20                  25                  30          


Trp Leu Gly Trp Ile Lys Leu Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Asn Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Arg Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Met Asp Ser Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  32
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_047H as described 
       in Table 3.

<400>  32

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Ser 
            20                  25                  30          


Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Asn Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Gly Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ala Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  33
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_053H as described 
       in Table 3.

<400>  33

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Ser 
            20                  25                  30          


Trp Leu Gly Trp Val Arg Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Asn Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Leu Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  34
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S14-11AH as 
       described in Table 3.

<400>  34

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 
            20                  25                  30          


Ala Met Ser Trp Ile Arg Gln Thr Pro Glu Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Ser Ile Thr Thr Gly Gly Ser Ser Tyr Ser Pro Asp Ser Leu Lys 
    50                  55                  60                  


Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Arg Asn Ile Val Tyr Leu 
65                  70                  75                  80  


Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Ala Cys Ala 
                85                  90                  95      


Arg Gly Gly Gly Gly Asn Tyr Phe Trp Phe Ala Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ala 
        115                 


<210>  35
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S14-8AH as described
       in Table 3.

<400>  35

Glu Val Lys Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Ser Ile Ser Thr Gly Gly Thr Thr Ser Tyr Tyr Ser Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Ile Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Gly Gly Gly Asn Tyr Phe Trp Phe Thr Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Ile Ser Ala 
        115                 120 


<210>  36
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-10AH as 
       described in Table 3.

<400>  36

Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Arg Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 
            20                  25                  30          


Gly Met His Trp Ile Arg Gln Ala Pro Glu Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Ser Ile Ser Ser Gly Ser Ser Thr Ile Tyr Phe Ala Asp Thr Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Pro Lys Asn Thr Leu Phe 
65                  70                  75                  80  


Leu Gln Met Thr Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Ala Tyr Gly Asn Phe Ala Trp Phe Pro Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  37
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-16AH as 
       described in Table 3.

<400>  37

Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Arg Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Glu Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala His Ile Ser Ser Gly Ser Ser Thr Ile Tyr Tyr Ala Asp Thr Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Pro Lys Asn Thr Leu Phe 
65                  70                  75                  80  


Leu Gln Met Thr Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Ala Tyr Gly Asn Phe Ala Trp Phe Pro Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  38
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-16BH as 
       described in Table 3.

<400>  38

Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Arg Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Glu Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala His Ile Ser Ser Gly Ser Ser Thr Ile Tyr Tyr Ala Asp Thr Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Pro Lys Asn Thr Leu Phe 
65                  70                  75                  80  


Leu Gln Met Thr Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Ala Tyr Gly Asn Phe Ala Trp Phe Pro Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Thr 
        115                 120 


<210>  39
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-20AH as 
       described in Table 3.

<400>  39

Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Arg Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Glu Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Ser Ile Ser Ser Gly Ser Ser Thr Ile Tyr Tyr Ala Asp Thr Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Pro Lys Asn Thr Leu Phe 
65                  70                  75                  80  


Leu Gln Met Thr Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Ala Tyr Gly Asn Phe Ala Trp Phe Ala Phe Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  40
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-9AH as described
       in Table 3.

<400>  40

Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Arg Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Phe 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Glu Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala His Ile Ser Ser Gly Ser Ser Thr Ile Tyr Tyr Ala Asp Thr Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Pro Lys Asn Thr Leu Phe 
65                  70                  75                  80  


Leu Gln Met Thr Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Ala Tyr Gly Asn Phe Ala Trp Phe Pro Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  41
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-11AH as 
       described in Table 3.

<400>  41

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Thr Pro Glu Thr Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Ser Ile Ser Ser Gly Gly Asn Thr Phe Tyr Pro Asp Ser Val Lys 
    50                  55                  60                  


Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Arg Asp Ile Leu Tyr Leu 
65                  70                  75                  80  


Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Phe Cys Thr 
                85                  90                  95      


Arg Gly Gly Tyr Gly Ser Ser Tyr Val Ile Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  42
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-11BH as 
       described in Table 3.

<400>  42

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Thr Pro Glu Thr Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Ser Ile Ser Ser Gly Gly Asn Thr Phe Tyr Pro Asp Ser Val Lys 
    50                  55                  60                  


Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Arg Asp Ile Leu Tyr Leu 
65                  70                  75                  80  


Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Phe Cys Thr 
                85                  90                  95      


Arg Gly Gly Tyr Gly Ser Ser Tyr Val Ile Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  43
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-11CH as 
       described in Table 3.

<400>  43

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Thr Pro Glu Thr Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Ser Ile Ser Ser Gly Gly Asn Thr Phe Tyr Pro Asp Ser Val Lys 
    50                  55                  60                  


Gly Arg Phe Thr Ile Ser Arg Asp Asp Val Arg Asp Ile Leu Tyr Leu 
65                  70                  75                  80  


Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Phe Cys Thr 
                85                  90                  95      


Arg Gly Gly Tyr Gly Ser Ser Tyr Val Ile Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  44
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-14AH as 
       described in Table 3.

<400>  44

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Thr Pro Glu Thr Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Ser Ile Ser Ser Gly Gly Asn Thr Tyr Tyr Pro Asp Ser Val Lys 
    50                  55                  60                  


Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Arg Asn Ile Leu Tyr Leu 
65                  70                  75                  80  


Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Phe Cys Thr 
                85                  90                  95      


Arg Gly Gly Tyr Gly Ser Ser Tyr Val Ile Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  45
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-14BH as 
       described in Table 3.

<400>  45

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Thr Pro Glu Thr Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Ser Ile Ser Ser Gly Gly Asn Thr Tyr Tyr Pro Asp Ser Val Lys 
    50                  55                  60                  


Gly Arg Phe Thr Ile Ser Arg Asp Asp Val Arg Asn Ile Leu Tyr Leu 
65                  70                  75                  80  


Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Phe Cys Thr 
                85                  90                  95      


Arg Gly Gly Tyr Gly Ser Ser Tyr Val Ile Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  46
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-14CH as 
       described in Table 3.

<400>  46

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Thr Pro Glu Thr Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Ser Ile Ser Ser Gly Gly Asn Thr Tyr Tyr Pro Asp Ser Val Lys 
    50                  55                  60                  


Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Arg Asp Ile Leu Tyr Leu 
65                  70                  75                  80  


Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Phe Cys Thr 
                85                  90                  95      


Arg Gly Gly Tyr Gly Ser Ser Tyr Val Ile Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  47
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-14DH as 
       described in Table 3.

<400>  47

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Met Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Thr Pro Glu Thr Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Ser Ile Ser Ser Gly Gly Asn Thr Tyr Tyr Pro Asp Ser Val Lys 
    50                  55                  60                  


Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Arg Asn Ile Leu Tyr Leu 
65                  70                  75                  80  


Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Phe Cys Thr 
                85                  90                  95      


Arg Gly Gly Tyr Gly Ser Ser Tyr Val Ile Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  48
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-1AH as described
       in Table 3.

<400>  48

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Thr Pro Glu Thr Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Ser Ile Ser Ser Gly Gly Asp Thr Phe Tyr Arg Asp Ser Val Lys 
    50                  55                  60                  


Ala Arg Phe Thr Ile Ser Arg Asp Asp Val Arg Asp Ile Leu Tyr Leu 
65                  70                  75                  80  


Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Phe Cys Thr 
                85                  90                  95      


Arg Gly Gly Tyr Gly Ser Ser Phe Val Ile Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  49
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-29AH as 
       described in Table 3.

<400>  49

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Thr Pro Glu Thr Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Ser Ile Ser Ser Gly Gly Asn Thr Phe Tyr Pro Asp Ser Val Lys 
    50                  55                  60                  


Gly Arg Phe Thr Ile Ser Arg Asp Asp Val Arg Asp Ile Leu Tyr Leu 
65                  70                  75                  80  


Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Phe Cys Thr 
                85                  90                  95      


Arg Gly Gly Tyr Gly Ser Ser Phe Val Ile Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  50
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-37AH as 
       described in Table 3.

<400>  50

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Thr Pro Glu Thr Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Ser Ile Ser Ser Gly Gly Lys Thr Phe Tyr Pro Asp Ser Val Lys 
    50                  55                  60                  


Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Arg Asp Ile Leu Tyr Leu 
65                  70                  75                  80  


Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Phe Cys Thr 
                85                  90                  95      


Arg Gly Gly Tyr Gly Ser Ser Tyr Val Ile Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  51
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-39AH as 
       described in Table 3.

<400>  51

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Thr Pro Glu Thr Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Ser Ile Ser Ser Gly Gly Asn Thr Tyr Tyr Pro Asp Ser Val Lys 
    50                  55                  60                  


Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Arg Asn Ile Leu Tyr Leu 
65                  70                  75                  80  


Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Phe Cys Thr 
                85                  90                  95      


Arg Gly Gly Tyr Gly Ser Ser His Val Ile Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  52
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-40AH as 
       described in Table 3.

<400>  52

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Thr Pro Glu Thr Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Ser Ile Ser Ser Gly Gly Asn Thr Tyr Tyr Pro Asp Ser Val Lys 
    50                  55                  60                  


Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Arg Asn Ile Leu Tyr Leu 
65                  70                  75                  80  


Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Phe Cys Thr 
                85                  90                  95      


Arg Gly Gly Tyr Gly Ser Ser Tyr Val Ile Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  53
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-4AH as described
       in Table 3.

<400>  53

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Met Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Thr Pro Glu Thr Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Ser Ile Ser Ser Gly Gly Ser Thr Tyr Tyr Pro Asp Ser Val Lys 
    50                  55                  60                  


Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Arg Asn Ile Leu Tyr Leu 
65                  70                  75                  80  


Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Phe Cys Thr 
                85                  90                  95      


Arg Gly Gly Tyr Gly Ser Ser Tyr Val Ile Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  54
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-4BH as described
       in Table 3.

<400>  54

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Thr Pro Glu Thr Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Ser Ile Ser Ser Gly Gly Ser Thr Tyr Tyr Pro Asp Ser Val Lys 
    50                  55                  60                  


Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Arg Asn Ile Leu Tyr Leu 
65                  70                  75                  80  


Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Phe Cys Thr 
                85                  90                  95      


Arg Gly Gly Tyr Gly Ser Ser Tyr Val Ile Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  55
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-61AH as 
       described in Table 3.

<400>  55

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Thr Pro Glu Thr Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Ser Ile Ser Ser Gly Gly Ser Thr Tyr Tyr Pro Asp Ser Val Lys 
    50                  55                  60                  


Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Arg Asn Ile Leu Tyr Leu 
65                  70                  75                  80  


Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Phe Cys Thr 
                85                  90                  95      


Arg Gly Gly Tyr Gly Ser Ser His Val Ile Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  56
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-6AH as described
       in Table 3.

<400>  56

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Ser Ile Ser Ser Gly Gly Asn Thr Tyr Tyr Pro Asp Asn Val Lys 
    50                  55                  60                  


Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Gly Asn Ile Leu Tyr Leu 
65                  70                  75                  80  


Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Gly Gly Tyr Gly Ser Ser Tyr Val Ile Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  57
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S19-12BH as 
       described in Table 3.

<400>  57

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Arg 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ala Gly Gly Ile Thr Asn Tyr Asn Ser Ala Leu Met 
    50                  55                  60                  


Ser Arg Leu Thr Ile Ser Asn Asp Asn Ser Arg Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asp Trp Glu Arg Asp Ser Ser Gly Pro Phe Pro Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  58
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S19-12CH as 
       described in Table 3.

<400>  58

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Arg 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ala Gly Gly Ile Thr Asn Tyr Asn Ser Ala Leu Met 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Asn Asp Asn Ser Arg Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asp Trp Glu Arg Asp Ser Ser Gly Pro Phe Pro Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  59
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S19-14AH as 
       described in Table 3.

<400>  59

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ala Gly Gly Ile Thr Asn Tyr Asn Ser Ala Leu Met 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Asn Asp Asn Ser Arg Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asp Trp Glu Arg Asp Ser Ser Gly Pro Phe Ala Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  60
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S19-14BH as 
       described in Table 3.

<400>  60

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ala Gly Gly Ile Thr Asn Tyr Asn Ser Ala Leu Met 
    50                  55                  60                  


Ser Arg Leu Ser Ile Asn Asn Asp Asn Ser Arg Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asp Trp Glu Arg Asp Ser Ser Gly Pro Phe Ala Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  61
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S19-17AH as 
       described in Table 3.

<400>  61

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ala Gly Gly Ile Thr Asn Tyr Asn Ser Ala Leu Met 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Thr Gly Asp Thr Ala Met Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asp Trp Glu Arg Asp Ser Ser Gly Pro Phe Ala Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  62
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S19-18AH as 
       described in Table 3.

<400>  62

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ile Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ala Gly Gly Ile Ile Asn Tyr Asn Ser Ala Leu Met 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Ser Asp Asp Thr Ala Met Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asp Trp Glu Arg Asp Ser Ser Gly Pro Phe Ala Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  63
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S19-20AH as 
       described in Table 3.

<400>  63

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ala Gly Gly Ile Thr Asn Tyr Asn Ser Ala Leu Met 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asp Trp Glu Arg Asp Ser Ser Gly Pro Phe Val Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  64
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S19-20BH as 
       described in Table 3.

<400>  64

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Pro Ala Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ala Gly Gly Ile Thr Asn Tyr Asn Ser Ala Leu Met 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ile Gln Asp Asn Ser Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asp Trp Glu Arg Asp Ser Ser Gly Pro Phe Val Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  65
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S19-20CH as 
       described in Table 3.

<400>  65

Gln Val Gln Leu Lys Glu Ser Gly Pro Val Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ala Gly Gly Ile Thr Asn Tyr Asn Ser Ala Leu Met 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asp Trp Glu Arg Asp Ser Ser Gly Pro Phe Val Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  66
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S19-21AH as 
       described in Table 3.

<400>  66

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ala Gly Gly Ile Thr Asn Tyr Asn Ser Ala Leu Met 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Thr Asp Asn Ser Arg Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asp Trp Glu Arg Asp Ser Ser Gly Pro Phe Pro Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  67
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S19-22AH as 
       described in Table 3.

<400>  67

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr 
            20                  25                  30          


Gly Val His Trp Leu Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ala Gly Gly Ile Thr Asn Tyr Asn Ser Ala Leu Met 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Asn Asp Asn Ser Arg Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asp Trp Glu Arg Asp Ser Ser Gly Pro Phe Ala Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  68
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S19-26AH as 
       described in Table 3.

<400>  68

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Gly Val Tyr Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ala Gly Gly Ile Thr Asn Tyr Asn Ser Ala Leu Met 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Thr Gly Asp Thr Ala Met Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asp Trp Glu Arg Asp Ser Ser Gly Pro Phe Ala Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  69
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S19-27AH as 
       described in Table 3.

<400>  69

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ala Gly Gly Ile Thr Ser Tyr Asn Ser Ala Leu Met 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Ser Asp Asn Ser Arg Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asp Trp Glu Arg Asp Ser Ser Gly Pro Phe Pro Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  70
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_144H as described 
       in Table 3.

<400>  70

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Asn Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ala Gly Gly Ile Thr Asn Tyr Asn Ser Ala Leu Met 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Lys Asp Asn Phe Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asp Trp Glu Arg Asp Ser Ser Gly Pro Phe Pro Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  71
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_145H as described 
       in Table 3.

<400>  71

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Asn Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Thr Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ala Gly Gly Ile Thr Asn Tyr Asn Ser Ala Leu Met 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Lys Asp Asn Phe Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asp Trp Glu Arg Asp Ser Ser Gly Pro Phe Pro Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  72
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_146H as described 
       in Table 3.

<400>  72

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ala Gly Gly Ile Thr Asn Tyr Asn Ser Ala Leu Met 
    50                  55                  60                  


Ser Arg Leu Asn Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Ser Asp Asp Thr Ala Met Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asp Trp Glu Arg Asp Ser Ser Gly Pro Phe Ala Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  73
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_162H as described 
       in Table 3.

<400>  73

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ala Gly Gly Ile Thr Asn Tyr Asn Ser Ala Leu Met 
    50                  55                  60                  


Ser Arg Leu Ser Ile Asn Ile Asp Asn Ser Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asp Trp Glu Arg Asp Ser Ser Gly Pro Phe Pro Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  74
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_164H as described 
       in Table 3.

<400>  74

Gly Ala Ala Glu Gly Val Arg Arg Pro Gly Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ala Gly Gly Ile Thr Asn Tyr Asn Ser Ala Leu Met 
    50                  55                  60                  


Ser Arg Leu Asn Ile Asn Lys Asp Asn Ser Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Thr Gly Asp Thr Ala Met Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asp Trp Glu Arg Asp Ser Ser Gly Pro Phe Ala Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  75
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_165H as described 
       in Table 3.

<400>  75

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ala Gly Gly Ile Thr Asn Tyr Asn Ser Ala Leu Met 
    50                  55                  60                  


Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asp Trp Glu Arg Asp Ser Ser Gly Pro Phe Ala Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  76
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_168H as described 
       in Table 3.

<400>  76

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ala Gly Gly Ile Thr Asn Tyr Asn Ser Ala Leu Met 
    50                  55                  60                  


Ser Arg Leu Asn Ile Asn Lys Asp Asn Ser Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Thr Gly Asp Thr Ala Met Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asp Trp Glu Arg Asp Ser Ser Gly Pro Phe Ala Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  77
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S14-15AH as 
       described in Table 3.

<400>  77

Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ser Gly Gly Ser Thr Asp Tyr Asn Ala Ala Phe Ile 
    50                  55                  60                  


Cys Arg Leu Ser Ile Ser Lys Asp Ser Ser Lys Ser Gln Val Phe Phe 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Ala Asp Asp Thr Ala Met Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asn Leu Gly Gly Ser Trp Val Asp Tyr Trp Gly Gln Gly Thr Ser 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  78
<211>  116
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S14-17AH as 
       described in Table 3.

<400>  78

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ala Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Trp Ile Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Thr Asn Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Ile Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu 
            100                 105                 110         


Thr Val Ser Ser 
        115     


<210>  79
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S14-25AH as 
       described in Table 3.

<400>  79

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Phe Gly Tyr Thr Phe Thr Thr Tyr 
            20                  25                  30          


Pro Ile Glu Trp Met Lys Gln Asn His Gly Lys Ser Leu Glu Trp Ile 
        35                  40                  45              


Gly Asn Phe His Pro Tyr Asn Asp Asp Thr Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Lys Leu Thr Val Glu Lys Ser Ser Ser Thr Val Tyr 
65                  70                  75                  80  


Leu Glu Leu Ser Arg Leu Thr Ser Asp Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Leu Tyr Gly Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Ser Val Thr Val Ser Ser 
        115             


<210>  80
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S14-6AH as described
       in Table 3.

<400>  80

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Thr Asp Tyr 
            20                  25                  30          


Tyr Met Ser Trp Val Arg Gln Thr Pro Gly Lys Ala Leu Glu Trp Leu 
        35                  40                  45              


Gly Phe Ile Arg Asn Gln Ala Asn Ala Tyr Thr Thr Glu Tyr Ser Val 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Gln Ser Ile 
65                  70                  75                  80  


Leu Tyr Leu Gln Met Asn Thr Leu Arg Val Glu Asp Ser Ala Thr Tyr 
                85                  90                  95      


Tyr Cys Ala Arg Val Pro Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr 
            100                 105                 110         


Val Ser Ser 
        115 


<210>  81
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-12AH as 
       described in Table 3.

<400>  81

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr 
            20                  25                  30          


Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Phe Asp Pro Lys Phe 
    50                  55                  60                  


Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Ser Arg Gly Gly Ser Ser Phe Asp Tyr Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  82
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-30AH as 
       described in Table 3.

<400>  82

Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Pro Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Trp Met Asn Trp Val Lys Gln Arg Pro Gly Arg Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Asp Pro Ser Asp Ser Glu Thr His Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Ile Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Glu Tyr Tyr Gly Asn His Phe Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Thr Leu Thr Val Ser Ser 
        115             


<210>  83
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-38AH as 
       described in Table 3.

<400>  83

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Val Met His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Met Tyr Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  84
<211>  116
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S19-11AH as 
       described in Table 3.

<400>  84

Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Asn Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Asp 
            20                  25                  30          


Tyr Ala Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp 
        35                  40                  45              


Met Gly Tyr Ile Ser Tyr Ser Gly Asn Thr Gly Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe 
65                  70                  75                  80  


Leu Gln Leu Asn Ser Val Thr Ser Glu Asp Thr Ala Thr Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Trp Gly Leu Arg Ile Asp Tyr Trp Gly Gln Gly Thr Thr Leu 
            100                 105                 110         


Thr Val Ser Ser 
        115     


<210>  85
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S19-25AH as 
       described in Table 3.

<400>  85

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Thr Gly Tyr Thr Phe Ser Ser Tyr 
            20                  25                  30          


Trp Ile Glu Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Glu Ile Leu Pro Gly Ser Gly Ser Thr Asn Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Phe Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Tyr Pro Arg Trp Gly Lys Ile Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Thr Leu Thr Val Ser Ser 
        115             


<210>  86
<211>  116
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S19-6AH as described
       in Table 3.

<400>  86

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ile Tyr 
            20                  25                  30          


Thr Met Ser Trp Val Arg Gln Ser Pro Glu Met Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Glu Ile Ser Ser Gly Gly Ser His Thr Tyr Tyr Pro Asp Thr Val 
    50                  55                  60                  


Thr Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Glu Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Ile Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Gly Ser Leu Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu 
            100                 105                 110         


Thr Val Ser Ser 
        115     


<210>  87
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-15AH as 
       described in Table 3.

<400>  87

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr 
            20                  25                  30          


Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Asp Pro Lys Phe 
    50                  55                  60                  


Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Ser Gly Gly Ser Ser Tyr Asp Tyr Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  88
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-25AH as 
       described in Table 3.

<400>  88

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr 
            20                  25                  30          


Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Asp Pro Lys Phe 
    50                  55                  60                  


Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Ser Gly Gly Ser Ser Tyr Asp Tyr Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  89
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-34AH as 
       described in Table 3.

<400>  89

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr 
            20                  25                  30          


Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Asp Pro Lys Phe 
    50                  55                  60                  


Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Ser Ser Gly Gly Ser Ser Phe Asp Tyr Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  90
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-42AH as 
       described in Table 3.

<400>  90

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr 
            20                  25                  30          


Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Asp Pro Lys Phe 
    50                  55                  60                  


Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Gly Ser Gly Gly Ser Ser Tyr Asp Tyr Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  91
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-8AH as described
       in Table 3.

<400>  91

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr 
            20                  25                  30          


Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Asp Pro Lys Phe 
    50                  55                  60                  


Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Ile Ser Gly Gly Ser Ser Tyr Asp Tyr Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  92
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_021H as described 
       in Table 3.

<400>  92

Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Asp 
            20                  25                  30          


Tyr Ala Trp Asn Trp Val Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp 
        35                  40                  45              


Val Gly Tyr Ile Ser Tyr Ser Gly Ser Thr Ser Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe 
65                  70                  75                  80  


Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Cys Tyr Tyr Gly Gly Arg Trp Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Thr Leu Thr Val Ser Ser 
        115             


<210>  93
<211>  116
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_173H as described 
       in Table 3.

<400>  93

Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Asn Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Asp 
            20                  25                  30          


Tyr Ala Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp 
        35                  40                  45              


Met Gly Tyr Ile Asn Tyr Ser Gly Asn Thr Gly Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe 
65                  70                  75                  80  


Leu Gln Leu Asn Ser Val Thr Ser Glu Asp Thr Ala Thr Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Trp Gly Leu Arg Ile Asp Tyr Trp Gly Gln Gly Thr Thr Leu 
            100                 105                 110         


Thr Val Ser Ser 
        115     


<210>  94
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_200H as described 
       in Table 3.

<400>  94

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr 
            20                  25                  30          


Tyr Ile His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Asp Pro Ala Asn Gly Asn Ile Lys Tyr Asp Pro Lys Phe 
    50                  55                  60                  


Gln Gly Lys Ala Thr Ile Met Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Gln Gly Gly Gly Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  95
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-11AH as 
       described in Table 3.

<400>  95

Glu Val Gln Leu Gln Gln Ser Gly Ala Asp Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr 
            20                  25                  30          


Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Ala Pro Ala Asn Gly Arg Thr Lys Tyr Asp Pro Lys Phe 
    50                  55                  60                  


Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Asn Tyr Tyr Ala Ser Ser Tyr Asp Trp Phe Ala Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  96
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-17AH as 
       described in Table 3.

<400>  96

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr 
            20                  25                  30          


Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Ala Pro Ala Asn Gly Lys Thr Lys Phe Asp Pro Lys Phe 
    50                  55                  60                  


Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Asn Tyr Tyr Gly Arg Ser Asn Asp Trp Phe Val Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  97
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-1AH as described
       in Table 3.

<400>  97

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr 
            20                  25                  30          


Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Ala Trp Ile 
        35                  40                  45              


Gly Arg Ile Ala Pro Ala Asn Gly Tyr Thr Lys Tyr Asp Pro Lys Phe 
    50                  55                  60                  


Gln Gly Lys Ala Thr Ile Thr Thr Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu His Leu Ser Arg Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Asn Tyr Phe Gly Asn Thr Tyr Asp Trp Phe Ala Phe Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  98
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-24AH as 
       described in Table 3.

<400>  98

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr 
            20                  25                  30          


Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Ala Pro Ala Asn Gly Arg Thr Lys Tyr Asp Pro Lys Phe 
    50                  55                  60                  


Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Asn Tyr Tyr Ala Ser Ser Tyr Asp Trp Phe Val Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  99
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-36AH as 
       described in Table 3.

<400>  99

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr 
            20                  25                  30          


Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Asp Pro Lys Phe 
    50                  55                  60                  


Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Pro Tyr Gly Asn Tyr Gly Phe Ala Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ala 
        115             


<210>  100
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-37AH as 
       described in Table 3.

<400>  100

Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Pro Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Thr Tyr 
            20                  25                  30          


Trp Met Asn Trp Val Lys Gln Arg Pro Gly Arg Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Asp Pro Ser Asp Ser Glu Thr His Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Ile Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Ile Tyr Tyr Ser Asn Pro Val Phe Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Thr Leu Thr Val Ser Ser 
        115             


<210>  101
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-3AH as described
       in Table 3.

<400>  101

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr 
            20                  25                  30          


Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Ala Trp Ile 
        35                  40                  45              


Gly Arg Ile Ala Pro Ala Asn Gly Tyr Thr Lys Tyr Asp Pro Lys Phe 
    50                  55                  60                  


Gln Gly Lys Ala Thr Ile Thr Thr Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Val Thr Tyr Phe Gly Asn Thr Tyr Asp Trp Phe Ala Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  102
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-10AH as 
       described in Table 3.

<400>  102

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr 
            20                  25                  30          


Tyr Met His Trp Val Asn Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Ala Pro Lys Phe 
    50                  55                  60                  


Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Val Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Gly Tyr Gly Asn Ser Pro Trp Phe Ala Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ala 
        115             


<210>  103
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-10BH as 
       described in Table 3.

<400>  103

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr 
            20                  25                  30          


Tyr Met His Trp Val Asn Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Ala Pro Lys Phe 
    50                  55                  60                  


Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Gly Tyr Gly Asn Ser Pro Trp Phe Ala Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ala 
        115             


<210>  104
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-17AH as 
       described in Table 3.

<400>  104

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr 
            20                  25                  30          


Tyr Met His Trp Val Asn Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Asp Pro Ala Asn Gly Lys Thr Lys Tyr Ala Pro Lys Phe 
    50                  55                  60                  


Gln Asp Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Gly Tyr Gly Asn Ser Pro Trp Phe Ala Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ala 
        115             


<210>  105
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-49AH as 
       described in Table 3.

<400>  105

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr 
            20                  25                  30          


Tyr Val His Trp Val Lys Glu Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Asp Pro Ala Asn Asp Asn Thr Lys Tyr Ala Pro Lys Phe 
    50                  55                  60                  


Gln Val Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Asn Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Pro Tyr Gly Asn Tyr Pro Ala Trp Phe Ala Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ala 
        115                 


<210>  106
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-52AH as 
       described in Table 3.

<400>  106

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr 
            20                  25                  30          


Tyr Ile His Trp Leu Asn Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Asp Pro Ala Asn Gly Lys Thr Lys Phe Ala Pro Lys Phe 
    50                  55                  60                  


Gln Asp Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Gly Tyr Gly Asn Ser Pro Trp Phe Ala Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ala 
        115             


<210>  107
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-58AH as 
       described in Table 3.

<400>  107

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Met Leu Ser Cys Thr Ala Ser Gly Phe Tyr Ile Lys Asp Thr 
            20                  25                  30          


Tyr Met His Trp Val Asn Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Asp Pro Ala Asn Gly Lys Thr Lys Tyr Ala Pro Lys Phe 
    50                  55                  60                  


Gln Asp Lys Ala Thr Ile Thr Ala Asp Ser Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Gly Tyr Gly Asn Ser Pro Trp Phe Ala Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ala 
        115             


<210>  108
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-9AH as described
       in Table 3.

<400>  108

Glu Val Gln Leu Gln Gln Ser Gly Ala Asp Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Arg Asp Thr 
            20                  25                  30          


Tyr Met His Trp Val Asn Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Ala Pro Lys Phe 
    50                  55                  60                  


Gln Gly Arg Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu His Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Gly Tyr Gly Asn Ser Pro Trp Phe Ala Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ala 
        115             


<210>  109
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_091H as described 
       in Table 3.

<400>  109

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Leu Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Arg Leu Ser Cys Thr Ala Ser Gly Phe Asn Phe Lys Asp Thr 
            20                  25                  30          


Tyr Met His Trp Val Asn Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Asp Pro Ala Asn Gly Lys Thr Lys Tyr Ala Pro Lys Phe 
    50                  55                  60                  


Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Ala Ala Val Phe Tyr Cys 
                85                  90                  95      


Ala Ala Tyr Gly Asn Ser Pro Trp Phe Ala Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ala 
        115             


<210>  110
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_122H as described 
       in Table 3.

<400>  110

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr 
            20                  25                  30          


Leu Ile Glu Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Val Ile Asn Pro Gly Ser Gly Gly Thr Asn Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Arg Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Arg Arg Gly His Asn Tyr Gly Pro Trp Phe Ala Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  111
<211>  122
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S14-10AH as 
       described in Table 3.

<400>  111

Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser 
            20                  25                  30          


Gly Met Gly Val Ser Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu 
        35                  40                  45              


Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser 
    50                  55                  60                  


Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val 
65                  70                  75                  80  


Phe Leu Lys Ile Thr Ser Val Asp Thr Ala Asp Thr Ala Thr Tyr Tyr 
                85                  90                  95      


Cys Ala Arg Ser Met Tyr Gly Asn Tyr Asn Tyr Ala Met Asp Tyr Trp 
            100                 105                 110         


Gly Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120         


<210>  112
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S14-16AH as 
       described in Table 3.

<400>  112

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr 
            20                  25                  30          


Tyr Met Tyr Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Thr Ile Ser Asp Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Asn Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Gly Asn Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Ser Val Thr Val Ser Ser 
        115             


<210>  113
<211>  122
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S14-20AH as 
       described in Table 3.

<400>  113

Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Trp Ile Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asn Ile Tyr Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Arg Gly His Tyr Gly Asn Tyr Asp Pro Tyr Ala Met Asp Tyr Trp 
            100                 105                 110         


Gly Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120         


<210>  114
<211>  125
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S14-22AH as 
       described in Table 3.

<400>  114

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Val Met His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Ile Ile Thr Thr Val Ile Glu Pro Ile Leu Tyr Ala Met 
            100                 105                 110         


Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120                 125 


<210>  115
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S14-26AH as 
       described in Table 3.

<400>  115

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr 
            20                  25                  30          


Leu Ile Glu Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Val Ile Asn Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Arg Asp Tyr Gly Ser Ser Tyr Gly Tyr Ala Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120     


<210>  116
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S14-28AH as 
       described in Table 3.

<400>  116

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Trp Leu Ser Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Thr Asn Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Cys Phe Cys 
                85                  90                  95      


Ala Arg Arg Val Asp Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  117
<211>  125
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S14-29AH as 
       described in Table 3.

<400>  117

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Val Met His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Ile Ile Thr Thr Val Val Glu Pro Ile Leu Tyr Ala Met 
            100                 105                 110         


Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120                 125 


<210>  118
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-33AH as 
       described in Table 3.

<400>  118

Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Pro Ala Phe Ile 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Phe 
65                  70                  75                  80  


Lys Met Asn Thr Leu Gln Ala Ser Asp Thr Ala Ile Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Arg Gly Tyr Asn Lys Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Ser Phe Thr Val Ser Ser 
        115                 


<210>  119
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-40AH as 
       described in Table 3.

<400>  119

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Ser Tyr 
            20                  25                  30          


Asp Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Tyr Ile Ser Ser Gly Gly Gly Ser Thr Tyr Tyr Pro Asp Thr Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Leu Leu Arg Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Ser Val Thr Val Ser Ser 
        115             


<210>  120
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S19-9AH as described
       in Table 3.

<400>  120

Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ser Gly Gly Ser Thr Asp Tyr Asn Ala Ala Phe Ile 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Phe 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Ala Asn Asp Thr Ala Ile Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Arg Gly Tyr Gly Ser Pro Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120     


<210>  121
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-21AH as 
       described in Table 3.

<400>  121

Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Met Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Val Ile Asp Pro Ser Asp Ser Phe Thr Asn Tyr Asn Gln Ser Phe 
    50                  55                  60                  


Arg Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Arg Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ser Arg Gly Glu Arg Arg Gly Ile Tyr Ala Met Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Ser Ser Val Thr Val Ser Ser 
        115                 120 


<210>  122
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_130H as described 
       in Table 3.

<400>  122

Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ser Gly Gly Ser Thr Asp Tyr Asn Ala Ala Phe Ile 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Phe 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Ala Asn Asp Thr Ala Ile Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Arg Gly Tyr Gly Lys Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Ser Val Thr Val Ser Ser 
        115                 


<210>  123
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_131H as described 
       in Table 3.

<400>  123

Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ser Gly Gly Ser Thr Asp Tyr Asn Ala Pro Phe Ile 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Phe 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Ala Asn Asp Thr Ala Ile Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Arg Gly Tyr Asn Lys Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Ser Val Thr Val Ser Ser 
        115                 


<210>  124
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_180H as described 
       in Table 3.

<400>  124

Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Gly Ile His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ser Gly Gly Ser Thr Asp Tyr Asn Ala Ala Phe Ile 
    50                  55                  60                  


Ser Arg Leu Ser Ile Thr Lys Asp Lys Ser Lys Ser Gln Val Phe Phe 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Ala Asn Asp Thr Ala Ile Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Arg Gly Tyr Gly Ser Pro Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120     


<210>  125
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-15AH as 
       described in Table 3.

<400>  125

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Leu Thr Asn Tyr 
            20                  25                  30          


Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Val 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Met Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Ser Phe Tyr Gly Ser Glu Ala Tyr Trp Gly Gln Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ala 
        115         


<210>  126
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-7AH as described
       in Table 3.

<400>  126

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Val 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Glu Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Met Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Ser Phe Tyr Gly Ser Glu Ala Tyr Trp Gly Gln Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ala 
        115         


<210>  127
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-7BH as described
       in Table 3.

<400>  127

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Val 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Met Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Ser Phe Tyr Gly Ser Glu Ala Tyr Trp Gly Gln Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ala 
        115         


<210>  128
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S19-13AH as 
       described in Table 3.

<400>  128

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Phe 
            20                  25                  30          


Gly Val Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Arg Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Ser Tyr Tyr Ala Asn Tyr Ala Tyr Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  129
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S19-3AH as described
       in Table 3.

<400>  129

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Phe 
            20                  25                  30          


Gly Val Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Arg Ile Asn Asn Leu Lys Asn Glu Asp Ser Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Ser Phe Tyr Lys Asn Tyr Ala Phe Trp Gly Gln Gly Thr Ile 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  130
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S19-3BH as described
       in Table 3.

<400>  130

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Phe 
            20                  25                  30          


Gly Val Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Arg Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Ser Phe Tyr Lys Asn Tyr Ala Phe Trp Gly Gln Gly Thr Ile 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  131
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S19-3CH as described
       in Table 3.

<400>  131

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Phe 
            20                  25                  30          


Gly Val Asn Trp Val Lys Gln Ala Pro Gly Lys Asp Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Arg Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Ser Phe Tyr Lys Asn Tyr Ala Phe Trp Gly Gln Gly Thr Ile 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  132
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S19-8AH as described
       in Table 3.

<400>  132

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Phe 
            20                  25                  30          


Gly Val Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Arg Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Ser Tyr Phe Cys 
                85                  90                  95      


Ala Arg Ser Tyr Tyr Ala Asn Asn Ala Tyr Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  133
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_032H as described 
       in Table 3.

<400>  133

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Phe 
            20                  25                  30          


Gly Val Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Arg Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Ser Phe Tyr Lys Asn Tyr Ala Phe Trp Gly Gln Ser Thr Ile 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  134
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_035H as described 
       in Table 3.

<400>  134

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Phe 
            20                  25                  30          


Gly Val Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Arg Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Ser Tyr Tyr Gly Asn Tyr Ala Tyr Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  135
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_082H as described 
       in Table 3.

<400>  135

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Ser Phe Thr Thr Ala Thr Cys Tyr Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  136
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_083H as described 
       in Table 3.

<400>  136

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Asp Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Ser Phe Thr Thr Ala Thr Cys Tyr Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  137
<211>  123
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S14-18AH as 
       described in Table 3.

<400>  137

Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Gln Pro Lys Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Asn 
            20                  25                  30          


Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Arg Ile Arg Ser Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 
    50                  55                  60                  


Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Gln Ser Met 
65                  70                  75                  80  


Leu Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Met Tyr 
                85                  90                  95      


Tyr Cys Val Arg Glu Gly Gly Tyr Gly Asn Tyr Pro Tyr Phe Asp Tyr 
            100                 105                 110         


Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser 
        115                 120             


<210>  138
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S14-23AH as 
       described in Table 3.

<400>  138

Leu Val Lys Thr Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly 
1               5                   10                  15      


Tyr Ser Phe Thr Gly Tyr Tyr Met His Trp Val Lys Gln Ser His Gly 
            20                  25                  30          


Lys Ser Leu Glu Trp Ile Gly Tyr Ile Ser Cys Tyr Asn Gly Ala Thr 
        35                  40                  45              


Ser Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Phe Thr Val Asp Thr 
    50                  55                  60                  


Ser Ser Ser Thr Ala Tyr Met Gln Phe Asn Ser Leu Thr Ser Glu Asp 
65                  70                  75                  80  


Ser Ala Val Tyr Tyr Cys Ala Arg Thr Tyr Tyr Tyr Gly Ser Ser Tyr 
                85                  90                  95      


Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 
            100                 105                 110         


<210>  139
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S14-30AH as 
       described in Table 3.

<400>  139

Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met Ser Trp Val Arg Gln Thr Pro Asp Lys Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Thr Ile Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gln Gly Gly His Gly Asn Tyr Gly Ala Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120     


<210>  140
<211>  123
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-14AH as 
       described in Table 3.

<400>  140

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Val Met His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Ile Asn Pro Tyr Asn Asp Asp Thr Asn Cys Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Arg Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Ala Arg Gly Tyr Gly Ser Thr Phe Tyr Tyr Ser Met Asp Tyr 
            100                 105                 110         


Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120             


<210>  141
<211>  123
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-25AH as 
       described in Table 3.

<400>  141

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Lys Phe Asn Ser Tyr 
            20                  25                  30          


Val Met His Trp Val Lys Gln Lys Pro Gly Gln Gly Pro Glu Trp Ile 
        35                  40                  45              


Gly Tyr Ile Asn Pro Tyr Asn Asp Asp Thr Asn Cys Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Ala Arg Gly Tyr Gly Gly Asn Phe Tyr Tyr Ser Met Asp Tyr 
            100                 105                 110         


Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120             


<210>  142
<211>  123
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-5AH as described
       in Table 3.

<400>  142

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Val Met His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Ile Asn Pro Tyr Asn Asp Asp Thr Asn Cys Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Asp Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Ala Arg Gly Tyr Gly Gly Ser Phe Tyr Tyr Ser Met Asp Tyr 
            100                 105                 110         


Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120             


<210>  143
<211>  123
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-44AH as 
       described in Table 3.

<400>  143

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Tyr Ile Ser Asn Gly Gly Gly Ser Thr Tyr Tyr Pro Asp Thr Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Ala Arg His Arg Gly Tyr Gly Ser Ser Tyr Asn Tyr Ala Met Asp Tyr 
            100                 105                 110         


Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120             


<210>  144
<211>  122
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-46AH as 
       described in Table 3.

<400>  144

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Tyr Ile Ser Asn Gly Gly Gly Ser Thr Tyr Tyr Pro Asp Thr Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Ala Arg His Arg Gly Tyr Gly Asn Tyr Val Tyr Ala Met Asp Tyr Trp 
            100                 105                 110         


Gly Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120         


<210>  145
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-51AH as 
       described in Table 3.

<400>  145

Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Arg Gly Gly Ser Thr Asp Tyr Asn Ala Ala Phe Met 
    50                  55                  60                  


Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Phe Phe 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Ala Asp Asp Thr Ala Ile Tyr Tyr Cys Ala 
                85                  90                  95      


Lys Asn Arg Gly Tyr Gly Glu Gly Tyr Tyr Ala Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120     


<210>  146
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-53AH as 
       described in Table 3.

<400>  146

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Ser Pro Glu Lys Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Glu Ile Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Thr Val 
    50                  55                  60                  


Thr Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Glu Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Glu Gly Leu Arg Arg Asp Tyr Tyr Ala Leu Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120     


<210>  147
<211>  122
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-55AH as 
       described in Table 3.

<400>  147

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Asp Ile Ser Asn Gly Gly Gly Ser Thr Tyr Tyr Pro Asp Thr Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Ala Arg His Arg Gly Tyr Gly Asn Tyr Val Tyr Ala Met Asp Tyr Trp 
            100                 105                 110         


Gly Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120         


<210>  148
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-59AH as 
       described in Table 3.

<400>  148

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Ser Ile Ser Ser Gly Ser Ser Thr Tyr Tyr Pro Asp Ser Val Lys 
    50                  55                  60                  


Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Ile Leu Tyr Leu 
65                  70                  75                  80  


Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala 
                85                  90                  95      


Lys Gly Arg Gly Tyr Gly Asn Tyr Leu Tyr Ala Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120     


<210>  149
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-19AH as 
       described in Table 3.

<400>  149

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Gly Tyr 
            20                  25                  30          


Gly Val Asn Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Met Ile Trp Gly Asp Gly Gly Thr Asp Tyr Asn Ser Ala Leu Lys 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Arg Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asp Asn Tyr His Thr Val Val Asn Gly Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Ser Val Thr Val Ser Ser 
        115                 


<210>  150
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-32AH as 
       described in Table 3.

<400>  150

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Gly Tyr 
            20                  25                  30          


Gly Val Asn Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Met Ile Trp Gly Asp Gly Ser Thr Asp Tyr Asn Ser Ala Leu Lys 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Ile Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Val Gln Thr Glu Asp Thr Ala Arg Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asp Ser Tyr Arg Thr Met Thr Asn Gly Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Ser Val Thr Val Ser Ser 
        115                 


<210>  151
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S19-16AH as 
       described in Table 3.

<400>  151

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Phe 
            20                  25                  30          


Gly Val Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 
                85                  90                  95      


Val Arg Ser Tyr Tyr Gly Asn Ser Gly Tyr Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  152
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S19-19AH as 
       described in Table 3.

<400>  152

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 
                85                  90                  95      


Val Arg Ser Tyr Tyr Gly Asn Ser Gly Tyr Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  153
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-12AH as 
       described in Table 3.

<400>  153

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Phe 
            20                  25                  30          


Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Lys Asn Asp Asp Met Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Ser Leu Tyr Gly Asn Arg Asp Tyr Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  154
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-18AH as 
       described in Table 3.

<400>  154

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Asn Tyr 
            20                  25                  30          


Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Met Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Ser Phe Tyr Gly Asn Arg Asp Tyr Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  155
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_100H as described 
       in Table 3.

<400>  155

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Leu Thr Asn Phe 
            20                  25                  30          


Gly Met Asn Trp Met Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Gly Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 
                85                  90                  95      


Val Arg Ser Tyr Tyr Gly Asn Ser Gly Tyr Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  156
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_101H as described 
       in Table 3.

<400>  156

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Leu Thr Asn Phe 
            20                  25                  30          


Gly Met Asn Trp Met Lys Gln Ala Pro Gly Lys Asp Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Gly Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 
                85                  90                  95      


Val Arg Ser Tyr Tyr Gly Asn Ser Gly Tyr Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  157
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-13AH as 
       described in Table 3.

<400>  157

Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Arg Gly Gly Ser Thr Asp Tyr Asn Ala Ala Phe Met 
    50                  55                  60                  


Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Phe Phe 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Ala Asp Asp Thr Ala Ile Tyr Tyr Cys Ala 
                85                  90                  95      


Lys Thr Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 
            100                 105                 110         


Ala 
    


<210>  158
<211>  114
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-28AH as 
       described in Table 3.

<400>  158

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Phe Gly Tyr Thr Phe Thr Thr Tyr 
            20                  25                  30          


Pro Ile Glu Trp Met Lys Gln Asn His Gly Lys Ser Leu Glu Trp Ile 
        35                  40                  45              


Gly Asn Phe His Pro Tyr Asn Asp Asp Thr Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Lys Leu Thr Val Glu Lys Ser Ser Ser Thr Val Tyr 
65                  70                  75                  80  


Leu Glu Leu Ser Arg Leu Thr Ser Asp Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val 
            100                 105                 110         


Ser Ala 
        


<210>  159
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-39AH as 
       described in Table 3.

<400>  159

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          


Ser Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Glu Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Leu Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Phe 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Asn Trp Ala Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 
            100                 105                 110         


Val Ser Ala 
        115 


<210>  160
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_236H as described 
       in Table 3.

<400>  160

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Val Met His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Glu Arg Thr Gly Pro Phe Ala Tyr Trp Gly Gln Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ala 
        115         


<210>  161
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_238H as described 
       in Table 3.

<400>  161

Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Met Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          


Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Ala Ile Asp Thr Ser Asp Ser Tyr Thr Ser Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Val Asp Glu Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Ser Ala Arg Ala Ala Trp Phe Ala Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ala 
        115             


<210>  162
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_240H as described 
       in Table 3.

<400>  162

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Lys Asn Asp Asp Thr Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Glu Leu Leu Arg Ser Ala Trp Phe Ala Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ala 
        115                 


<210>  163
<211>  114
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-20AH as 
       described in Table 3.

<400>  163

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Ser Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Tyr 
            20                  25                  30          


Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Pro Lys Phe 
    50                  55                  60                  


Gln Gly Lys Ala Thr Met Thr Ala Asp Thr Ser Ser Asn Ala Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Asn Ser Arg Thr Leu Gly Tyr Trp Gly Gln Gly Thr Leu Val Thr Val 
            100                 105                 110         


Ser Ala 
        


<210>  164
<211>  114
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-20BH as 
       described in Table 3.

<400>  164

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Ser Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Tyr 
            20                  25                  30          


Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Pro Lys Phe 
    50                  55                  60                  


Gln Gly Lys Ala Thr Met Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Asn Ser Arg Thr Leu Gly Tyr Trp Gly Gln Gly Thr Leu Val Thr Val 
            100                 105                 110         


Ser Ala 
        


<210>  165
<211>  114
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-31AH as 
       described in Table 3.

<400>  165

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Ser Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Thr Ser Gly Phe Asn Ile Lys Asp Tyr 
            20                  25                  30          


Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Pro Lys Phe 
    50                  55                  60                  


Gln Gly Lys Ala Thr Met Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Asn Ser Arg Thr Leu Gly Tyr Trp Gly Gln Gly Thr Leu Val Thr Val 
            100                 105                 110         


Ser Ala 
        


<210>  166
<211>  114
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-31BH as 
       described in Table 3.

<400>  166

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Ser Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Thr Ser Gly Phe Asn Ile Lys Asp Tyr 
            20                  25                  30          


Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Pro Lys Phe 
    50                  55                  60                  


Gln Gly Lys Ala Thr Met Thr Ala Asp Thr Cys Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Asn Ser Arg Thr Leu Gly Tyr Trp Gly Gln Gly Thr Leu Val Thr Val 
            100                 105                 110         


Ser Ala 
        


<210>  167
<211>  114
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-45AH as 
       described in Table 3.

<400>  167

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Ser Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Tyr 
            20                  25                  30          


Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Phe Ala Pro Lys Phe 
    50                  55                  60                  


Gln Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Asn Thr Arg Thr Leu Gly Tyr Trp Gly Gln Gly Thr Leu Val Thr Val 
            100                 105                 110         


Ser Ala 
        


<210>  168
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-18AH as 
       described in Table 3.

<400>  168

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ala Gly Tyr Thr Phe Thr Asn Ser 
            20                  25                  30          


Trp Ile Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Thr Asn Tyr Tyr Glu Lys Phe 
    50                  55                  60                  


Lys Val Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Ile Tyr Tyr Cys 
                85                  90                  95      


Ala Ser Ser Gly Ala Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  169
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-26AH as 
       described in Table 3.

<400>  169

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ala Gly Tyr Thr Phe Thr Asn Ser 
            20                  25                  30          


Trp Met Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Ala Asp Ile Tyr Pro Gly Gly Gly Tyr Ser Asn Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Ile Tyr Tyr Cys 
                85                  90                  95      


Ala Ser Ser Gly Ala Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  170
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-8AH as described
       in Table 3.

<400>  170

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ala Gly Tyr Thr Phe Thr Asp Ser 
            20                  25                  30          


Trp Ile Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Thr Asn Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Arg Leu Thr Ser Glu Asp Ser Ala Ile Tyr Tyr Cys 
                85                  90                  95      


Ala Ser Ser Gly Ala Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  171
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S19-4AH as described
       in Table 3.

<400>  171

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Gly Tyr 
            20                  25                  30          


Gly Val Asn Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Met Ile Trp Gly Asp Gly Asn Thr Asp Tyr Asn Ser Ala Leu Lys 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Arg Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Ser Tyr Gly Ser Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 
            100                 105                 110         


Ala 
    


<210>  172
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-56AH as 
       described in Table 3.

<400>  172

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Thr Ile Ser Gly Gly Gly Ser Tyr Thr Phe Tyr Pro Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Asn Leu Tyr 
65                  70                  75                  80  


Leu Gln Val Ser Ser Leu Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys 
                85                  90                  95      


Ile Tyr Asp Gly Ser Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 
            100                 105                 110         


Ala 
    


<210>  173
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S14-24AH as 
       described in Table 3.

<400>  173

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Ile Thr Glu Tyr 
            20                  25                  30          


Thr Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 
        35                  40                  45              


Gly Gly Ile Asn Pro Asn Asn Gly Gly Thr Ile Asn Asn Gln Lys Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Leu Thr Val Asp Met Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Gly Ser Val Val Asp Arg Tyr Trp Tyr Phe Asp Val Trp Gly Ala 
            100                 105                 110         


Gly Thr Thr Val Thr Val Ser Ser 
        115                 120 


<210>  174
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S14-4AH as described
       in Table 3.

<400>  174

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr 
            20                  25                  30          


Thr Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 
        35                  40                  45              


Gly Gly Ile Asn Pro Tyr Asn Gly Gly Thr Ile Asn Asn Gln Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Val Asp Met Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Gly Ser Val Val Asp Arg Tyr Trp Tyr Phe Asp Val Trp Gly Ala 
            100                 105                 110         


Gly Thr Thr Val Thr Val Ser Ser 
        115                 120 


<210>  175
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S14-7AH as described
       in Table 3.

<400>  175

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr 
            20                  25                  30          


Thr Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 
        35                  40                  45              


Gly Gly Ile Asn Pro Asn Asn Gly Gly Thr Ile Asn Asn Gln Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Val Asp Met Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Gly Ser Val Val Asp Arg Tyr Trp Tyr Phe Asp Val Trp Gly Ala 
            100                 105                 110         


Gly Thr Thr Val Thr Val Ser Ser 
        115                 120 


<210>  176
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_040H as described 
       in Table 3.

<400>  176

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr 
            20                  25                  30          


Thr Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 
        35                  40                  45              


Gly Gly Ile Asn Pro Asn Asn Gly Gly Thr Ile Asn Asn Gln Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Val Asp Met Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Gly Ser Val Val Asp Arg Tyr Trp Tyr Phe Asp Val Trp Gly Ala 
            100                 105                 110         


Gly Thr Thr Val Thr Val Ser Ser 
        115                 120 


<210>  177
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S14-2AH as described
       in Table 3.

<400>  177

Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Ser Asp Ser Thr Asn Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Ser Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Ser Gly Tyr Tyr Gly Ser Tyr Leu Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Thr Leu Thr Val Ser Ser 
        115                 


<210>  178
<211>  116
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-27AH as 
       described in Table 3.

<400>  178

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr 
            20                  25                  30          


Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Asp Pro Lys Phe 
    50                  55                  60                  


Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Ser Arg Arg Tyr Phe Asp Val Trp Gly Ala Gly Thr Thr Val 
            100                 105                 110         


Thr Val Ser Ser 
        115     


<210>  179
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-22AH as 
       described in Table 3.

<400>  179

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr 
            20                  25                  30          


Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Ala Pro Lys Phe 
    50                  55                  60                  


Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Ser Phe Gly Asn Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  180
<211>  114
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_237H as described 
       in Table 3.

<400>  180

Leu Gln Gln Ser Gly Ala Gly Leu Val Lys Pro Gly Ala Ser Val Lys 
1               5                   10                  15      


Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr Ile Ile Tyr 
            20                  25                  30          


Trp Val Lys Gln Arg Ser Gly Gln Gly Leu Glu Trp Ile Gly Trp Phe 
        35                  40                  45              


Tyr Pro Gly Ser Gly Ser Ile Arg Tyr Asn Glu Lys Phe Lys Asp Lys 
    50                  55                  60                  


Ala Thr Leu Thr Ala Asp Lys Ser Ser Thr Thr Val Tyr Met Asp Leu 
65                  70                  75                  80  


Ser Arg Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg His 
                85                  90                  95      


Glu Asp Gly Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  181
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-21AH as 
       described in Table 3.

<400>  181

Gln Ile Gln Leu Val Gln Ser Gly Pro Asp Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Asp Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Lys Asn Asp Asp Thr Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Ser Ile Asn Tyr Asp Ser Asp Glu Lys Trp Gly Gln Gly Thr 
            100                 105                 110         


Ser Val Thr Val Ser Ser 
        115             


<210>  182
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-26AH as 
       described in Table 3.

<400>  182

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Arg Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Ser Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Met Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Ser Leu Tyr Tyr Gly Asp Asn Tyr Glu Ala Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  183
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_127H as described 
       in Table 3.

<400>  183

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys His Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Asn Tyr 
            20                  25                  30          


Gly Ile Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Arg Glu Pro Thr Tyr Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Ser Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Ser Asn Leu Thr Thr Glu Asp Met Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Ser Leu Tyr Tyr Val Asn Asn Tyr Glu Ala Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  184
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_128H as described 
       in Table 3.

<400>  184

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys His Gly Glu 
1               5                   10                  15      


Thr Val Arg Ile Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Asp Tyr 
            20                  25                  30          


Gly Ile Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Lys Pro Thr Tyr Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Lys Thr Glu Asp Met Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Ser Leu Tyr Tyr Gly Asn Asn Tyr Glu Ala Cys Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser 
        115                 


<210>  185
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-6AH as described
       in Table 3.

<400>  185

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ala Gly Tyr Thr Phe Thr Asn Ser 
            20                  25                  30          


Trp Ile Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Tyr Pro Gly Gly Ala Tyr Thr Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Ile Tyr Tyr Cys 
                85                  90                  95      


Ala Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  186
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_045H as described 
       in Table 3.

<400>  186

Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln 
1               5                   10                  15      


Asn Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr 
            20                  25                  30          


Gly Val His Trp Ile Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ser Gly Gly Gly Thr Asp Tyr Asn Ala Ala Phe Ile 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Phe 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Ala Asp Asp Thr Ala Ile Tyr Tyr Cys Ala 
                85                  90                  95      


Ser Leu Tyr Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala 
            100                 105                 110     


<210>  187
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_046H as described 
       in Table 3.

<400>  187

Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln 
1               5                   10                  15      


Asn Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr 
            20                  25                  30          


Gly Val His Trp Ile Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ser Gly Gly Gly Thr Asp Tyr Asn Ala Ala Phe Ile 
    50                  55                  60                  


Ser Arg Leu Thr Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Phe 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Ala Asp Asp Thr Ala Ile Tyr Tyr Cys Ala 
                85                  90                  95      


Ser Leu Tyr Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala 
            100                 105                 110     


<210>  188
<211>  116
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-29AH as 
       described in Table 3.

<400>  188

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala 
1               5                   10                  15      


Leu Val Lys Leu Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Asp 
            20                  25                  30          


Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Trp Ile Asp Pro Glu Asn Gly Asn Thr Ile Tyr Asp Pro Lys Phe 
    50                  55                  60                  


Gln Gly Lys Ala Ser Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Tyr Ser Ser Ser Pro Tyr Trp Gly Gln Gly Thr Leu Val 
            100                 105                 110         


Thr Val Ser Ala 
        115     


<210>  189
<211>  116
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-2AH as described
       in Table 3.

<400>  189

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr 
            20                  25                  30          


Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Asp Pro Ala Asn Asp Asn Thr Lys Tyr Asp Pro Lys Phe 
    50                  55                  60                  


Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Val Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val 
            100                 105                 110         


Thr Val Ser Ser 
        115     


<210>  190
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S19-24AH as 
       described in Table 3.

<400>  190

Gln Val Gln Leu Gln Gln Ser Gly Gly Glu Leu Leu Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr 
            20                  25                  30          


Leu Ile Glu Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Val Ile Asn Pro Gly Ser Gly Gly Ile Tyr Tyr Lys Glu Lys Phe 
    50                  55                  60                  


Lys Asp Lys Ala Ile Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Arg Gly Asp Ala Met Asp Phe Trp Gly Gln Gly Thr Ser Val Thr 
            100                 105                 110         


Val Ser Ser 
        115 


<210>  191
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S14-1AH as described
       in Table 3.

<400>  191

Asp Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Val Phe Thr Phe Ser Arg Tyr 
            20                  25                  30          


Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Thr Ile Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Ile Tyr Tyr Cys 
                85                  90                  95      


Thr Arg Gly Gly Asp Gly Leu Phe Asp Tyr Trp Gly Gln Gly Thr Ala 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  192
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S19-5AH as described
       in Table 3.

<400>  192

Asp Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Thr Ile Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Thr Arg Gly Asp Asp Tyr Gly Phe Asp Tyr Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  193
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_203H as described 
       in Table 3.

<400>  193

Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met Ser Trp Val Arg Gln Thr Pro Asp Lys Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Thr Ile Ser Ser Gly Gly Ser Ser Thr Tyr Tyr Pro Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Thr Arg His Glu Leu Gly Asn Arg Ser Arg Phe Pro Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  194
<211>  114
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S14-21AH as 
       described in Table 3.

<400>  194

Gln Val Gln Leu Gln Gln Pro Gly Ser Glu Leu Val Arg Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asn Ile Tyr Pro Gly Ser Gly Ser Thr Asn Tyr Asp Glu Lys Phe 
    50                  55                  60                  


Lys Ser Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Ile Tyr Asp Gly Tyr Tyr Trp Gly Gln Gly Thr Leu Val Thr Val 
            100                 105                 110         


Ser Ala 
        


<210>  195
<211>  114
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S14-27AH as 
       described in Table 3.

<400>  195

Glu Val Lys Leu Asp Glu Thr Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Pro Met Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asp Tyr 
            20                  25                  30          


Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Arg Asn Lys Pro Tyr Asn Tyr Glu Thr Tyr Tyr Ser Asp 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 
65                  70                  75                  80  


Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Met Gly Ile Tyr 
                85                  90                  95      


Tyr Cys Thr Trp Gly Asn Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  196
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S14-5AH as described
       in Table 3.

<400>  196

Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Asp 
            20                  25                  30          


Phe Ala Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp 
        35                  40                  45              


Met Gly Tyr Ile Val Tyr Ser Gly Ser Thr Ser Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe 
65                  70                  75                  80  


Leu Gln Leu Asn Ser Val Thr Ala Glu Asp Thr Ala Thr Tyr Phe Cys 
                85                  90                  95      


Thr Arg Gly Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  197
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S19-1AH as described
       in Table 3.

<400>  197

Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Asp 
            20                  25                  30          


Tyr Ala Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp 
        35                  40                  45              


Met Gly Tyr Ile Ala Tyr Ser Gly Gly Thr Ser Tyr Ser Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe 
65                  70                  75                  80  


Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys 
                85                  90                  95      


Val Tyr Phe Lys Tyr Gly Gly Ala Phe Ala Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ala 
        115             


<210>  198
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of ITI_023H as described 
       in Table 3.

<400>  198

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Ser Pro Gly Ala 
1               5                   10                  15      


Ser Val Asn Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr 
            20                  25                  30          


Tyr Ile His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Lys Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Asp Pro Lys Phe 
    50                  55                  60                  


Gln Asp Lys Ala Thr Ile Thr Thr Asp Ala Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Lys Ser Leu Leu Trp Ser Leu Gly Gly Phe Ala Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  199
<211>  114
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S14-3AH as described
       in Table 3.

<400>  199

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Gly Val Asn Trp Val Lys Gln Ala Pro Gly Lys Asp Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Met Ala Thr Tyr Phe Cys 
                85                  90                  95      


Thr Ser Arg Ser Trp Val Leu Trp Gly Gln Gly Thr Leu Val Thr Val 
            100                 105                 110         


Ser Ala 
        


<210>  200
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S20-27AH as 
       described in Table 3.

<400>  200

Glu Val Gln Leu Gln Gln Ser Gly Thr Val Leu Ala Arg Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr 
            20                  25                  30          


Trp Met His Trp Leu Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Ala Ile Tyr Pro Gly Asn Ser Asp Thr Val Phe Asn Gln Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Lys Leu Thr Ala Val Thr Ser Ala Thr Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Thr Asn Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Lys Glu Pro Arg Thr Ile Glu Gly Ala Trp Phe Thr Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ala 
        115                 120     


<210>  201
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Heavy Chain of H5S15-23AH as 
       described in Table 3.

<400>  201

Glu Val Gln Leu Gln Gln Ser Gly Thr Val Leu Ala Arg Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Phe 
            20                  25                  30          


Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Ala Ile Ser Pro Gly Asn Ser Glu Thr Thr Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Thr Gly Lys Ala Lys Leu Thr Ala Val Thr Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Thr Asn Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Lys Ile Tyr Tyr Asp Tyr Asp Asp Gly Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Thr Leu Thr Val Ser Ser 
        115             


<210>  202
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of Consensus Cluster #11 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Alanine or Threonine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Leucine or Valine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Valine or Isoleucine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Arginine, Lysine, Glutamine or Methionine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Isoleucine or Methionine

<400>  202

Gln Val Gln Leu Gln Gln Ser Gly Xaa Glu Xaa Xaa Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Xaa Xaa Ser Cys Lys Ala Ser 
            20                  25  


<210>  203
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  203

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser 
            20                  25  


<210>  204
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S20-28AH as described 
       in Table 2.

<400>  204

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Val Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Gln Ile Ser Cys Lys Ala Ser 
            20                  25  


<210>  205
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  205

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Val Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser 
            20                  25  


<210>  206
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S20-30AH as described 
       in Table 2.

<400>  206

Gln Val Gln Leu Gln Gln Ser Gly Thr Glu Val Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser 
            20                  25  


<210>  207
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  207

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Arg Ile Ser Cys Lys Ala Ser 
            20                  25  


<210>  208
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S20-36AH as described 
       in Table 2.

<400>  208

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser 
            20                  25  


<210>  209
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S20-43AH as described 
       in Table 2.

<400>  209

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Met Ile Ser Cys Lys Ala Ser 
            20                  25  


<210>  210
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S20-7BH as described 
       in Table 2.

<400>  210

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ile Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser 
            20                  25  


<210>  211
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of Consensus Cluster #20 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Glutamate or Aspartate

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Lysine or Glutamine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Glycine or Aspartate

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Valine or Methionine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Lysine, Methionine or Glutamine

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Leucine or Arginine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Lysine or Arginine

<400>  211

Xaa Val Xaa Leu Val Glu Ser Gly Gly Xaa Leu Xaa Xaa Pro Gly Gly 
1               5                   10                  15      


Ser Xaa Xaa Leu Ser Cys Ala Ala Ser 
            20                  25  


<210>  212
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S14-11AH as described 
       in Table 2.

<400>  212

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser 
            20                  25  


<210>  213
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S14-8AH as described 
       in Table 2.

<400>  213

Glu Val Lys Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser 
            20                  25  


<210>  214
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  214

Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Arg Lys Leu Ser Cys Ala Ala Ser 
            20                  25  


<210>  215
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  215

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser 
            20                  25  


<210>  216
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S20-14DH as described 
       in Table 2.

<400>  216

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Met Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser 
            20                  25  


<210>  217
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S20-4AH as described 
       in Table 2.

<400>  217

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Met Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser 
            20                  25  


<210>  218
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of Consensus Cluster #5 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Glutamine or Glycine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Valine or Alanine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Glutamine or Alanine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Leucine or Glutamate

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Lysine or Glycine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Glutamate or Valine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Serine or Arginine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Glycine or Arginine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Glycine or Valine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Glutamine or Arginine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Serine or Asparagine

<400>  218

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Pro Xaa Leu Val Ala Pro Ser Xaa 
1               5                   10                  15      


Xaa Leu Ser Ile Thr Cys Thr Val Ser 
            20                  25  


<210>  219
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  219

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Arg 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser 
            20                  25  


<210>  220
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  220

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser 
            20                  25  


<210>  221
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S19-20CH as described 
       in Table 2.

<400>  221

Gln Val Gln Leu Lys Glu Ser Gly Pro Val Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser 
            20                  25  


<210>  222
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  222

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Asn Leu Ser Ile Thr Cys Thr Val Ser 
            20                  25  


<210>  223
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of ITI_164H as described in
       Table 2.

<400>  223

Gly Ala Ala Glu Gly Val Arg Arg Pro Gly Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser 
            20                  25  


<210>  224
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of Consensus Cluster #23 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Glutamate, Aspartate or Glutamine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Glutamine or Lysine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Glutamine, Valine or Lysine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Glutamine or Glutamate

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Serine or Proline

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Alanine, Proline or Glycine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Glutamate or Glycine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Valine or Methionine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Lysine, Glutamine, Asparagine or Arginine

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Glycine or Serine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Alanine, Glycine, Glutamine or Threonine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Serine or Proline

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Valine or Leucine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Lysine, Arginine or Serine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Leucine, Methionine or Isoleucine

<220>
<221>  misc_feature
<222>  (21)..(21)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (23)..(23)
<223>  Xaa is Threonine, Lysine or Alanine

<220>
<221>  misc_feature
<222>  (24)..(24)
<223>  Xaa is Alanine, Threonine or Valine

<220>
<221>  misc_feature
<222>  (25)..(25)
<223>  Xaa is Serine, Threonine, Alanine or Phenylalanine

<400>  224

Xaa Val Xaa Leu Xaa Xaa Xaa Gly Xaa Xaa Leu Xaa Xaa Pro Xaa Xaa 
1               5                   10                  15      


Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa 
            20                  25  


<210>  225
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  225

Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser 
            20                  25  


<210>  226
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  226

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ala 
            20                  25  


<210>  227
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  227

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Phe 
            20                  25  


<210>  228
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S14-6AH as described 
       in Table 2.

<400>  228

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Thr Ser 
            20                  25  


<210>  229
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  229

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Ala Ser 
            20                  25  


<210>  230
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  230

Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Pro Val Lys Leu Ser Cys Lys Ala Ser 
            20                  25  


<210>  231
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  231

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser 
            20                  25  


<210>  232
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  232

Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Asn Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Leu Thr Cys Thr Val Thr 
            20                  25  


<210>  233
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S19-25AH as described 
       in Table 2.

<400>  233

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Thr 
            20                  25  


<210>  234
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  234

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser 
            20                  25  


<210>  235
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  235

Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Leu Thr Cys Thr Val Thr 
            20                  25  


<210>  236
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of Consensus Cluster #21 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Glutamine or Glutamate

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Proline or Serine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Glutamate or Aspartate

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Valine or Leucine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Lysine or Arginine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Alanine or Threonine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Proline or Serine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Lysine, Arginine or Methionine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Leucine or Valine

<220>
<221>  misc_feature
<222>  (23)..(23)
<223>  Xaa is Lysine or Threonine

<400>  236

Xaa Val Gln Leu Gln Gln Xaa Gly Ala Xaa Leu Xaa Xaa Pro Gly Xaa 
1               5                   10                  15      


Xaa Val Xaa Xaa Ser Cys Xaa Ala Ser 
            20                  25  


<210>  237
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  237

Glu Val Gln Leu Gln Gln Ser Gly Ala Asp Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Ala Ser 
            20                  25  


<210>  238
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S20-58AH as described 
       in Table 2.

<400>  238

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Met Leu Ser Cys Thr Ala Ser 
            20                  25  


<210>  239
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of ITI_091H as described in
       Table 2.

<400>  239

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Leu Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Arg Leu Ser Cys Thr Ala Ser 
            20                  25  


<210>  240
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  240

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser 
            20                  25  


<210>  241
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of Consensus Cluster #10 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Glutamate or Glutamine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Glutamine or Threonine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Glutamine, Valine or Lysine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Glutamine or Glutamate

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Serine or Proline

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Proline, Alanine or Glycine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Glutamate or Glycine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Leucine or Isoleucine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Valine or Leucine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Lysine, Arginine or Glutamine

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Glycine or Serine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Alanine, Threonine, Glycine or Glutamine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Valine or Leucine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Lysine, Methionine or Serine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Methionine, Leucine, Isoleucine or Valine

<220>
<221>  misc_feature
<222>  (21)..(21)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (23)..(23)
<223>  Xaa is Lysine, Alanine, Serine or Threonine

<220>
<221>  misc_feature
<222>  (24)..(24)
<223>  Xaa is Alanine, Phenylalanine or Valine

<400>  241

Xaa Val Xaa Leu Xaa Xaa Xaa Gly Xaa Xaa Xaa Xaa Xaa Pro Xaa Xaa 
1               5                   10                  15      


Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Ser 
            20                  25  


<210>  242
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S14-10AH as described 
       in Table 2.

<400>  242

Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Ser Phe Ser 
            20                  25  


<210>  243
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S14-20AH as described 
       in Table 2.

<400>  243

Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Lys Ala Ser 
            20                  25  


<210>  244
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S20-21AH as described 
       in Table 2.

<400>  244

Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Met Met Ser Cys Lys Ala Ser 
            20                  25  


<210>  245
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of Consensus Cluster #8 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Leucine or Valine

<400>  245

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Xaa Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser 
            20                  25  


<210>  246
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S15-15AH as described 
       in Table 2.

<400>  246

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser 
            20                  25  


<210>  247
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  247

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser 
            20                  25  


<210>  248
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of Consensus Cluster #15 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Glutamate, no amino acid or Glutamine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Valine or no amino acid

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Glutamine, no amino acid or Lysine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Leucine or no amino acid

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Valine, no amino acid, Glutamine or Lysine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Glutamate, no amino acid or Glutamine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Serine, no amino acid or Threonine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Glycine or no amino acid

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Glycine, no amino acid or Proline

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Aspartate, no amino acid, Glycine or Glutamate

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Lysine or Glutamine

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa is Proline or Threonine

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Glycine, Serine or Lysine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Glycine, Alanine or Glutamine

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Leucine or Valine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Lysine or Serine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Leucine, Isoleucine or Methionine

<220>
<221>  misc_feature
<222>  (21)..(21)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (23)..(23)
<223>  Xaa is Alanine, Lysine or Threonine

<220>
<221>  misc_feature
<222>  (24)..(24)
<223>  Xaa is Alanine or Valine

<400>  248

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Val Xaa Xaa Xaa Xaa 
1               5                   10                  15      


Ser Xaa Xaa Xaa Xaa Cys Xaa Xaa Ser 
            20                  25  


<210>  249
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S14-18AH as described 
       in Table 2.

<400>  249

Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Gln Pro Lys Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser 
            20                  25  


<210>  250
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S14-23AH as described 
       in Table 2.

<400>  250

Leu Val Lys Thr Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser 
1               5                   10                  15  


<210>  251
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  251

Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser 
            20                  25  


<210>  252
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  252

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser 
            20                  25  


<210>  253
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of Consensus Cluster #19 as
       described in Table 2.


<220>
<221>  misc_feature
<223>  Framework Region 1 of the Heavy Chain of Consensus Cluster #19 as
       described in Table 2.

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Valine or Isoleucine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Lysine or Valine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Glutamate or Glutamine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Glycine or Glutamate

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Valine or Lysine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Alanine or Lysine

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Serine or Glycine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Glutamine or Glutamate

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Leucine or Valine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Serine or Lysine

<220>
<221>  misc_feature
<222>  (21)..(21)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (23)..(23)
<223>  Xaa is Threonine or Lysine

<220>
<221>  misc_feature
<222>  (24)..(24)
<223>  Xaa is Valine or Alanine

<400>  253

Gln Xaa Gln Leu Xaa Xaa Ser Gly Pro Xaa Leu Xaa Xaa Pro Xaa Xaa 
1               5                   10                  15      


Xaa Xaa Xaa Ile Xaa Cys Xaa Xaa Ser 
            20                  25  


<210>  254
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of Consensus Cluster #14 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Glutamine or Glutamate

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Isoleucine or Valine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Valine, Glutamine or Lysine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Serine or Proline

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Proline or Alanine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Glutamate or Glycine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Lysine or Valine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Lysine, Glutamine or Methionine

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Glycine or Serine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Glutamate, Alanine or Glutamine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Valine or Leucine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Lysine or Serine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Isoleucine or Methionine

<220>
<221>  misc_feature
<222>  (21)..(21)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (23)..(23)
<223>  Xaa is Lysine or Threonine

<220>
<221>  misc_feature
<222>  (24)..(24)
<223>  Xaa is Alanine or Valine

<220>
<221>  misc_feature
<222>  (25)..(25)
<223>  Xaa is Serine or Phenylalanine

<400>  254

Xaa Xaa Gln Leu Xaa Gln Xaa Gly Xaa Xaa Leu Xaa Xaa Pro Xaa Xaa 
1               5                   10                  15      


Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa 
            20                  25  


<210>  255
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of ITI_238H as described in
       Table 2.

<400>  255

Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Met Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser 
            20                  25  


<210>  256
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of Consensus Cluster #6 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (23)..(23)
<223>  Xaa is Alanine or Threonine

<220>
<221>  misc_feature
<222>  (24)..(24)
<223>  Xaa is Alanine or Threonine

<400>  256

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Ser Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Xaa Xaa Ser 
            20                  25  


<210>  257
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  257

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Ser Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Ala Ser 
            20                  25  


<210>  258
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  258

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Ser Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Thr Ser 
            20                  25  


<210>  259
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S20-45AH as described 
       in Table 2.

<400>  259

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Ser Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Ala Ala Ser 
            20                  25  


<210>  260
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of Consensus Cluster #12 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Glutamate or Glutamine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Lysine or Glutamine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Valine, Lysine or Glutamine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Glutamate or Glutamine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Glycine, Proline or Alanine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Glycine or Glutamate

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Lysine, Alanine or Arginine

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Glycine or Serine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Glycine, Glutamine or Threonine

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Leucine or Valine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Lysine or Serine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Leucine, Isoleucine or Methionine

<220>
<221>  misc_feature
<222>  (21)..(21)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (23)..(23)
<223>  Xaa is Alanine, Threonine or Lysine

<220>
<221>  misc_feature
<222>  (24)..(24)
<223>  Xaa is Alanine or Valine

<220>
<221>  misc_feature
<222>  (25)..(25)
<223>  Xaa is Serine or Alanine

<400>  260

Xaa Val Xaa Leu Xaa Xaa Ser Gly Xaa Xaa Leu Val Xaa Pro Xaa Xaa 
1               5                   10                  15      


Ser Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa 
            20                  25  


<210>  261
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of Consensus Cluster #4 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Alanine or Threonine

<400>  261

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Xaa 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Thr Ser 
            20                  25  


<210>  262
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  262

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Thr Ser 
            20                  25  


<210>  263
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  263

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Thr Ser 
            20                  25  


<210>  264
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of Consensus Cluster #9 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Glutamate, no amino acid or Glutamine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Valine or no amino acid

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Glutamine or no amino acid

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Serine or Proline

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Glutamate or Glycine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Alanine or Threonine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Leucine or Methionine

<220>
<221>  misc_feature
<222>  (23)..(23)
<223>  Xaa is Threonine or Lysine

<400>  264

Xaa Xaa Xaa Leu Gln Gln Xaa Gly Ala Xaa Leu Val Lys Pro Gly Xaa 
1               5                   10                  15      


Ser Val Lys Xaa Ser Cys Xaa Ala Ser 
            20                  25  


<210>  265
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S14-2AH as described 
       in Table 2.

<400>  265

Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser 
            20                  25  


<210>  266
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of ITI_237H as described in
       Table 2.

<400>  266

Leu Gln Gln Ser Gly Ala Gly Leu Val Lys Pro Gly Ala Ser Val Lys 
1               5                   10                  15      


Leu Ser Cys Lys Ala Ser 
            20          


<210>  267
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of Consensus Cluster #17 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Aspartate or Glutamate

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Leucine or Valine

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa is Proline or Histidine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Lysine or Arginine

<220>
<221>  misc_feature
<222>  (23)..(23)
<223>  Xaa is Lysine or Arginine

<400>  267

Gln Ile Gln Leu Val Gln Ser Gly Pro Xaa Xaa Lys Lys Xaa Gly Glu 
1               5                   10                  15      


Thr Val Xaa Ile Ser Cys Xaa Ala Ser 
            20                  25  


<210>  268
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S15-21AH as described 
       in Table 2.

<400>  268

Gln Ile Gln Leu Val Gln Ser Gly Pro Asp Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser 
            20                  25  


<210>  269
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S20-26AH as described 
       in Table 2.

<400>  269

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Arg Ala Ser 
            20                  25  


<210>  270
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of ITI_127H as described in
       Table 2.

<400>  270

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys His Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser 
            20                  25  


<210>  271
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of ITI_128H as described in
       Table 2.

<400>  271

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys His Gly Glu 
1               5                   10                  15      


Thr Val Arg Ile Ser Cys Lys Ala Ser 
            20                  25  


<210>  272
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of Consensus Cluster #7 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Glutamine or Lysine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Alanine or Proline

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Glutamate or Glycine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Arginine or Glutamine

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Glycine or Serine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Threonine or Glutamine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Serine or Asparagine

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Valine or Leucine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Lysine or Serine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Methionine or Isoleucine

<220>
<221>  misc_feature
<222>  (21)..(21)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (23)..(23)
<223>  Xaa is Lysine or Threonine

<220>
<221>  misc_feature
<222>  (24)..(24)
<223>  Xaa is Alanine or Valine

<220>
<221>  misc_feature
<222>  (25)..(25)
<223>  Xaa is Alanine or Serine

<400>  272

Gln Val Gln Leu Xaa Gln Ser Gly Xaa Xaa Leu Val Xaa Pro Xaa Xaa 
1               5                   10                  15      


Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa 
            20                  25  


<210>  273
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  273

Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln 
1               5                   10                  15      


Asn Leu Ser Ile Thr Cys Thr Val Ser 
            20                  25  


<210>  274
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of Consensus Cluster #13 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Glutamate or Glutamine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Alanine or Glycine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Valine or Leucine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Arginine or Lysine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Alanine or Threonine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Leucine or Serine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Leucine or Valine

<220>
<221>  misc_feature
<222>  (23)..(23)
<223>  Xaa is Lysine or Threonine

<400>  274

Xaa Val Gln Leu Gln Gln Ser Gly Xaa Glu Leu Xaa Xaa Pro Gly Xaa 
1               5                   10                  15      


Xaa Val Lys Xaa Ser Cys Xaa Ala Ser 
            20                  25  


<210>  275
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S15-29AH as described 
       in Table 2.

<400>  275

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala 
1               5                   10                  15      


Leu Val Lys Leu Ser Cys Lys Ala Ser 
            20                  25  


<210>  276
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S19-24AH as described 
       in Table 2.

<400>  276

Gln Val Gln Leu Gln Gln Ser Gly Gly Glu Leu Leu Arg Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser 
            20                  25  


<210>  277
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of Consensus Cluster #18 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Glutamate or Aspartate

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Glutamine or Lysine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Aspartate or Glycine

<400>  277

Xaa Val Xaa Leu Val Glu Ser Gly Gly Xaa Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser 
            20                  25  


<210>  278
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  278

Asp Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser 
            20                  25  


<210>  279
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of Consensus Cluster #22 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Glutamine, Aspartate or Glutamate

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Glutamine or Lysine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Glutamine or Aspartate

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Glutamine or Glutamate

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Proline, Serine or Threonine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Serine, Proline or Glycine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Glutamate or Glycine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Arginine, Lysine or Glutamine

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Glycine or Serine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Alanine, Glutamine or Arginine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Serine or Proline

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Valine, Leucine or Methionine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Lysine or Serine

<220>
<221>  misc_feature
<222>  (21)..(21)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (23)..(23)
<223>  Xaa is Lysine, Threonine or Valine

<220>
<221>  misc_feature
<222>  (24)..(24)
<223>  Xaa is Alanine or Valine

<220>
<221>  misc_feature
<222>  (25)..(25)
<223>  Xaa is Serine or Threonine

<400>  279

Xaa Val Xaa Leu Xaa Xaa Xaa Gly Xaa Xaa Leu Val Xaa Pro Xaa Xaa 
1               5                   10                  15      


Xaa Xaa Xaa Leu Xaa Cys Xaa Xaa Xaa 
            20                  25  


<210>  280
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S14-21AH as described 
       in Table 2.

<400>  280

Gln Val Gln Leu Gln Gln Pro Gly Ser Glu Leu Val Arg Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Lys Ala Ser 
            20                  25  


<210>  281
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S14-27AH as described 
       in Table 2.

<400>  281

Glu Val Lys Leu Asp Glu Thr Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Pro Met Lys Leu Ser Cys Val Ala Ser 
            20                  25  


<210>  282
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of Consensus Cluster #16 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Aspartate or Glutamate

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Glutamate or Glutamine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Proline or Alanine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Glycine or Glutamate

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Valine or Methionine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Lysine or Serine

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Serine or Glycine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Glutamine or Alanine

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Leucine or Valine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Serine or Asparagine

<220>
<221>  misc_feature
<222>  (21)..(21)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (24)..(24)
<223>  Xaa is Valine or Alanine

<220>
<221>  misc_feature
<222>  (25)..(25)
<223>  Xaa is Threonine or Serine

<400>  282

Xaa Val Gln Leu Gln Xaa Ser Gly Xaa Xaa Leu Xaa Xaa Pro Xaa Xaa 
1               5                   10                  15      


Ser Xaa Xaa Leu Xaa Cys Thr Xaa Xaa 
            20                  25  


<210>  283
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of ITI_023H as described in
       Table 2.

<400>  283

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Ser Pro Gly Ala 
1               5                   10                  15      


Ser Val Asn Leu Ser Cys Thr Ala Ser 
            20                  25  


<210>  284
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of Consensus Cluster #2 as 
       described in Table 2.

<400>  284

Glu Val Gln Leu Gln Gln Ser Gly Thr Val Leu Ala Arg Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser 
            20                  25  


<210>  285
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of Consensus Cluster #11 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Tyrosine, Phenylalanine or Asparagine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Threonine, Arginine, Alanine, Isoleucine or Serine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Leucine or Phenylalanine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Threonine or Isoleucine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Serine or Tyrosine

<400>  285

Gly Xaa Xaa Xaa Xaa Asn Xaa Trp 
1               5               


<210>  286
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S14-12AH as described in Table 2.

<400>  286

Gly Asn Ile Phe Thr Asn Ser Trp 
1               5               


<210>  287
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S14-13AH as described in Table 2.

<400>  287

Gly Tyr Ile Phe Thr Asn Ser Trp 
1               5               


<210>  288
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S14-14AH as described in Table 2.

<400>  288

Gly Tyr Ile Phe Thr Asn Tyr Trp 
1               5               


<210>  289
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  289

Gly Tyr Thr Phe Thr Asn Ser Trp 
1               5               


<210>  290
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  290

Gly Tyr Ala Phe Thr Asn Ser Trp 
1               5               


<210>  291
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S20-23AH as described in Table 2.

<400>  291

Gly Tyr Thr Leu Ile Asn Ser Trp 
1               5               


<210>  292
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  292

Gly Tyr Thr Phe Thr Asn Tyr Trp 
1               5               


<210>  293
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  293

Gly Phe Thr Leu Thr Asn Tyr Trp 
1               5               


<210>  294
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  294

Gly Tyr Thr Leu Thr Asn Ser Trp 
1               5               


<210>  295
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  295

Gly Tyr Arg Phe Thr Asn Tyr Trp 
1               5               


<210>  296
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  296

Gly Tyr Arg Phe Thr Asn Ser Trp 
1               5               


<210>  297
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S20-62AH as described in Table 2.

<400>  297

Gly Tyr Ser Phe Thr Asn Tyr Trp 
1               5               


<210>  298
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of Consensus Cluster #20 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Serine, Asparagine or Aspartate

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Tyrosine or Phenylalanine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Alanine or Glycine

<400>  298

Gly Phe Thr Phe Ser Xaa Xaa Xaa 
1               5               


<210>  299
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  299

Gly Phe Thr Phe Ser Ser Phe Ala 
1               5               


<210>  300
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  300

Gly Phe Thr Phe Ser Asn Tyr Ala 
1               5               


<210>  301
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  301

Gly Phe Thr Phe Ser Ser Phe Gly 
1               5               


<210>  302
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S15-9AH as described in Table 2.

<400>  302

Gly Phe Thr Phe Ser Asp Phe Gly 
1               5               


<210>  303
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  303

Gly Phe Thr Phe Ser Ser Tyr Ala 
1               5               


<210>  304
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of Consensus Cluster #5 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Isoleucine, Threonine, Serine or Asparagine

<400>  304

Gly Phe Ser Leu Xaa Xaa Tyr Gly 
1               5               


<210>  305
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  305

Gly Phe Ser Leu Thr Thr Tyr Gly 
1               5               


<210>  306
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  306

Gly Phe Ser Leu Thr Ser Tyr Gly 
1               5               


<210>  307
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S19-18AH as described in Table 2.

<400>  307

Gly Phe Ser Leu Thr Ile Tyr Gly 
1               5               


<210>  308
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S19-22AH as described in Table 2.

<400>  308

Gly Phe Ser Leu Thr Asn Tyr Gly 
1               5               


<210>  309
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of ITI_145H as described in Table 2.

<400>  309

Gly Phe Ser Leu Ser Thr Tyr Gly 
1               5               


<210>  310
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of Consensus Cluster #23 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Phenylalanine or Tyrosine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Asparagine, Threonine or Serine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Isoleucine, Phenylalanine or Leucine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is no amino acid or Threonine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Lysine, Threonine, Serine or Asparagine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Aspartate, Serine, Isoleucine, Asparagine or Threonine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Threonine or Tyrosine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Tyrosine, Valine, Alanine, Threonine, Tryptophan, Glycine 
       or Proline

<400>  310

Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   


<210>  311
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S14-15AH as described in Table 2.

<400>  311

Gly Phe Ser Leu Thr Ser Tyr Gly 
1               5               


<210>  312
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S14-17AH as described in Table 2.

<400>  312

Gly Tyr Thr Phe Thr Asn Tyr Trp 
1               5               


<210>  313
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S14-25AH as described in Table 2.

<400>  313

Gly Tyr Thr Phe Thr Thr Tyr Pro 
1               5               


<210>  314
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S14-6AH as described in Table 2.

<400>  314

Gly Phe Thr Phe Thr Asp Tyr Tyr 
1               5               


<210>  315
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  315

Gly Phe Asn Ile Lys Asp Thr Tyr 
1               5               


<210>  316
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  316

Gly Tyr Thr Phe Thr Ser Tyr Trp 
1               5               


<210>  317
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S15-38AH as described in Table 2.

<400>  317

Gly Tyr Thr Phe Thr Ser Tyr Val 
1               5               


<210>  318
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  318

Gly Tyr Ser Ile Thr Ser Asp Tyr Ala 
1               5                   


<210>  319
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S19-25AH as described in Table 2.

<400>  319

Gly Tyr Thr Phe Ser Ser Tyr Trp 
1               5               


<210>  320
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S19-6AH as described in Table 2.

<400>  320

Gly Phe Thr Phe Asn Ile Tyr Thr 
1               5               


<210>  321
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of Consensus Cluster #21 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Tyrosine or Phenylalanine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Threonine, Alanine, Asparagine or Tyrosine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Phenylalanine or Isoleucine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Serine, Threonine, Lysine or Arginine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Threonine, Asparagine or Aspartate

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Tyrosine or Threonine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Tryptophan, Leucine or Tyrosine

<400>  321

Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5               


<210>  322
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  322

Gly Phe Asn Ile Lys Asp Thr Tyr 
1               5               


<210>  323
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S15-37AH as described in Table 2.

<400>  323

Gly Tyr Thr Phe Ser Thr Tyr Trp 
1               5               


<210>  324
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S20-58AH as described in Table 2.

<400>  324

Gly Phe Tyr Ile Lys Asp Thr Tyr 
1               5               


<210>  325
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S20-9AH as described in Table 2.

<400>  325

Gly Phe Asn Ile Arg Asp Thr Tyr 
1               5               


<210>  326
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of ITI_091H as described in Table 2.

<400>  326

Gly Phe Asn Phe Lys Asp Thr Tyr 
1               5               


<210>  327
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  327

Gly Tyr Ala Phe Thr Asn Tyr Leu 
1               5               


<210>  328
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of Consensus Cluster #10 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Tyrosine or Phenylalanine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Threonine, Alanine or Serine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Phenylalanine or Leucine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is no amino acid or Serine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is no amino acid or Threonine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Serine, Asparagine, Aspartate, Glycine or Threonine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Tyrosine or Methionine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Valine, Tryptophan, Aspartate, Tyrosine, Glycine or 
       Leucine

<400>  328

Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10  


<210>  329
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S14-10AH as described in Table 2.

<400>  329

Gly Phe Ser Leu Ser Thr Ser Gly Met Gly 
1               5                   10  


<210>  330
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S14-16AH as described in Table 2.

<400>  330

Gly Phe Thr Phe Ser Asp Tyr Tyr 
1               5               


<210>  331
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  331

Gly Tyr Thr Phe Thr Asn Tyr Trp 
1               5               


<210>  332
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  332

Gly Tyr Thr Phe Thr Ser Tyr Val 
1               5               


<210>  333
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S14-26AH as described in Table 2.

<400>  333

Gly Tyr Ala Phe Thr Asn Tyr Leu 
1               5               


<210>  334
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  334

Gly Phe Ser Leu Thr Thr Tyr Gly 
1               5               


<210>  335
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S15-40AH as described in Table 2.

<400>  335

Gly Phe Ala Phe Ser Ser Tyr Asp 
1               5               


<210>  336
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of Consensus Cluster #8 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Phenylalanine or Leucine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Tyrosine or Phenylalanine

<400>  336

Gly Tyr Thr Xaa Thr Asn Xaa Gly 
1               5               


<210>  337
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S15-15AH as described in Table 2.

<400>  337

Gly Tyr Thr Leu Thr Asn Tyr Gly 
1               5               


<210>  338
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  338

Gly Tyr Thr Phe Thr Asn Tyr Gly 
1               5               


<210>  339
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  339

Gly Tyr Thr Phe Thr Asn Phe Gly 
1               5               


<210>  340
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of Consensus Cluster #15 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Phenylalanine or Tyrosine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Threonine, Serine or Lysine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Phenylalanine or Leucine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Serine, Threonine or Asparagine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Serine, Glycine or Threonine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Tyrosine or Asparagine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Glycine, Tyrosine, Threonine, Valine or Alanine

<400>  340

Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5               


<210>  341
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S14-18AH as described in Table 2.

<400>  341

Gly Phe Thr Phe Asn Thr Asn Ala 
1               5               


<210>  342
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S14-23AH as described in Table 2.

<400>  342

Gly Tyr Ser Phe Thr Gly Tyr Tyr 
1               5               


<210>  343
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  343

Gly Phe Thr Phe Ser Ser Tyr Gly 
1               5               


<210>  344
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  344

Gly Tyr Thr Phe Thr Ser Tyr Val 
1               5               


<210>  345
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S15-25AH as described in Table 2.

<400>  345

Gly Tyr Lys Phe Asn Ser Tyr Val 
1               5               


<210>  346
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  346

Gly Phe Thr Phe Ser Ser Tyr Thr 
1               5               


<210>  347
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of Consensus Cluster #19 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Phenylalanine or Tyrosine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Serine, Threonine or Isoleucine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Leucine or Phenylalanine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Glycine or Asparagine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Tyrosine or Phenylalanine

<400>  347

Gly Xaa Xaa Xaa Thr Xaa Xaa Gly 
1               5               


<210>  348
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  348

Gly Phe Ser Leu Thr Gly Tyr Gly 
1               5               


<210>  349
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  349

Gly Tyr Ile Phe Thr Asn Tyr Gly 
1               5               


<210>  350
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  350

Gly Tyr Thr Leu Thr Asn Phe Gly 
1               5               


<210>  351
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of Consensus Cluster #14 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Tyrosine or Phenylalanine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Phenylalanine or Leucine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Aspartate, Threonine, Serine or Asparagine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Serine, Proline, Glycine, Valine or Tryptophan

<400>  351

Gly Xaa Xaa Xaa Thr Xaa Tyr Xaa 
1               5               


<210>  352
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S15-28AH as described in Table 2.

<400>  352

Gly Tyr Thr Phe Thr Thr Tyr Pro 
1               5               


<210>  353
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S15-39AH as described in Table 2.

<400>  353

Gly Tyr Thr Phe Thr Asp Tyr Ser 
1               5               


<210>  354
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of ITI_238H as described in Table 2.

<400>  354

Gly Tyr Thr Phe Thr Asp Tyr Trp 
1               5               


<210>  355
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of Consensus Cluster #6 as described in 
       Table 2.

<400>  355

Gly Phe Asn Ile Lys Asp Tyr Tyr 
1               5               


<210>  356
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of Consensus Cluster #12 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Phenylalanine or Tyrosine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Phenylalanine or Leucine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Serine, Glycine, Aspartate or Asparagine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Tyrosine or Serine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Glycine or Tryptophan

<400>  356

Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5               


<210>  357
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S15-8AH as described in Table 2.

<400>  357

Gly Tyr Thr Phe Thr Asp Ser Trp 
1               5               


<210>  358
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of Consensus Cluster #4 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Phenylalanine or Isoleucine

<400>  358

Gly Tyr Thr Xaa Thr Glu Tyr Thr 
1               5               


<210>  359
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S14-24AH as described in Table 2.

<400>  359

Gly Tyr Thr Ile Thr Glu Tyr Thr 
1               5               


<210>  360
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  360

Gly Tyr Thr Phe Thr Glu Tyr Thr 
1               5               


<210>  361
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of Consensus Cluster #9 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Phenylalanine or Tyrosine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Asparagine or Threonine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Isoleucine or Phenylalanine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Lysine or Threonine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Aspartate, Glutamate or Serine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Threonine or Tyrosine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Tyrosine, Isoleucine or Tryptophan

<400>  361

Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5               


<210>  362
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S14-2AH as described in Table 2.

<400>  362

Gly Tyr Thr Phe Thr Ser Tyr Trp 
1               5               


<210>  363
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of ITI_237H as described in Table 2.

<400>  363

Gly Tyr Thr Phe Thr Glu Tyr Ile 
1               5               


<210>  364
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of Consensus Cluster #17 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Threonine or Isoleucine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Asparagine or Aspartate

<400>  364

Gly Tyr Xaa Phe Thr Xaa Tyr Gly 
1               5               


<210>  365
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of ITI_128H as described in Table 2.

<400>  365

Gly Tyr Ile Phe Thr Asp Tyr Gly 
1               5               


<210>  366
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of Consensus Cluster #7 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Tyrosine or Phenylalanine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Phenylalanine or Leucine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Asparagine or Serine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Serine or Tyrosine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Tryptophan or Glycine

<400>  366

Gly Xaa Xaa Xaa Thr Xaa Xaa Xaa 
1               5               


<210>  367
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of Consensus Cluster #13 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Phenylalanine or Tyrosine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Asparagine or Alanine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Isoleucine or Phenylalanine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Lysine or Threonine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Aspartate or Asparagine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Aspartate, Threonine or Tyrosine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Tyrosine or Leucine

<400>  367

Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5               


<210>  368
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S15-29AH as described in Table 2.

<400>  368

Gly Phe Asn Ile Lys Asp Asp Tyr 
1               5               


<210>  369
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of Consensus Cluster #18 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Glycine or Valine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Serine or Arginine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Glycine or Threonine

<400>  369

Xaa Phe Thr Phe Ser Xaa Tyr Xaa 
1               5               


<210>  370
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S14-1AH as described in Table 2.

<400>  370

Val Phe Thr Phe Ser Arg Tyr Thr 
1               5               


<210>  371
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of Consensus Cluster #22 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Tyrosine or Phenylalanine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Phenylalanine or Isoleucine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is no amino acid or Threonine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Serine or Aspartate

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Tyrosine or Phenylalanine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Tryptophan or Alanine

<400>  371

Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   


<210>  372
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S14-27AH as described in Table 2.

<400>  372

Gly Phe Thr Phe Ser Asp Tyr Trp 
1               5               


<210>  373
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S14-5AH as described in Table 2.

<400>  373

Gly Tyr Ser Ile Thr Ser Asp Phe Ala 
1               5                   


<210>  374
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of Consensus Cluster #16 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Tyrosine or Phenylalanine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Serine or Asparagine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Threonine or no amino acid

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Serine or Lysine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Tyrosine or Threonine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Alanine or Tyrosine

<400>  374

Gly Xaa Xaa Ile Xaa Xaa Asp Xaa Xaa 
1               5                   


<210>  375
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of Consensus Cluster #2 as described in 
       Table 2.

<400>  375

Gly Tyr Ser Phe Thr Ser Tyr Trp 
1               5               


<210>  376
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of Consensus Cluster #3 as described in 
       Table 2.

<400>  376

Gly Tyr Thr Phe Thr Ser Phe Trp 
1               5               


<210>  377
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of Consensus Cluster #11 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Valine or Isoleucine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Lysine or Arginine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Glutamine or Leucine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Arginine or Tryptophan

<400>  377

Leu Gly Trp Xaa Xaa Xaa Xaa Pro Gly His Gly Leu Glu Trp Ile Gly 
1               5                   10                  15      


Asp 
    


<210>  378
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  378

Leu Gly Trp Ile Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile Gly 
1               5                   10                  15      


Asp 
    


<210>  379
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  379

Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile Gly 
1               5                   10                  15      


Asp 
    


<210>  380
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S20-32AH as described 
       in Table 2.

<400>  380

Leu Gly Trp Val Lys Gln Trp Pro Gly His Gly Leu Glu Trp Ile Gly 
1               5                   10                  15      


Asp 
    


<210>  381
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S20-7BH as described 
       in Table 2.

<400>  381

Leu Gly Trp Ile Lys Leu Arg Pro Gly His Gly Leu Glu Trp Ile Gly 
1               5                   10                  15      


Asp 
    


<210>  382
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of ITI_053H as described in
       Table 2.

<400>  382

Leu Gly Trp Val Arg Gln Arg Pro Gly His Gly Leu Glu Trp Ile Gly 
1               5                   10                  15      


Asp 
    


<210>  383
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of Consensus Cluster #20 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Serine or Histidine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Valine or Isoleucine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Threonine or Alanine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Threonine or Lysine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Arginine or Glycine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Serine or Histidine

<400>  383

Met Xaa Trp Xaa Arg Gln Xaa Pro Glu Xaa Xaa Leu Glu Trp Val Ala 
1               5                   10                  15      


Xaa 
    


<210>  384
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S14-11AH as described 
       in Table 2.

<400>  384

Met Ser Trp Ile Arg Gln Thr Pro Glu Lys Gly Leu Glu Trp Val Ala 
1               5                   10                  15      


Ser 
    


<210>  385
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  385

Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala 
1               5                   10                  15      


Ser 
    


<210>  386
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S15-10AH as described 
       in Table 2.

<400>  386

Met His Trp Ile Arg Gln Ala Pro Glu Lys Gly Leu Glu Trp Val Ala 
1               5                   10                  15      


Ser 
    


<210>  387
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  387

Met His Trp Val Arg Gln Ala Pro Glu Lys Gly Leu Glu Trp Val Ala 
1               5                   10                  15      


His 
    


<210>  388
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S15-20AH as described 
       in Table 2.

<400>  388

Met His Trp Val Arg Gln Ala Pro Glu Lys Gly Leu Glu Trp Val Ala 
1               5                   10                  15      


Ser 
    


<210>  389
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  389

Met Ser Trp Val Arg Gln Thr Pro Glu Thr Arg Leu Glu Trp Val Ala 
1               5                   10                  15      


Ser 
    


<210>  390
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of Consensus Cluster #5 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Histidine or Tyrosine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Valine or Leucine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Proline or Alanine

<400>  390

Val Xaa Trp Xaa Arg Gln Pro Xaa Gly Lys Gly Leu Glu Trp Leu Gly 
1               5                   10                  15      


Val 
    


<210>  391
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  391

Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu Gly 
1               5                   10                  15      


Val 
    


<210>  392
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S19-20BH as described 
       in Table 2.

<400>  392

Val His Trp Val Arg Gln Pro Ala Gly Lys Gly Leu Glu Trp Leu Gly 
1               5                   10                  15      


Val 
    


<210>  393
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S19-22AH as described 
       in Table 2.

<400>  393

Val His Trp Leu Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu Gly 
1               5                   10                  15      


Val 
    


<210>  394
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S19-26AH as described 
       in Table 2.

<400>  394

Val Tyr Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu Gly 
1               5                   10                  15      


Val 
    


<210>  395
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of Consensus Cluster #23 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Isoleucine, Methionine, Tryptophan or Valine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Histidine, Serine, Asparagine, Glycine or Glutamate

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Valine, Isoleucine or Methionine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Lysine or Arginine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Arginine, Lysine, Threonine, Phenylalanine, Serine or 
       Asparagine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Proline or Histidine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Glutamate or Glycine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Glutamine, Lysine, Asparagine, Methionine, Histidine or 
       Arginine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Glycine, Alanine, Lysine, Arginine or Serine

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Isoleucine, Leucine, Methionine or Valine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Glycine or Alanine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Arginine, Tyrosine, Phenylalanine, Glutamate, Aspartate, 
       Valine or Asparagine

<400>  395

Xaa Xaa Trp Xaa Xaa Gln Xaa Xaa Xaa Xaa Xaa Leu Glu Trp Xaa Xaa 
1               5                   10                  15      


Xaa 
    


<210>  396
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  396

Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu Gly 
1               5                   10                  15      


Val 
    


<210>  397
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  397

Ile Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile Gly 
1               5                   10                  15      


Asp 
    


<210>  398
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  398

Ile Glu Trp Met Lys Gln Asn His Gly Lys Ser Leu Glu Trp Ile Gly 
1               5                   10                  15      


Asn 
    


<210>  399
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S14-6AH as described 
       in Table 2.

<400>  399

Met Ser Trp Val Arg Gln Thr Pro Gly Lys Ala Leu Glu Trp Leu Gly 
1               5                   10                  15      


Phe 
    


<210>  400
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  400

Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly 
1               5                   10                  15      


Arg 
    


<210>  401
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  401

Met Asn Trp Val Lys Gln Arg Pro Gly Arg Gly Leu Glu Trp Ile Gly 
1               5                   10                  15      


Arg 
    


<210>  402
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  402

Met His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile Gly 
1               5                   10                  15      


Tyr 
    


<210>  403
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  403

Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp Met Gly 
1               5                   10                  15      


Tyr 
    


<210>  404
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S19-25AH as described 
       in Table 2.

<400>  404

Ile Glu Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile Gly 
1               5                   10                  15      


Glu 
    


<210>  405
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S19-6AH as described 
       in Table 2.

<400>  405

Met Ser Trp Val Arg Gln Ser Pro Glu Met Arg Leu Glu Trp Val Ala 
1               5                   10                  15      


Glu 
    


<210>  406
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of ITI_021H as described in
       Table 2.

<400>  406

Trp Asn Trp Val Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp Val Gly 
1               5                   10                  15      


Tyr 
    


<210>  407
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of ITI_200H as described in
       Table 2.

<400>  407

Ile His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly 
1               5                   10                  15      


Arg 
    


<210>  408
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of Consensus Cluster #21 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Methionine, Isoleucine or Valine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Asparagine, Glutamate or Histidine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Valine or Leucine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Lysine or Asparagine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Glutamine or Glutamate

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Glycine or Glutamate

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Arginine or Glutamine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Glutamate or Alanine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Arginine or Valine

<400>  408

Xaa Xaa Trp Xaa Xaa Xaa Arg Pro Xaa Xaa Gly Leu Xaa Trp Ile Gly 
1               5                   10                  15      


Xaa 
    


<210>  409
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  409

Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Ala Trp Ile Gly 
1               5                   10                  15      


Arg 
    


<210>  410
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  410

Met His Trp Val Asn Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly 
1               5                   10                  15      


Arg 
    


<210>  411
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S20-49AH as described 
       in Table 2.

<400>  411

Val His Trp Val Lys Glu Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly 
1               5                   10                  15      


Arg 
    


<210>  412
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S20-52AH as described 
       in Table 2.

<400>  412

Ile His Trp Leu Asn Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly 
1               5                   10                  15      


Arg 
    


<210>  413
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  413

Ile Glu Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly 
1               5                   10                  15      


Val 
    


<210>  414
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of Consensus Cluster #10 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Methionine, Isoleucine, Leucine or Valine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Histidine, Asparagine, Serine, Tyrosine or Glutamate

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Valine or Isoleucine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Lysine or Arginine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Lysine, Arginine, Threonine, Proline or Serine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Proline or Serine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Glycine or Glutamate

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Glutamine, Histidine or Lysine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Glycine or Arginine

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Isoleucine, Valine or Leucine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Glycine or Alanine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Tyrosine, Valine, Asparagine, Aspartate, Threonine or 
       Histidine

<400>  414

Xaa Xaa Trp Xaa Xaa Gln Xaa Xaa Xaa Xaa Xaa Leu Glu Trp Xaa Xaa 
1               5                   10                  15      


Xaa 
    


<210>  415
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S14-10AH as described 
       in Table 2.

<400>  415

Val Ser Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu Trp Leu Ala 
1               5                   10                  15      


His 
    


<210>  416
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S14-16AH as described 
       in Table 2.

<400>  416

Met Tyr Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala 
1               5                   10                  15      


Thr 
    


<210>  417
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S14-20AH as described 
       in Table 2.

<400>  417

Ile Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly 
1               5                   10                  15      


Asn 
    


<210>  418
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S14-28AH as described 
       in Table 2.

<400>  418

Leu Ser Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile Gly 
1               5                   10                  15      


Asp 
    


<210>  419
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  419

Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala 
1               5                   10                  15      


Tyr 
    


<210>  420
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S20-21AH as described 
       in Table 2.

<400>  420

Met His Trp Val Arg Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly 
1               5                   10                  15      


Val 
    


<210>  421
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of ITI_180H as described in
       Table 2.

<400>  421

Ile His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu Gly 
1               5                   10                  15      


Val 
    


<210>  422
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of Consensus Cluster #8 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Methionine or Valine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Glycine or Aspartate

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Methionine or Valine

<400>  422

Xaa Asn Trp Val Lys Gln Ala Pro Gly Lys Xaa Leu Lys Trp Xaa Gly 
1               5                   10                  15      


Trp 
    


<210>  423
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  423

Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Val Gly 
1               5                   10                  15      


Trp 
    


<210>  424
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  424

Val Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly 
1               5                   10                  15      


Trp 
    


<210>  425
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  425

Val Asn Trp Val Lys Gln Ala Pro Gly Lys Asp Leu Lys Trp Met Gly 
1               5                   10                  15      


Trp 
    


<210>  426
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  426

Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly 
1               5                   10                  15      


Trp 
    


<210>  427
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of Consensus Cluster #15 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Methionine or Valine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Serine, Histidine or Asparagine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Arginine or Lysine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Threonine, Serine, Lysine or Alanine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Proline or Histidine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Aspartate, Glycine or Glutamate

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Lysine or Glutamine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Arginine, Serine or Glycine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Leucine or Proline

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Valine, Isoleucine or Leucine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Alanine or Glycine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Threonine, Tyrosine, Aspartate, Serine, Valine, Glutamate 
       or Arginine

<400>  427

Xaa Xaa Trp Val Xaa Gln Xaa Xaa Xaa Xaa Xaa Xaa Glu Trp Xaa Xaa 
1               5                   10                  15      


Xaa 
    


<210>  428
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S14-18AH as described 
       in Table 2.

<400>  428

Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala 
1               5                   10                  15      


Arg 
    


<210>  429
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S14-23AH as described 
       in Table 2.

<400>  429

Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly 
1               5                   10                  15      


Tyr 
    


<210>  430
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  430

Met Ser Trp Val Arg Gln Thr Pro Asp Lys Arg Leu Glu Trp Val Ala 
1               5                   10                  15      


Thr 
    


<210>  431
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S15-25AH as described 
       in Table 2.

<400>  431

Met His Trp Val Lys Gln Lys Pro Gly Gln Gly Pro Glu Trp Ile Gly 
1               5                   10                  15      


Tyr 
    


<210>  432
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S20-53AH as described 
       in Table 2.

<400>  432

Met Ser Trp Val Arg Gln Ser Pro Glu Lys Arg Leu Glu Trp Val Ala 
1               5                   10                  15      


Glu 
    


<210>  433
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S20-55AH as described 
       in Table 2.

<400>  433

Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala 
1               5                   10                  15      


Asp 
    


<210>  434
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of Consensus Cluster #19 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Valine or Methionine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Valine or Methionine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Arginine or Lysine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Proline, Serine or Alanine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Glycine or Aspartate

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Glutamate or Lysine

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Leucine or Methionine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Methionine or Tryptophan

<400>  434

Xaa Asn Trp Xaa Xaa Gln Xaa Pro Gly Lys Xaa Leu Xaa Trp Xaa Gly 
1               5                   10                  15      


Xaa 
    


<210>  435
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  435

Val Asn Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu Gly 
1               5                   10                  15      


Met 
    


<210>  436
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S15-32AH as described 
       in Table 2.

<400>  436

Val Asn Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu Gly 
1               5                   10                  15      


Met 
    


<210>  437
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  437

Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly 
1               5                   10                  15      


Trp 
    


<210>  438
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of ITI_100H as described in
       Table 2.

<400>  438

Met Asn Trp Met Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly 
1               5                   10                  15      


Trp 
    


<210>  439
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of ITI_101H as described in
       Table 2.

<400>  439

Met Asn Trp Met Lys Gln Ala Pro Gly Lys Asp Leu Lys Trp Met Gly 
1               5                   10                  15      


Trp 
    


<210>  440
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of Consensus Cluster #14 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Methionine, Isoleucine or Valine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Histidine, Glutamate or Asparagine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Valine or Methionine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Lysine or Arginine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Alanine, Asparagine, Serine, Lysine or Arginine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Proline or Histidine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Lysine or Glutamine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Glycine or Serine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Lysine or Glutamate

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Methionine, Isoleucine or Leucine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Tryptophan, Asparagine, Valine, Tyrosine or Alanine

<400>  440

Xaa Xaa Trp Xaa Xaa Gln Xaa Xaa Gly Xaa Xaa Leu Xaa Trp Xaa Gly 
1               5                   10                  15      


Xaa 
    


<210>  441
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S15-39AH as described 
       in Table 2.

<400>  441

Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly 
1               5                   10                  15      


Trp 
    


<210>  442
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  442

Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly 
1               5                   10                  15      


Ala 
    


<210>  443
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of Consensus Cluster #6 as 
       described in Table 2.

<400>  443

Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly 
1               5                   10                  15      


Trp 
    


<210>  444
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of Consensus Cluster #12 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Methionine, Valine or Isoleucine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Serine, Asparagine or Glycine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Arginine or Lysine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Threonine, Proline or Arginine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Glutamate or Glycine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Lysine or Histidine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Arginine or Glycine

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Valine, Leucine or Isoleucine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Alanine or Glycine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Threonine, Methionine or Aspartate

<400>  444

Xaa Xaa Trp Val Xaa Gln Xaa Pro Xaa Xaa Xaa Leu Glu Trp Xaa Xaa 
1               5                   10                  15      


Xaa 
    


<210>  445
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S15-26AH as described 
       in Table 2.

<400>  445

Met Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile Ala 
1               5                   10                  15      


Asp 
    


<210>  446
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  446

Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala 
1               5                   10                  15      


Thr 
    


<210>  447
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of Consensus Cluster #4 as 
       described in Table 2.

<400>  447

Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly 
1               5                   10                  15      


Gly 
    


<210>  448
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of Consensus Cluster #9 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Methionine or Isoleucine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Histidine or Tyrosine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Proline or Serine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Glutamate or Glycine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Arginine, Tryptophan or Aspartate

<400>  448

Xaa Xaa Trp Val Lys Gln Arg Xaa Xaa Gln Gly Leu Glu Trp Ile Gly 
1               5                   10                  15      


Xaa 
    


<210>  449
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S14-2AH as described 
       in Table 2.

<400>  449

Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly 
1               5                   10                  15      


Asp 
    


<210>  450
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of ITI_237H as described in
       Table 2.

<400>  450

Ile Tyr Trp Val Lys Gln Arg Ser Gly Gln Gly Leu Glu Trp Ile Gly 
1               5                   10                  15      


Trp 
    


<210>  451
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of Consensus Cluster #17 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Methionine or Isoleucine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Aspartate or Glycine

<400>  451

Xaa Asn Trp Val Lys Gln Ala Pro Gly Lys Xaa Leu Lys Trp Met Gly 
1               5                   10                  15      


Trp 
    


<210>  452
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S15-21AH as described 
       in Table 2.

<400>  452

Met Asn Trp Val Lys Gln Ala Pro Gly Lys Asp Leu Lys Trp Met Gly 
1               5                   10                  15      


Trp 
    


<210>  453
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  453

Ile Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly 
1               5                   10                  15      


Trp 
    


<210>  454
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of Consensus Cluster #7 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Isoleucine or Valine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Glycine or Histidine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Valine or Isoleucine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Lysine or Arginine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Arginine or Serine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Histidine or Lysine

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Isoleucine or Leucine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Aspartate or Valine

<400>  454

Xaa Xaa Trp Xaa Xaa Gln Xaa Pro Gly Xaa Gly Leu Glu Trp Xaa Gly 
1               5                   10                  15      


Xaa 
    


<210>  455
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  455

Val His Trp Ile Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu Gly 
1               5                   10                  15      


Val 
    


<210>  456
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of Consensus Cluster #13 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Methionine or Isoleucine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Histidine or Glutamate

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Glutamate or Glycine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Tryptophan, Arginine or Valine

<400>  456

Xaa Xaa Trp Val Lys Gln Arg Pro Xaa Gln Gly Leu Glu Trp Ile Gly 
1               5                   10                  15      


Xaa 
    


<210>  457
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of Consensus Cluster #18 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Aspartate or Glutamate

<400>  457

Met Ser Trp Val Arg Gln Thr Pro Xaa Lys Arg Leu Glu Trp Val Ala 
1               5                   10                  15      


Thr 
    


<210>  458
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of Consensus Cluster #22 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Methionine or Tryptophan

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Histidine or Asparagine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Valine or Isoleucine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Lysine or Arginine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Arginine, Phenylalanine or Serine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Glycine or Glutamate

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Glutamine, Asparagine or Lysine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Glycine or Lysine

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Isoleucine, Methionine or Valine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Glycine or Alanine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Asparagine, Tyrosine or Glutamine

<400>  458

Xaa Xaa Trp Xaa Xaa Gln Xaa Pro Xaa Xaa Xaa Leu Glu Trp Xaa Xaa 
1               5                   10                  15      


Xaa 
    


<210>  459
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S14-21AH as described 
       in Table 2.

<400>  459

Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly 
1               5                   10                  15      


Asn 
    


<210>  460
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S14-27AH as described 
       in Table 2.

<400>  460

Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala 
1               5                   10                  15      


Gln 
    


<210>  461
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of Consensus Cluster #16 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Tryptophan or Isoleucine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Asparagine or Histidine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Isoleucine or Valine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Arginine or Lysine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Phenylalanine or Arginine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Glycine or Glutamate

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Asparagine or Glutamine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Lysine or Glycine

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Methionine or Isoleucine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Tyrosine or Lysine

<400>  461

Xaa Xaa Trp Xaa Xaa Gln Xaa Pro Xaa Xaa Xaa Leu Glu Trp Xaa Gly 
1               5                   10                  15      


Xaa 
    


<210>  462
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of ITI_023H as described in
       Table 2.

<400>  462

Ile His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly 
1               5                   10                  15      


Lys 
    


<210>  463
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of Consensus Cluster #2 as 
       described in Table 2.

<400>  463

Met His Trp Leu Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly 
1               5                   10                  15      


Ala 
    


<210>  464
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of Consensus Cluster #11 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Isoleucine or Valine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Threonine, Asparagine, Isoleucine or Alanine

<400>  464

Xaa Tyr Pro Gly Gly Gly Tyr Xaa 
1               5               


<210>  465
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  465

Val Tyr Pro Gly Gly Gly Tyr Asn 
1               5               


<210>  466
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  466

Ile Tyr Pro Gly Gly Gly Tyr Asn 
1               5               


<210>  467
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  467

Ile Tyr Pro Gly Gly Gly Tyr Ile 
1               5               


<210>  468
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  468

Ile Tyr Pro Gly Gly Gly Tyr Thr 
1               5               


<210>  469
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S20-30AH as described in Table 2.

<400>  469

Ile Tyr Pro Gly Gly Gly Tyr Ala 
1               5               


<210>  470
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of Consensus Cluster #20 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is no amino acid, Glycine or Serine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Glycine, Threonine or Serine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Aspartate, Asparagine, Serine, Lysine or Threonine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Threonine, Serine or Isoleucine

<400>  470

Ile Xaa Xaa Gly Xaa Xaa Xaa Xaa 
1               5               


<210>  471
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S14-11AH as described in Table 2.

<400>  471

Ile Thr Thr Gly Gly Ser Ser 
1               5           


<210>  472
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S14-8AH as described in Table 2.

<400>  472

Ile Ser Thr Gly Gly Thr Thr Ser 
1               5               


<210>  473
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  473

Ile Ser Ser Gly Ser Ser Thr Ile 
1               5               


<210>  474
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  474

Ile Ser Ser Gly Gly Asn Thr 
1               5           


<210>  475
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S20-1AH as described in Table 2.

<400>  475

Ile Ser Ser Gly Gly Asp Thr 
1               5           


<210>  476
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S20-37AH as described in Table 2.

<400>  476

Ile Ser Ser Gly Gly Lys Thr 
1               5           


<210>  477
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  477

Ile Ser Ser Gly Gly Ser Thr 
1               5           


<210>  478
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of Consensus Cluster #5 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Isoleucine or Threonine

<400>  478

Ile Trp Ala Gly Gly Ile Xaa 
1               5           


<210>  479
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  479

Ile Trp Ala Gly Gly Ile Thr 
1               5           


<210>  480
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S19-18AH as described in Table 2.

<400>  480

Ile Trp Ala Gly Gly Ile Ile 
1               5           


<210>  481
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of Consensus Cluster #23 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Isoleucine or Phenylalanine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Aspartate, Asparagine, Arginine, Serine, Tyrosine, 
       Leucine, Tryptophan or Histidine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Proline, Asparagine, Tyrosine or Serine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Alanine, Tyrosine, Glutamine, Serine or Glycine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is no amino acid or Alanine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is no amino acid or Asparagine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Asparagine, Alanine, no amino acid, Glycine, Serine or 
       Aspartate

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Glycine, Aspartate, Tyrosine or Serine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Asparagine, Glycine, Threonine, Histidine, Tyrosine, 
       Serine, Glutamate or Aspartate

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Isoleucine or Threonine

<400>  481

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10  


<210>  482
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S14-15AH as described in Table 2.

<400>  482

Ile Trp Ser Gly Gly Ser Thr 
1               5           


<210>  483
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S14-17AH as described in Table 2.

<400>  483

Ile Tyr Pro Gly Gly Gly Tyr Thr 
1               5               


<210>  484
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S14-25AH as described in Table 2.

<400>  484

Phe His Pro Tyr Asn Asp Asp Thr 
1               5               


<210>  485
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S14-6AH as described in Table 2.

<400>  485

Ile Arg Asn Gln Ala Asn Ala Tyr Thr Thr 
1               5                   10  


<210>  486
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  486

Ile Asp Pro Ala Asn Gly Asn Thr 
1               5               


<210>  487
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S15-30AH as described in Table 2.

<400>  487

Ile Asp Pro Ser Asp Ser Glu Thr 
1               5               


<210>  488
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S15-38AH as described in Table 2.

<400>  488

Ile Asn Pro Tyr Asn Asp Gly Thr 
1               5               


<210>  489
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S19-11AH as described in Table 2.

<400>  489

Ile Ser Tyr Ser Gly Asn Thr 
1               5           


<210>  490
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S19-25AH as described in Table 2.

<400>  490

Ile Leu Pro Gly Ser Gly Ser Thr 
1               5               


<210>  491
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S19-6AH as described in Table 2.

<400>  491

Ile Ser Ser Gly Gly Ser His Thr 
1               5               


<210>  492
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of ITI_021H as described in Table 2.

<400>  492

Ile Ser Tyr Ser Gly Ser Thr 
1               5           


<210>  493
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of ITI_173H as described in Table 2.

<400>  493

Ile Asn Tyr Ser Gly Asn Thr 
1               5           


<210>  494
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of ITI_200H as described in Table 2.

<400>  494

Ile Asp Pro Ala Asn Gly Asn Ile 
1               5               


<210>  495
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of Consensus Cluster #21 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Aspartate, Asparagine or Alanine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Serine, Glycine or Alanine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Aspartate, Serine or Asparagine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Serine, Glycine or Aspartate

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Glutamate, Glycine, Asparagine, Lysine, Tyrosine or 
       Arginine

<400>  495

Ile Xaa Pro Xaa Xaa Xaa Xaa Thr 
1               5               


<210>  496
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  496

Ile Ala Pro Ala Asn Gly Arg Thr 
1               5               


<210>  497
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S15-17AH as described in Table 2.

<400>  497

Ile Ala Pro Ala Asn Gly Lys Thr 
1               5               


<210>  498
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  498

Ile Ala Pro Ala Asn Gly Tyr Thr 
1               5               


<210>  499
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  499

Ile Asp Pro Ala Asn Gly Asn Thr 
1               5               


<210>  500
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S15-37AH as described in Table 2.

<400>  500

Ile Asp Pro Ser Asp Ser Glu Thr 
1               5               


<210>  501
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  501

Ile Asp Pro Ala Asn Gly Lys Thr 
1               5               


<210>  502
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  502

Ile Asp Pro Ala Asn Asp Asn Thr 
1               5               


<210>  503
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  503

Ile Asn Pro Gly Ser Gly Gly Thr 
1               5               


<210>  504
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of Consensus Cluster #10 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Asparagine, Aspartate, Tyrosine, Serine or Tryptophan

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Proline, Serine, Aspartate or Tryptophan

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Tyrosine, Serine, Glycine or Aspartate

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Asparagine, Aspartate, Glycine, no amino acid or Serine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Aspartate, Serine or Glycine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Glycine, Phenylalanine, Tyrosine, Serine, Aspartate or 
       Asparagine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Threonine or Lysine

<400>  504

Ile Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5               


<210>  505
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S14-10AH as described in Table 2.

<400>  505

Ile Tyr Trp Asp Asp Asp Lys 
1               5           


<210>  506
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S14-16AH as described in Table 2.

<400>  506

Ile Ser Asp Gly Gly Ser Tyr Thr 
1               5               


<210>  507
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S14-20AH as described in Table 2.

<400>  507

Ile Tyr Pro Ser Asp Ser Tyr Thr 
1               5               


<210>  508
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  508

Ile Asn Pro Tyr Asn Asp Gly Thr 
1               5               


<210>  509
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S15-33AH as described in Table 2.

<400>  509

Ile Trp Ser Gly Gly Asn Thr 
1               5           


<210>  510
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S15-40AH as described in Table 2.

<400>  510

Ile Ser Ser Gly Gly Gly Ser Thr 
1               5               


<210>  511
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  511

Ile Trp Ser Gly Gly Ser Thr 
1               5           


<210>  512
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S20-21AH as described in Table 2.

<400>  512

Ile Asp Pro Ser Asp Ser Phe Thr 
1               5               


<210>  513
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of Consensus Cluster #8 as described in 
       Table 2.

<400>  513

Ile Asn Thr Tyr Thr Gly Glu Pro 
1               5               


<210>  514
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of Consensus Cluster #15 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Serine, Asparagine, Tryptophan or Arginine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Serine, Cysteine, Asparagine, Proline or Arginine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Glycine, Tyrosine or Lysine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is no amino acid or Serine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is no amino acid or Asparagine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Glycine, Asparagine or no amino acid

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Serine, Glycine, Aspartate or Tyrosine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Tyrosine, Alanine, Serine or Aspartate

<400>  514

Ile Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Thr 
1               5                   10  


<210>  515
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S14-18AH as described in Table 2.

<400>  515

Ile Arg Ser Lys Ser Asn Asn Tyr Ala Thr 
1               5                   10  


<210>  516
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S14-23AH as described in Table 2.

<400>  516

Ile Ser Cys Tyr Asn Gly Ala Thr 
1               5               


<210>  517
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  517

Ile Ser Ser Gly Gly Ser Tyr Thr 
1               5               


<210>  518
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  518

Ile Asn Pro Tyr Asn Asp Asp Thr 
1               5               


<210>  519
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  519

Ile Ser Asn Gly Gly Gly Ser Thr 
1               5               


<210>  520
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S20-51AH as described in Table 2.

<400>  520

Ile Trp Arg Gly Gly Ser Thr 
1               5           


<210>  521
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S20-59AH as described in Table 2.

<400>  521

Ile Ser Ser Gly Ser Ser Thr 
1               5           


<210>  522
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of Consensus Cluster #19 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Tryptophan or Asparagine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Glycine or Threonine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Aspartate or Tyrosine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is no amino acid or Threonine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Glycine, Serine or Glutamate

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Threonine or Proline

<400>  522

Ile Xaa Xaa Xaa Xaa Gly Xaa Xaa 
1               5               


<210>  523
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S15-19AH as described in Table 2.

<400>  523

Ile Trp Gly Asp Gly Gly Thr 
1               5           


<210>  524
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S15-32AH as described in Table 2.

<400>  524

Ile Trp Gly Asp Gly Ser Thr 
1               5           


<210>  525
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of Consensus Cluster #14 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Isoleucine or Phenylalanine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Asparagine, Histidine, Tryptophan or Aspartate

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Threonine, Proline or Arginine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Glutamate, Tyrosine, Glycine or Serine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Threonine, Asparagine, no amino acid or Aspartate

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Glycine, Aspartate or Serine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Glutamate, Aspartate, Serine, Glycine or Tyrosine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Proline or Threonine

<400>  525

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5               


<210>  526
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S15-13AH as described in Table 2.

<400>  526

Ile Trp Arg Gly Gly Ser Thr 
1               5           


<210>  527
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S15-28AH as described in Table 2.

<400>  527

Phe His Pro Tyr Asn Asp Asp Thr 
1               5               


<210>  528
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S15-39AH as described in Table 2.

<400>  528

Ile Asn Thr Glu Thr Gly Glu Pro 
1               5               


<210>  529
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of ITI_238H as described in Table 2.

<400>  529

Ile Asp Thr Ser Asp Ser Tyr Thr 
1               5               


<210>  530
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of Consensus Cluster #6 as described in 
       Table 2.

<400>  530

Ile Asp Pro Glu Asn Gly Asp Thr 
1               5               


<210>  531
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of Consensus Cluster #12 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Serine, Tryptophan or Tyrosine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Glycine or Proline

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Glycine or Aspartate

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Glycine or no amino acid

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Serine or Glycine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Tyrosine or Asparagine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Threonine or Serine

<400>  531

Ile Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5               


<210>  532
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S15-26AH as described in Table 2.

<400>  532

Ile Tyr Pro Gly Gly Gly Tyr Ser 
1               5               


<210>  533
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S19-4AH as described in Table 2.

<400>  533

Ile Trp Gly Asp Gly Asn Thr 
1               5           


<210>  534
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S20-56AH as described in Table 2.

<400>  534

Ile Ser Gly Gly Gly Ser Tyr Thr 
1               5               


<210>  535
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of Consensus Cluster #4 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Tyrosine or Asparagine

<400>  535

Ile Asn Pro Xaa Asn Gly Gly Thr 
1               5               


<210>  536
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  536

Ile Asn Pro Asn Asn Gly Gly Thr 
1               5               


<210>  537
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S14-4AH as described in Table 2.

<400>  537

Ile Asn Pro Tyr Asn Gly Gly Thr 
1               5               


<210>  538
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of Consensus Cluster #9 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Isoleucine or Phenylalanine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Aspartate or Tyrosine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Alanine or Glycine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Asparagine or Serine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Glycine or Aspartate

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Asparagine or Serine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Threonine or Isoleucine

<400>  538

Xaa Xaa Pro Xaa Xaa Xaa Xaa Xaa 
1               5               


<210>  539
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S14-2AH as described in Table 2.

<400>  539

Ile Tyr Pro Gly Ser Asp Ser Thr 
1               5               


<210>  540
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of ITI_237H as described in Table 2.

<400>  540

Phe Tyr Pro Gly Ser Gly Ser Ile 
1               5               


<210>  541
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of Consensus Cluster #17 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Glycine or Arginine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Glutamate or Lysine

<400>  541

Ile Asn Thr Tyr Thr Xaa Xaa Pro 
1               5               


<210>  542
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of ITI_127H as described in Table 2.

<400>  542

Ile Asn Thr Tyr Thr Arg Glu Pro 
1               5               


<210>  543
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of ITI_128H as described in Table 2.

<400>  543

Ile Asn Thr Tyr Thr Gly Lys Pro 
1               5               


<210>  544
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of Consensus Cluster #7 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Tyrosine or Tryptophan

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Proline or Serine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Glycine or no amino acid

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Alanine or Glycine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Tyrosine or Glycine

<400>  544

Ile Xaa Xaa Gly Xaa Xaa Xaa Thr 
1               5               


<210>  545
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S15-6AH as described in Table 2.

<400>  545

Ile Tyr Pro Gly Gly Ala Tyr Thr 
1               5               


<210>  546
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  546

Ile Trp Ser Gly Gly Gly Thr 
1               5           


<210>  547
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of Consensus Cluster #13 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Aspartate or Asparagine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Glutamate, Alanine or Glycine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Asparagine or Serine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Glycine or Aspartate

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Asparagine or Glycine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Threonine or Isoleucine

<400>  547

Ile Xaa Pro Xaa Xaa Xaa Xaa Xaa 
1               5               


<210>  548
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S15-29AH as described in Table 2.

<400>  548

Ile Asp Pro Glu Asn Gly Asn Thr 
1               5               


<210>  549
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S19-24AH as described in Table 2.

<400>  549

Ile Asn Pro Gly Ser Gly Gly Ile 
1               5               


<210>  550
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of Consensus Cluster #18 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Serine or Tyrosine

<400>  550

Ile Ser Ser Gly Gly Ser Xaa Thr 
1               5               


<210>  551
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  551

Ile Ser Ser Gly Gly Ser Tyr Thr 
1               5               


<210>  552
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of ITI_203H as described in Table 2.

<400>  552

Ile Ser Ser Gly Gly Ser Ser Thr 
1               5               


<210>  553
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of Consensus Cluster #22 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Tyrosine, Valine or Arginine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Proline, Tyrosine or Asparagine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Glycine, Serine or Lysine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is no amino acid or Proline

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is no amino acid or Tyrosine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Serine, no amino acid or Asparagine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Glycine or Tyrosine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Serine or Glutamate

<400>  553

Ile Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Thr 
1               5                   10  


<210>  554
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S14-21AH as described in Table 2.

<400>  554

Ile Tyr Pro Gly Ser Gly Ser Thr 
1               5               


<210>  555
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S14-27AH as described in Table 2.

<400>  555

Ile Arg Asn Lys Pro Tyr Asn Tyr Glu Thr 
1               5                   10  


<210>  556
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S14-5AH as described in Table 2.

<400>  556

Ile Val Tyr Ser Gly Ser Thr 
1               5           


<210>  557
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of Consensus Cluster #16 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Alanine or Aspartate

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Tyrosine or Proline

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Serine or Alanine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is no amino acid or Asparagine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Glycine or Asparagine

<400>  557

Ile Xaa Xaa Xaa Xaa Gly Xaa Thr 
1               5               


<210>  558
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S19-1AH as described in Table 2.

<400>  558

Ile Ala Tyr Ser Gly Gly Thr 
1               5           


<210>  559
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of Consensus Cluster #2 as described in 
       Table 2.

<400>  559

Ile Tyr Pro Gly Asn Ser Asp Thr 
1               5               


<210>  560
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of Consensus Cluster #3 as described in 
       Table 2.

<400>  560

Ile Ser Pro Gly Asn Ser Glu Thr 
1               5               


<210>  561
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of Consensus Cluster #11 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Lysine, Asparagine, Isoleucine or Methionine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Asparagine or Lysine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Lysine or Arginine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Threonine or Isoleucine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa is Alanine, Valine or Isoleucine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Serine or Alanine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Serine, Asparagine or Threonine

<220>
<221>  misc_feature
<222>  (23)..(23)
<223>  Xaa is Methionine or Isoleucine

<220>
<221>  misc_feature
<222>  (26)..(26)
<223>  Xaa is Serine, Asparagine or Glycine

<220>
<221>  misc_feature
<222>  (27)..(27)
<223>  Xaa is Arginine, Serine or Glycine

<220>
<221>  misc_feature
<222>  (31)..(31)
<223>  Xaa is Glutamate or Glycine

<220>
<221>  misc_feature
<222>  (34)..(34)
<223>  Xaa is Glycine or Alanine

<400>  561

Xaa Tyr Asn Glu Xaa Phe Xaa Gly Lys Ala Xaa Leu Xaa Xaa Asp Xaa 
1               5                   10                  15      


Ser Xaa Xaa Thr Ala Tyr Xaa Gln Leu Xaa Xaa Leu Thr Ser Xaa Asp 
            20                  25                  30          


Ser Xaa Val Tyr Phe Cys 
        35              


<210>  562
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S14-12AH as described 
       in Table 2.

<400>  562

Lys Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ile Asp Thr 
1               5                   10                  15      


Ser Ala Ser Thr Ala Tyr Met Gln Leu Ser Arg Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Gly Val Tyr Phe Cys 
        35              


<210>  563
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S14-13AH as described 
       in Table 2.

<400>  563

Lys Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ile Asp Thr 
1               5                   10                  15      


Ser Ala Ser Thr Ala Tyr Met Gln Leu Ser Arg Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Phe Cys 
        35              


<210>  564
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S14-14AH as described 
       in Table 2.

<400>  564

Lys Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Thr 
1               5                   10                  15      


Ser Ala Ser Thr Ala Tyr Met Gln Leu Ser Arg Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Phe Cys 
        35              


<210>  565
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  565

Lys Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Phe Cys 
        35              


<210>  566
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S15-35AH as described 
       in Table 2.

<400>  566

Lys Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Gln Leu Gly Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Phe Cys 
        35              


<210>  567
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-23AH as described 
       in Table 2.

<400>  567

Lys Tyr Asn Glu Lys Phe Lys Gly Lys Ala Ile Leu Thr Ala Asp Thr 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Phe Cys 
        35              


<210>  568
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-24AH as described 
       in Table 2.

<400>  568

Ile Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Ser 
1               5                   10                  15      


Ser Ala Thr Thr Ala Tyr Ile Gln Leu Asn Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Phe Cys 
        35              


<210>  569
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  569

Asn Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr 
1               5                   10                  15      


Ser Ser Asn Thr Ala Tyr Met Gln Leu Ser Gly Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Phe Cys 
        35              


<210>  570
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  570

Ile Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Thr 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Phe Cys 
        35              


<210>  571
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-32CH as described 
       in Table 2.

<400>  571

Ile Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ile Asp Thr 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Phe Cys 
        35              


<210>  572
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-33AH as described 
       in Table 2.

<400>  572

Lys Tyr Asn Glu Asn Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Arg Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Gly Val Tyr Phe Cys 
        35              


<210>  573
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  573

Lys Tyr Asn Glu Lys Phe Arg Gly Lys Ala Thr Leu Thr Ala Asp Thr 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Phe Cys 
        35              


<210>  574
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-43AH as described 
       in Table 2.

<400>  574

Ile Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Ser 
1               5                   10                  15      


Ser Ala Thr Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Phe Cys 
        35              


<210>  575
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-50AH as described 
       in Table 2.

<400>  575

Lys Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr 
1               5                   10                  15      


Ser Ser Asn Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Phe Cys 
        35              


<210>  576
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-60AH as described 
       in Table 2.

<400>  576

Lys Tyr Asn Glu Asn Phe Lys Gly Lys Ala Thr Leu Ser Ala Asp Thr 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Gly Asp 
            20                  25                  30          


Ser Ala Val Tyr Phe Cys 
        35              


<210>  577
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-62AH as described 
       in Table 2.

<400>  577

Met Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Thr 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Phe Cys 
        35              


<210>  578
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_047H as described in
       Table 2.

<400>  578

Lys Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Gly Val Tyr Phe Cys 
        35              


<210>  579
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of Consensus Cluster #20 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Phenylalanine or Tyrosine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Tyrosine, Serine or Phenylalanine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Arginine, Proline, Serine or Alanine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Serine, Asparagine or Threonine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Valine or Leucine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Alanine or Glycine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Aspartate or Asparagine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Valine, Alanine or Proline

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Arginine, Glycine or Lysine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Aspartate or Asparagine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Isoleucine or Threonine

<220>
<221>  misc_feature
<222>  (21)..(21)
<223>  Xaa is Leucine or Valine

<220>
<221>  misc_feature
<222>  (22)..(22)
<223>  Xaa is Tyrosine or Phenylalanine

<220>
<221>  misc_feature
<222>  (26)..(26)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (29)..(29)
<223>  Xaa is Arginine or Lysine

<220>
<221>  misc_feature
<222>  (37)..(37)
<223>  Xaa is Phenylalanine, Tyrosine or Alanine

<400>  579

Xaa Xaa Xaa Asp Xaa Xaa Lys Xaa Arg Phe Thr Ile Ser Arg Asp Xaa 
1               5                   10                  15      


Xaa Xaa Xaa Xaa Xaa Xaa Leu Gln Met Xaa Ser Leu Xaa Ser Glu Asp 
            20                  25                  30          


Thr Ala Met Tyr Xaa Cys 
        35              


<210>  580
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S14-11AH as described 
       in Table 2.

<400>  580

Tyr Ser Pro Asp Ser Leu Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 
1               5                   10                  15      


Val Arg Asn Ile Val Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp 
            20                  25                  30          


Thr Ala Met Tyr Ala Cys 
        35              


<210>  581
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S14-8AH as described 
       in Table 2.

<400>  581

Tyr Tyr Ser Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 
1               5                   10                  15      


Ala Arg Asn Ile Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp 
            20                  25                  30          


Thr Ala Met Tyr Tyr Cys 
        35              


<210>  582
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S15-10AH as described 
       in Table 2.

<400>  582

Tyr Phe Ala Asp Thr Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 
1               5                   10                  15      


Pro Lys Asn Thr Leu Phe Leu Gln Met Thr Ser Leu Arg Ser Glu Asp 
            20                  25                  30          


Thr Ala Met Tyr Tyr Cys 
        35              


<210>  583
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  583

Tyr Tyr Ala Asp Thr Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 
1               5                   10                  15      


Pro Lys Asn Thr Leu Phe Leu Gln Met Thr Ser Leu Arg Ser Glu Asp 
            20                  25                  30          


Thr Ala Met Tyr Tyr Cys 
        35              


<210>  584
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  584

Phe Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 
1               5                   10                  15      


Val Arg Asp Ile Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp 
            20                  25                  30          


Thr Ala Met Tyr Phe Cys 
        35              


<210>  585
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  585

Phe Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp 
1               5                   10                  15      


Val Arg Asp Ile Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp 
            20                  25                  30          


Thr Ala Met Tyr Phe Cys 
        35              


<210>  586
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  586

Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 
1               5                   10                  15      


Val Arg Asn Ile Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp 
            20                  25                  30          


Thr Ala Met Tyr Phe Cys 
        35              


<210>  587
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-14BH as described 
       in Table 2.

<400>  587

Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp 
1               5                   10                  15      


Val Arg Asn Ile Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp 
            20                  25                  30          


Thr Ala Met Tyr Phe Cys 
        35              


<210>  588
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-14CH as described 
       in Table 2.

<400>  588

Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 
1               5                   10                  15      


Val Arg Asp Ile Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp 
            20                  25                  30          


Thr Ala Met Tyr Phe Cys 
        35              


<210>  589
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-1AH as described 
       in Table 2.

<400>  589

Phe Tyr Arg Asp Ser Val Lys Ala Arg Phe Thr Ile Ser Arg Asp Asp 
1               5                   10                  15      


Val Arg Asp Ile Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp 
            20                  25                  30          


Thr Ala Met Tyr Phe Cys 
        35              


<210>  590
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-6AH as described 
       in Table 2.

<400>  590

Tyr Tyr Pro Asp Asn Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 
1               5                   10                  15      


Ala Gly Asn Ile Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp 
            20                  25                  30          


Thr Ala Met Tyr Tyr Cys 
        35              


<210>  591
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of Consensus Cluster #5 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Asparagine or Serine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Serine, Asparagine or Threonine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Serine, Asparagine, Threonine or Isoleucine

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa is Lysine, Asparagine, Glutamine, Isoleucine, Threonine or 
       Serine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Serine or Phenylalanine

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Lysine or Arginine

<220>
<221>  misc_feature
<222>  (30)..(30)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (31)..(31)
<223>  Xaa is Aspartate or Glycine

<220>
<221>  misc_feature
<222>  (35)..(35)
<223>  Xaa is Methionine or Isoleucine

<400>  591

Xaa Tyr Asn Ser Ala Leu Met Ser Arg Leu Xaa Ile Xaa Xaa Asp Asn 
1               5                   10                  15      


Xaa Xaa Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln Xaa Xaa Asp 
            20                  25                  30          


Thr Ala Xaa Tyr Tyr Cys 
        35              


<210>  592
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S19-12BH as described 
       in Table 2.

<400>  592

Asn Tyr Asn Ser Ala Leu Met Ser Arg Leu Thr Ile Ser Asn Asp Asn 
1               5                   10                  15      


Ser Arg Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp 
            20                  25                  30          


Thr Ala Met Tyr Tyr Cys 
        35              


<210>  593
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  593

Asn Tyr Asn Ser Ala Leu Met Ser Arg Leu Ser Ile Ser Asn Asp Asn 
1               5                   10                  15      


Ser Arg Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp 
            20                  25                  30          


Thr Ala Met Tyr Tyr Cys 
        35              


<210>  594
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S19-14BH as described 
       in Table 2.

<400>  594

Asn Tyr Asn Ser Ala Leu Met Ser Arg Leu Ser Ile Asn Asn Asp Asn 
1               5                   10                  15      


Ser Arg Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp 
            20                  25                  30          


Thr Ala Met Tyr Tyr Cys 
        35              


<210>  595
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  595

Asn Tyr Asn Ser Ala Leu Met Ser Arg Leu Ser Ile Ser Lys Asp Asn 
1               5                   10                  15      


Ser Lys Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln Thr Gly Asp 
            20                  25                  30          


Thr Ala Met Tyr Tyr Cys 
        35              


<210>  596
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S19-18AH as described 
       in Table 2.

<400>  596

Asn Tyr Asn Ser Ala Leu Met Ser Arg Leu Ser Ile Ser Lys Asp Asn 
1               5                   10                  15      


Ser Lys Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln Ser Asp Asp 
            20                  25                  30          


Thr Ala Met Tyr Tyr Cys 
        35              


<210>  597
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  597

Asn Tyr Asn Ser Ala Leu Met Ser Arg Leu Ser Ile Ser Lys Asp Asn 
1               5                   10                  15      


Ser Lys Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp 
            20                  25                  30          


Thr Ala Met Tyr Tyr Cys 
        35              


<210>  598
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S19-20BH as described 
       in Table 2.

<400>  598

Asn Tyr Asn Ser Ala Leu Met Ser Arg Leu Ser Ile Ile Gln Asp Asn 
1               5                   10                  15      


Ser Lys Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp 
            20                  25                  30          


Thr Ala Met Tyr Tyr Cys 
        35              


<210>  599
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S19-21AH as described 
       in Table 2.

<400>  599

Asn Tyr Asn Ser Ala Leu Met Ser Arg Leu Ser Ile Ser Thr Asp Asn 
1               5                   10                  15      


Ser Arg Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp 
            20                  25                  30          


Thr Ala Met Tyr Tyr Cys 
        35              


<210>  600
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S19-27AH as described 
       in Table 2.

<400>  600

Ser Tyr Asn Ser Ala Leu Met Ser Arg Leu Ser Ile Ser Ser Asp Asn 
1               5                   10                  15      


Ser Arg Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp 
            20                  25                  30          


Thr Ala Met Tyr Tyr Cys 
        35              


<210>  601
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  601

Asn Tyr Asn Ser Ala Leu Met Ser Arg Leu Ser Ile Ser Lys Asp Asn 
1               5                   10                  15      


Phe Lys Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp 
            20                  25                  30          


Thr Ala Ile Tyr Tyr Cys 
        35              


<210>  602
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_146H as described in
       Table 2.

<400>  602

Asn Tyr Asn Ser Ala Leu Met Ser Arg Leu Asn Ile Ser Lys Asp Asn 
1               5                   10                  15      


Ser Lys Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln Ser Asp Asp 
            20                  25                  30          


Thr Ala Met Tyr Tyr Cys 
        35              


<210>  603
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_162H as described in
       Table 2.

<400>  603

Asn Tyr Asn Ser Ala Leu Met Ser Arg Leu Ser Ile Asn Ile Asp Asn 
1               5                   10                  15      


Ser Lys Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp 
            20                  25                  30          


Thr Ala Met Tyr Tyr Cys 
        35              


<210>  604
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  604

Asn Tyr Asn Ser Ala Leu Met Ser Arg Leu Asn Ile Asn Lys Asp Asn 
1               5                   10                  15      


Ser Lys Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln Thr Gly Asp 
            20                  25                  30          


Thr Ala Met Tyr Tyr Cys 
        35              


<210>  605
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_165H as described in
       Table 2.

<400>  605

Asn Tyr Asn Ser Ala Leu Met Ser Arg Leu Ser Ile Thr Lys Asp Asn 
1               5                   10                  15      


Ser Lys Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp 
            20                  25                  30          


Thr Ala Met Tyr Tyr Cys 
        35              


<210>  606
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of Consensus Cluster #23 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Lysine, Glutamate, Glycine, Tyrosine, Asparagine, 
       Aspartate, Histidine or Serine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Tyrosine or Phenylalanine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Aspartate, Asparagine, Serine or Proline

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Proline, Glutamate, Valine, Aspartate, Alanine or 
       Glutamine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Lysine, Serine, Threonine or Alanine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Phenylalanine, Valine or Leucine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Glutamine, Lysine, Threonine or Isoleucine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Glycine, Serine, Cysteine or Aspartate

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Lysine or Arginine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Alanine, Phenylalanine, Isoleucine or Leucine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Threonine, Serine or Lysine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Isoleucine, Leucine or Phenylalanine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Methionine, Threonine or Serine

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa is Alanine, Serine, Arginine, Lysine or Valine

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Aspartate or Glutamate

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Threonine, Lysine, Asparagine or Serine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Serine or Alanine

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Serine, Glutamine or Lysine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Asparagine or Serine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Threonine, Isoleucine or Glutamine

<220>
<221>  misc_feature
<222>  (21)..(21)
<223>  Xaa is Alanine, Leucine, Phenylalanine or Valine

<220>
<221>  misc_feature
<222>  (22)..(22)
<223>  Xaa is Tyrosine or Phenylalanine

<220>
<221>  misc_feature
<222>  (23)..(23)
<223>  Xaa is Leucine, Methionine, Phenylalanine or Isoleucine

<220>
<221>  misc_feature
<222>  (24)..(24)
<223>  Xaa is Glutamine, Glutamate or Lysine

<220>
<221>  misc_feature
<222>  (25)..(25)
<223>  Xaa is Leucine or Methionine

<220>
<221>  misc_feature
<222>  (26)..(26)
<223>  Xaa is Serine or Asparagine

<220>
<221>  misc_feature
<222>  (27)..(27)
<223>  Xaa is Serine, Threonine or Arginine

<220>
<221>  misc_feature
<222>  (28)..(28)
<223>  Xaa is Leucine or Valine

<220>
<221>  misc_feature
<222>  (29)..(29)
<223>  Xaa is Threonine, Arginine or Glutamine

<220>
<221>  misc_feature
<222>  (30)..(30)
<223>  Xaa is Serine, Valine, Alanine or Threonine

<220>
<221>  misc_feature
<222>  (31)..(31)
<223>  Xaa is Glutamate or Aspartate

<220>
<221>  misc_feature
<222>  (33)..(33)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (35)..(35)
<223>  Xaa is Valine, Threonine, Isoleucine or Methionine

<400>  606

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10                  15      


Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp 
            20                  25                  30          


Xaa Ala Xaa Tyr Tyr Cys 
        35              


<210>  607
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S14-15AH as described 
       in Table 2.

<400>  607

Asp Tyr Asn Ala Ala Phe Ile Cys Arg Leu Ser Ile Ser Lys Asp Ser 
1               5                   10                  15      


Ser Lys Ser Gln Val Phe Phe Lys Met Asn Ser Leu Gln Ala Asp Asp 
            20                  25                  30          


Thr Ala Met Tyr Tyr Cys 
        35              


<210>  608
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  608

Asn Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Ile Tyr Tyr Cys 
        35              


<210>  609
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  609

Lys Tyr Asn Glu Lys Phe Lys Gly Lys Ala Lys Leu Thr Val Glu Lys 
1               5                   10                  15      


Ser Ser Ser Thr Val Tyr Leu Glu Leu Ser Arg Leu Thr Ser Asp Asp 
            20                  25                  30          


Ser Ala Val Tyr Tyr Cys 
        35              


<210>  610
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S14-6AH as described 
       in Table 2.

<400>  610

Glu Tyr Ser Val Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 
1               5                   10                  15      


Ser Gln Ser Ile Leu Tyr Leu Gln Met Asn Thr Leu Arg Val Glu Asp 
            20                  25                  30          


Ser Ala Thr Tyr Tyr Cys 
        35              


<210>  611
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  611

Lys Phe Asp Pro Lys Phe Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr 
1               5                   10                  15      


Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Thr Ala Val Tyr Tyr Cys 
        35              


<210>  612
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  612

His Tyr Asn Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr Val Asp Lys 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Ile Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Tyr Cys 
        35              


<210>  613
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  613

Lys Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Tyr Cys 
        35              


<210>  614
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  614

Gly Tyr Asn Pro Ser Leu Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr 
1               5                   10                  15      


Ser Lys Asn Gln Phe Phe Leu Gln Leu Asn Ser Val Thr Ser Glu Asp 
            20                  25                  30          


Thr Ala Thr Tyr Tyr Cys 
        35              


<210>  615
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S19-25AH as described 
       in Table 2.

<400>  615

Asn Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Phe Thr Ala Asp Thr 
1               5                   10                  15      


Ser Ser Asn Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Tyr Cys 
        35              


<210>  616
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S19-6AH as described 
       in Table 2.

<400>  616

Tyr Tyr Pro Asp Thr Val Thr Gly Arg Phe Thr Ile Ser Arg Asp Asn 
1               5                   10                  15      


Ala Lys Asn Thr Leu Tyr Leu Glu Met Ser Ser Leu Arg Ser Glu Asp 
            20                  25                  30          


Thr Ala Ile Tyr Tyr Cys 
        35              


<210>  617
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  617

Lys Tyr Asp Pro Lys Phe Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr 
1               5                   10                  15      


Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Thr Ala Val Tyr Tyr Cys 
        35              


<210>  618
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_021H as described in
       Table 2.

<400>  618

Ser Tyr Asn Pro Ser Leu Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr 
1               5                   10                  15      


Ser Lys Asn Gln Phe Phe Leu Gln Leu Asn Ser Val Thr Thr Glu Asp 
            20                  25                  30          


Thr Ala Thr Tyr Tyr Cys 
        35              


<210>  619
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_200H as described in
       Table 2.

<400>  619

Lys Tyr Asp Pro Lys Phe Gln Gly Lys Ala Thr Ile Met Ala Asp Thr 
1               5                   10                  15      


Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Thr Ala Val Tyr Tyr Cys 
        35              


<210>  620
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of Consensus Cluster #21 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Histidine, Asparagine or Lysine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Tyrosine or Phenylalanine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Asparagine, Aspartate or Alanine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Glutamine, Glutamate or Proline

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Lysine, Arginine or Glutamine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Aspartate, Glycine or Valine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Lysine or Arginine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Leucine or Isoleucine

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa is Valine, Alanine or Threonine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Lysine, Threonine or Serine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Serine or Asparagine

<220>
<221>  misc_feature
<222>  (21)..(21)
<223>  Xaa is Alanine or Valine

<220>
<221>  misc_feature
<222>  (23)..(23)
<223>  Xaa is Isoleucine, Methionine or Leucine

<220>
<221>  misc_feature
<222>  (24)..(24)
<223>  Xaa is Glutamine or Histidine

<220>
<221>  misc_feature
<222>  (27)..(27)
<223>  Xaa is Serine or Arginine

<220>
<221>  misc_feature
<222>  (31)..(31)
<223>  Xaa is Glutamate or Aspartate

<220>
<221>  misc_feature
<222>  (33)..(33)
<223>  Xaa is Serine, Threonine, Asparagine or Alanine

<220>
<221>  misc_feature
<222>  (36)..(36)
<223>  Xaa is Tyrosine or Phenylalanine

<220>
<221>  misc_feature
<222>  (37)..(37)
<223>  Xaa is Tyrosine or Phenylalanine

<400>  620

Xaa Xaa Xaa Xaa Lys Phe Xaa Xaa Xaa Ala Thr Xaa Thr Xaa Asp Xaa 
1               5                   10                  15      


Ser Ser Xaa Thr Xaa Tyr Xaa Xaa Leu Ser Xaa Leu Thr Ser Xaa Asp 
            20                  25                  30          


Xaa Ala Val Xaa Xaa Cys 
        35              


<210>  621
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S15-1AH as described 
       in Table 2.

<400>  621

Lys Tyr Asp Pro Lys Phe Gln Gly Lys Ala Thr Ile Thr Thr Asp Thr 
1               5                   10                  15      


Ser Ser Asn Thr Ala Tyr Leu His Leu Ser Arg Leu Thr Ser Glu Asp 
            20                  25                  30          


Thr Ala Val Tyr Tyr Cys 
        35              


<210>  622
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S15-3AH as described 
       in Table 2.

<400>  622

Lys Tyr Asp Pro Lys Phe Gln Gly Lys Ala Thr Ile Thr Thr Asp Thr 
1               5                   10                  15      


Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Thr Ala Val Tyr Tyr Cys 
        35              


<210>  623
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-10AH as described 
       in Table 2.

<400>  623

Lys Tyr Ala Pro Lys Phe Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr 
1               5                   10                  15      


Ser Ser Asn Thr Val Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Thr Ala Val Tyr Tyr Cys 
        35              


<210>  624
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  624

Lys Tyr Ala Pro Lys Phe Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr 
1               5                   10                  15      


Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Thr Ala Val Tyr Tyr Cys 
        35              


<210>  625
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-17AH as described 
       in Table 2.

<400>  625

Lys Tyr Ala Pro Lys Phe Gln Asp Lys Ala Thr Ile Thr Ala Asp Thr 
1               5                   10                  15      


Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Thr Ala Val Tyr Tyr Cys 
        35              


<210>  626
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-49AH as described 
       in Table 2.

<400>  626

Lys Tyr Ala Pro Lys Phe Gln Val Lys Ala Thr Ile Thr Ala Asp Thr 
1               5                   10                  15      


Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Asn Ala Val Tyr Tyr Cys 
        35              


<210>  627
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-52AH as described 
       in Table 2.

<400>  627

Lys Phe Ala Pro Lys Phe Gln Asp Lys Ala Thr Ile Thr Ala Asp Thr 
1               5                   10                  15      


Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Thr Ala Val Tyr Tyr Cys 
        35              


<210>  628
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-58AH as described 
       in Table 2.

<400>  628

Lys Tyr Ala Pro Lys Phe Gln Asp Lys Ala Thr Ile Thr Ala Asp Ser 
1               5                   10                  15      


Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Thr Ala Val Tyr Tyr Cys 
        35              


<210>  629
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-9AH as described 
       in Table 2.

<400>  629

Lys Tyr Ala Pro Lys Phe Gln Gly Arg Ala Thr Ile Thr Ala Asp Thr 
1               5                   10                  15      


Ser Ser Asn Thr Ala Tyr Leu His Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Thr Ala Val Tyr Tyr Cys 
        35              


<210>  630
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_091H as described in
       Table 2.

<400>  630

Lys Tyr Ala Pro Lys Phe Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr 
1               5                   10                  15      


Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Ala Ala Val Phe Tyr Cys 
        35              


<210>  631
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_122H as described in
       Table 2.

<400>  631

Asn Tyr Asn Glu Lys Phe Arg Gly Lys Ala Thr Leu Thr Ala Asp Lys 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Asp Asp 
            20                  25                  30          


Ser Ala Val Tyr Phe Cys 
        35              


<210>  632
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of Consensus Cluster #10 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Lysine, Asparagine, Tyrosine, Arginine or Aspartate

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Asparagine or Proline

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Glutamate, Glutamine, Aspartate, Proline or Alanine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Lysine, Serine, Threonine, Alanine or Proline

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Phenylalanine, Valine or Leucine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Lysine, Arginine or Isoleucine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Glycine, Aspartate or Serine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Lysine or Arginine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Alanine, Phenylalanine or Leucine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Leucine or Isoleucine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa is Serine, Valine, Alanine, Arginine or Lysine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Lysine, Threonine or Asparagine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Serine or Alanine

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Serine, Lysine or Arginine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Serine or Asparagine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Threonine, Asparagine or Glutamine

<220>
<221>  misc_feature
<222>  (21)..(21)
<223>  Xaa is Alanine, Leucine or Valine

<220>
<221>  misc_feature
<222>  (22)..(22)
<223>  Xaa is Tyrosine or Phenylalanine

<220>
<221>  misc_feature
<222>  (23)..(23)
<223>  Xaa is Methionine, Leucine or Phenylalanine

<220>
<221>  misc_feature
<222>  (24)..(24)
<223>  Xaa is Glutamate, Arginine, Glutamine or Lysine

<220>
<221>  misc_feature
<222>  (25)..(25)
<223>  Xaa is Leucine, Methionine or Isoleucine

<220>
<221>  misc_feature
<222>  (26)..(26)
<223>  Xaa is Serine, Threonine or Asparagine

<220>
<221>  misc_feature
<222>  (27)..(27)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (28)..(28)
<223>  Xaa is Leucine, Proline or Valine

<220>
<221>  misc_feature
<222>  (29)..(29)
<223>  Xaa is Threonine, Lysine, Aspartate or Glutamine

<220>
<221>  misc_feature
<222>  (30)..(30)
<223>  Xaa is Serine, Threonine or Alanine

<220>
<221>  misc_feature
<222>  (31)..(31)
<223>  Xaa is Glutamate, Alanine, Asparagine, Aspartate or Serine

<220>
<221>  misc_feature
<222>  (33)..(33)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (35)..(35)
<223>  Xaa is Valine, Methionine, Threonine or Isoleucine

<220>
<221>  misc_feature
<222>  (36)..(36)
<223>  Xaa is Tyrosine or Cysteine

<220>
<221>  misc_feature
<222>  (37)..(37)
<223>  Xaa is Tyrosine or Phenylalanine

<400>  632

Xaa Tyr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa 
1               5                   10                  15      


Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp 
            20                  25                  30          


Xaa Ala Xaa Xaa Xaa Cys 
        35              


<210>  633
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S14-10AH as described 
       in Table 2.

<400>  633

Arg Tyr Asn Pro Ser Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr 
1               5                   10                  15      


Ser Arg Asn Gln Val Phe Leu Lys Ile Thr Ser Val Asp Thr Ala Asp 
            20                  25                  30          


Thr Ala Thr Tyr Tyr Cys 
        35              


<210>  634
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S14-16AH as described 
       in Table 2.

<400>  634

Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 
1               5                   10                  15      


Ala Lys Asn Asn Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp 
            20                  25                  30          


Thr Ala Met Tyr Tyr Cys 
        35              


<210>  635
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S14-20AH as described 
       in Table 2.

<400>  635

Asn Tyr Asn Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr Val Asp Lys 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Pro Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Tyr Cys 
        35              


<210>  636
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S14-26AH as described 
       in Table 2.

<400>  636

Lys Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Asp Asp 
            20                  25                  30          


Ser Ala Val Tyr Phe Cys 
        35              


<210>  637
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S14-28AH as described 
       in Table 2.

<400>  637

Asn Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Cys Phe Cys 
        35              


<210>  638
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S15-33AH as described 
       in Table 2.

<400>  638

Asp Tyr Asn Pro Ala Phe Ile Ser Arg Leu Ser Ile Ser Lys Asp Asn 
1               5                   10                  15      


Ser Lys Ser Gln Val Phe Phe Lys Met Asn Thr Leu Gln Ala Ser Asp 
            20                  25                  30          


Thr Ala Ile Tyr Tyr Cys 
        35              


<210>  639
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  639

Tyr Tyr Pro Asp Thr Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 
1               5                   10                  15      


Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp 
            20                  25                  30          


Thr Ala Met Tyr Tyr Cys 
        35              


<210>  640
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  640

Asp Tyr Asn Ala Ala Phe Ile Ser Arg Leu Ser Ile Ser Lys Asp Asn 
1               5                   10                  15      


Ser Lys Ser Gln Val Phe Phe Lys Met Asn Ser Leu Gln Ala Asn Asp 
            20                  25                  30          


Thr Ala Ile Tyr Tyr Cys 
        35              


<210>  641
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-21AH as described 
       in Table 2.

<400>  641

Asn Tyr Asn Gln Ser Phe Arg Gly Lys Ala Thr Leu Thr Val Asp Thr 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Arg Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Phe Cys 
        35              


<210>  642
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_131H as described in
       Table 2.

<400>  642

Asp Tyr Asn Ala Pro Phe Ile Ser Arg Leu Ser Ile Ser Lys Asp Asn 
1               5                   10                  15      


Ser Lys Ser Gln Val Phe Phe Lys Met Asn Ser Leu Gln Ala Asn Asp 
            20                  25                  30          


Thr Ala Ile Tyr Tyr Cys 
        35              


<210>  643
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_180H as described in
       Table 2.

<400>  643

Asp Tyr Asn Ala Ala Phe Ile Ser Arg Leu Ser Ile Thr Lys Asp Lys 
1               5                   10                  15      


Ser Lys Ser Gln Val Phe Phe Lys Met Asn Ser Leu Gln Ala Asn Asp 
            20                  25                  30          


Thr Ala Ile Tyr Tyr Cys 
        35              


<210>  644
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of Consensus Cluster #8 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Aspartate or Alanine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Aspartate or Glutamate

<220>
<221>  misc_feature
<222>  (24)..(24)
<223>  Xaa is Glutamine or Arginine

<220>
<221>  misc_feature
<222>  (33)..(33)
<223>  Xaa is Threonine, Methionine or Serine

<220>
<221>  misc_feature
<222>  (35)..(35)
<223>  Xaa is Threonine or Serine

<400>  644

Thr Tyr Xaa Xaa Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr 
1               5                   10                  15      


Ser Ala Ser Thr Ala Tyr Leu Xaa Ile Asn Asn Leu Lys Asn Glu Asp 
            20                  25                  30          


Xaa Ala Xaa Tyr Phe Cys 
        35              


<210>  645
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  645

Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr 
1               5                   10                  15      


Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp 
            20                  25                  30          


Met Ala Thr Tyr Phe Cys 
        35              


<210>  646
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S15-7AH as described 
       in Table 2.

<400>  646

Thr Tyr Ala Glu Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr 
1               5                   10                  15      


Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp 
            20                  25                  30          


Met Ala Thr Tyr Phe Cys 
        35              


<210>  647
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  647

Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr 
1               5                   10                  15      


Ser Ala Ser Thr Ala Tyr Leu Arg Ile Asn Asn Leu Lys Asn Glu Asp 
            20                  25                  30          


Thr Ala Thr Tyr Phe Cys 
        35              


<210>  648
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S19-3AH as described 
       in Table 2.

<400>  648

Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr 
1               5                   10                  15      


Ser Ala Ser Thr Ala Tyr Leu Arg Ile Asn Asn Leu Lys Asn Glu Asp 
            20                  25                  30          


Ser Ala Thr Tyr Phe Cys 
        35              


<210>  649
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S19-8AH as described 
       in Table 2.

<400>  649

Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr 
1               5                   10                  15      


Ser Ala Ser Thr Ala Tyr Leu Arg Ile Asn Asn Leu Lys Asn Glu Asp 
            20                  25                  30          


Thr Ala Ser Tyr Phe Cys 
        35              


<210>  650
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  650

Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr 
1               5                   10                  15      


Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp 
            20                  25                  30          


Thr Ala Thr Tyr Phe Cys 
        35              


<210>  651
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_083H as described in
       Table 2.

<400>  651

Thr Tyr Asp Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr 
1               5                   10                  15      


Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp 
            20                  25                  30          


Thr Ala Thr Tyr Phe Cys 
        35              


<210>  652
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of Consensus Cluster #15 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Tyrosine, Serine, Asparagine or Aspartate

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Tyrosine or Cysteine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Proline, Asparagine or Alanine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Aspartate, Glutamine, Glutamate or Alanine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Serine, Lysine, Threonine or Alanine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Valine or Phenylalanine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Lysine, Methionine or Threonine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Glycine, Serine or Aspartate

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Arginine or Lysine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Phenylalanine, Alanine or Leucine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Isoleucine, Phenylalanine or Leucine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa is Arginine, Valine, Serine or Lysine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Asparagine, Threonine, Lysine or Aspartate

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Alanine or Serine

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Lysine, Serine, Arginine or Glutamine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Asparagine or Serine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Threonine, Isoleucine, Glutamine or Methionine

<220>
<221>  misc_feature
<222>  (21)..(21)
<223>  Xaa is Leucine, Alanine or Valine

<220>
<221>  misc_feature
<222>  (22)..(22)
<223>  Xaa is Tyrosine or Phenylalanine

<220>
<221>  misc_feature
<222>  (23)..(23)
<223>  Xaa is Leucine, Methionine or Phenylalanine

<220>
<221>  misc_feature
<222>  (24)..(24)
<223>  Xaa is Glutamine, Glutamate, Aspartate or Lysine

<220>
<221>  misc_feature
<222>  (25)..(25)
<223>  Xaa is Methionine, Phenylalanine or Leucine

<220>
<221>  misc_feature
<222>  (26)..(26)
<223>  Xaa is Serine or Asparagine

<220>
<221>  misc_feature
<222>  (27)..(27)
<223>  Xaa is Serine, Arginine or Asparagine

<220>
<221>  misc_feature
<222>  (29)..(29)
<223>  Xaa is Lysine, Threonine, Arginine or Glutamine

<220>
<221>  misc_feature
<222>  (30)..(30)
<223>  Xaa is Serine, Alanine or Threonine

<220>
<221>  misc_feature
<222>  (31)..(31)
<223>  Xaa is Glutamate or Aspartate

<220>
<221>  misc_feature
<222>  (33)..(33)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (35)..(35)
<223>  Xaa is Methionine, Valine or Isoleucine

<400>  652

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa 
1               5                   10                  15      


Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa Asp 
            20                  25                  30          


Xaa Ala Xaa Tyr Tyr Cys 
        35              


<210>  653
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S14-18AH as described 
       in Table 2.

<400>  653

Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp 
1               5                   10                  15      


Ser Gln Ser Met Leu Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp 
            20                  25                  30          


Thr Ala Met Tyr Tyr Cys 
        35              


<210>  654
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S14-23AH as described 
       in Table 2.

<400>  654

Ser Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Phe Thr Val Asp Thr 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Gln Phe Asn Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Tyr Cys 
        35              


<210>  655
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  655

Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 
1               5                   10                  15      


Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp 
            20                  25                  30          


Thr Ala Met Tyr Tyr Cys 
        35              


<210>  656
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S15-14AH as described 
       in Table 2.

<400>  656

Asn Cys Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Tyr Cys 
        35              


<210>  657
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S15-25AH as described 
       in Table 2.

<400>  657

Asn Cys Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Tyr Cys 
        35              


<210>  658
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S15-5AH as described 
       in Table 2.

<400>  658

Asn Cys Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Asp Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Tyr Cys 
        35              


<210>  659
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  659

Asp Tyr Asn Ala Ala Phe Met Ser Arg Leu Ser Ile Thr Lys Asp Asn 
1               5                   10                  15      


Ser Lys Ser Gln Val Phe Phe Lys Met Asn Ser Leu Gln Ala Asp Asp 
            20                  25                  30          


Thr Ala Ile Tyr Tyr Cys 
        35              


<210>  660
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-53AH as described 
       in Table 2.

<400>  660

Tyr Tyr Pro Asp Thr Val Thr Gly Arg Phe Thr Ile Ser Arg Asp Asn 
1               5                   10                  15      


Ala Lys Asn Thr Leu Tyr Leu Glu Met Ser Ser Leu Arg Ser Glu Asp 
            20                  25                  30          


Thr Ala Met Tyr Tyr Cys 
        35              


<210>  661
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-59AH as described 
       in Table 2.

<400>  661

Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 
1               5                   10                  15      


Ala Arg Asn Ile Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp 
            20                  25                  30          


Thr Ala Met Tyr Tyr Cys 
        35              


<210>  662
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of Consensus Cluster #19 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Aspartate or Threonine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Asparagine or Alanine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Serine, Aspartate or Glycine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Alanine or Aspartate

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Leucine or Phenylalanine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Serine or Glycine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Leucine or Phenylalanine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Serine or Alanine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Isoleucine or Phenylalanine

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa is Lysine or Leucine

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Aspartate or Glutamate

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Asparagine or Threonine

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Lysine or Alanine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Glutamine or Threonine

<220>
<221>  misc_feature
<222>  (21)..(21)
<223>  Xaa is Valine, Isoleucine or Alanine

<220>
<221>  misc_feature
<222>  (22)..(22)
<223>  Xaa is Phenylalanine or Tyrosine

<220>
<221>  misc_feature
<222>  (24)..(24)
<223>  Xaa is Lysine or Glutamine

<220>
<221>  misc_feature
<222>  (25)..(25)
<223>  Xaa is Methionine or Isoleucine

<220>
<221>  misc_feature
<222>  (27)..(27)
<223>  Xaa is Serine or Asparagine

<220>
<221>  misc_feature
<222>  (28)..(28)
<223>  Xaa is Leucine or Valine

<220>
<221>  misc_feature
<222>  (29)..(29)
<223>  Xaa is Glutamine or Lysine

<220>
<221>  misc_feature
<222>  (30)..(30)
<223>  Xaa is Threonine or Asparagine

<220>
<221>  misc_feature
<222>  (31)..(31)
<223>  Xaa is Aspartate or Glutamate

<220>
<221>  misc_feature
<222>  (33)..(33)
<223>  Xaa is Threonine or Methionine

<220>
<221>  misc_feature
<222>  (35)..(35)
<223>  Xaa is Arginine or Threonine

<220>
<221>  misc_feature
<222>  (37)..(37)
<223>  Xaa is Tyrosine or Phenylalanine

<400>  662

Xaa Tyr Xaa Xaa Xaa Xaa Lys Xaa Arg Xaa Xaa Xaa Ser Xaa Xaa Xaa 
1               5                   10                  15      


Ser Xaa Ser Xaa Xaa Xaa Leu Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Asp 
            20                  25                  30          


Xaa Ala Xaa Tyr Xaa Cys 
        35              


<210>  663
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  663

Asp Tyr Asn Ser Ala Leu Lys Ser Arg Leu Ser Ile Ser Lys Asp Asn 
1               5                   10                  15      


Ser Lys Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp 
            20                  25                  30          


Thr Ala Arg Tyr Tyr Cys 
        35              


<210>  664
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S15-32AH as described 
       in Table 2.

<400>  664

Asp Tyr Asn Ser Ala Leu Lys Ser Arg Leu Ser Ile Ser Lys Asp Asn 
1               5                   10                  15      


Ser Lys Ser Gln Ile Phe Leu Lys Met Asn Ser Val Gln Thr Glu Asp 
            20                  25                  30          


Thr Ala Arg Tyr Tyr Cys 
        35              


<210>  665
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-12AH as described 
       in Table 2.

<400>  665

Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr 
1               5                   10                  15      


Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Asp Asp 
            20                  25                  30          


Met Ala Thr Tyr Phe Cys 
        35              


<210>  666
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  666

Thr Tyr Ala Gly Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr 
1               5                   10                  15      


Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp 
            20                  25                  30          


Thr Ala Thr Tyr Phe Cys 
        35              


<210>  667
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of Consensus Cluster #14 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Threonine, Lysine, Aspartate or Serine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Alanine or Asparagine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Aspartate, Glutamate, Alanine or Glutamine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Aspartate, Lysine or Alanine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Lysine or Methionine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Glycine or Serine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Arginine or Lysine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Leucine, Alanine or Phenylalanine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Alanine, Lysine, Serine or Threonine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Phenylalanine, Leucine or Isoleucine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa is Leucine, Valine, Lysine or Serine

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Glutamate or Aspartate

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Threonine, Lysine, Asparagine or Glutamate

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Alanine, Serine or Lysine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Threonine or Glutamine

<220>
<221>  misc_feature
<222>  (21)..(21)
<223>  Xaa is Alanine or Valine

<220>
<221>  misc_feature
<222>  (22)..(22)
<223>  Xaa is Phenylalanine or Tyrosine

<220>
<221>  misc_feature
<222>  (23)..(23)
<223>  Xaa is Leucine, Phenylalanine or Methionine

<220>
<221>  misc_feature
<222>  (24)..(24)
<223>  Xaa is Glutamine, Glutamate or Lysine

<220>
<221>  misc_feature
<222>  (25)..(25)
<223>  Xaa is Isoleucine, Leucine or Methionine

<220>
<221>  misc_feature
<222>  (26)..(26)
<223>  Xaa is Asparagine or Serine

<220>
<221>  misc_feature
<222>  (27)..(27)
<223>  Xaa is Asparagine, Arginine or Serine

<220>
<221>  misc_feature
<222>  (29)..(29)
<223>  Xaa is Lysine, Threonine or Glutamine

<220>
<221>  misc_feature
<222>  (30)..(30)
<223>  Xaa is Asparagine, Serine or Alanine

<220>
<221>  misc_feature
<222>  (31)..(31)
<223>  Xaa is Glutamate or Aspartate

<220>
<221>  misc_feature
<222>  (33)..(33)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (35)..(35)
<223>  Xaa is Threonine, Valine or Isoleucine

<220>
<221>  misc_feature
<222>  (37)..(37)
<223>  Xaa is Phenylalanine or Tyrosine

<400>  667

Xaa Tyr Xaa Xaa Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10                  15      


Ser Xaa Ser Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa Asp 
            20                  25                  30          


Xaa Ala Xaa Tyr Xaa Cys 
        35              


<210>  668
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S15-39AH as described 
       in Table 2.

<400>  668

Thr Tyr Ala Asp Asp Phe Lys Gly Arg Leu Ala Phe Ser Leu Glu Thr 
1               5                   10                  15      


Ser Ala Ser Thr Ala Phe Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp 
            20                  25                  30          


Thr Ala Thr Tyr Phe Cys 
        35              


<210>  669
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_238H as described in
       Table 2.

<400>  669

Ser Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Glu 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Tyr Cys 
        35              


<210>  670
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  670

Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr 
1               5                   10                  15      


Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Asp Asp 
            20                  25                  30          


Thr Ala Thr Tyr Phe Cys 
        35              


<210>  671
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of Consensus Cluster #6 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Phenylalanine or Tyrosine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Leucine or Methionine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Serine or Cysteine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Threonine or Alanine

<400>  671

Glu Xaa Ala Pro Lys Phe Gln Gly Lys Ala Thr Xaa Thr Ala Asp Thr 
1               5                   10                  15      


Xaa Ser Asn Xaa Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Thr Ala Val Tyr Tyr Cys 
        35              


<210>  672
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-20AH as described 
       in Table 2.

<400>  672

Glu Tyr Ala Pro Lys Phe Gln Gly Lys Ala Thr Met Thr Ala Asp Thr 
1               5                   10                  15      


Ser Ser Asn Ala Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Thr Ala Val Tyr Tyr Cys 
        35              


<210>  673
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  673

Glu Tyr Ala Pro Lys Phe Gln Gly Lys Ala Thr Met Thr Ala Asp Thr 
1               5                   10                  15      


Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Thr Ala Val Tyr Tyr Cys 
        35              


<210>  674
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-31BH as described 
       in Table 2.

<400>  674

Glu Tyr Ala Pro Lys Phe Gln Gly Lys Ala Thr Met Thr Ala Asp Thr 
1               5                   10                  15      


Cys Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Thr Ala Val Tyr Tyr Cys 
        35              


<210>  675
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-45AH as described 
       in Table 2.

<400>  675

Glu Phe Ala Pro Lys Phe Gln Gly Lys Ala Thr Leu Thr Ala Asp Thr 
1               5                   10                  15      


Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Thr Ala Val Tyr Tyr Cys 
        35              


<210>  676
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of Consensus Cluster #12 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Phenylalanine, Aspartate or Asparagine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Proline, Asparagine or Tyrosine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Aspartate, Serine or Glutamate

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Serine, Alanine or Lysine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Valine, Leucine or Phenylalanine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Glycine, Serine or Valine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Arginine or Lysine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Phenylalanine, Leucine or Alanine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Isoleucine or Leucine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa is Arginine, Lysine or Alanine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Asparagine or Threonine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Alanine or Serine

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Lysine or Serine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Asparagine or Serine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Asparagine, Glutamine or Threonine

<220>
<221>  misc_feature
<222>  (21)..(21)
<223>  Xaa is Leucine, Valine or Alanine

<220>
<221>  misc_feature
<222>  (22)..(22)
<223>  Xaa is Tyrosine or Phenylalanine

<220>
<221>  misc_feature
<222>  (23)..(23)
<223>  Xaa is Leucine or Methionine

<220>
<221>  misc_feature
<222>  (24)..(24)
<223>  Xaa is Glutamine or Lysine

<220>
<221>  misc_feature
<222>  (25)..(25)
<223>  Xaa is Valine, Methionine or Leucine

<220>
<221>  misc_feature
<222>  (26)..(26)
<223>  Xaa is Serine or Asparagine

<220>
<221>  misc_feature
<222>  (27)..(27)
<223>  Xaa is Serine or Arginine

<220>
<221>  misc_feature
<222>  (29)..(29)
<223>  Xaa is Arginine, Glutamine or Threonine

<220>
<221>  misc_feature
<222>  (30)..(30)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (31)..(31)
<223>  Xaa is Glutamate or Aspartate

<220>
<221>  misc_feature
<222>  (33)..(33)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (35)..(35)
<223>  Xaa is Leucine, Arginine or Isoleucine

<400>  676

Xaa Tyr Xaa Xaa Xaa Xaa Lys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa 
1               5                   10                  15      


Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa Asp 
            20                  25                  30          


Xaa Ala Xaa Tyr Tyr Cys 
        35              


<210>  677
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S15-18AH as described 
       in Table 2.

<400>  677

Asn Tyr Tyr Glu Lys Phe Lys Val Lys Ala Thr Leu Thr Ala Asp Thr 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Ile Tyr Tyr Cys 
        35              


<210>  678
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S15-8AH as described 
       in Table 2.

<400>  678

Asn Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Arg Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Ile Tyr Tyr Cys 
        35              


<210>  679
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-56AH as described 
       in Table 2.

<400>  679

Phe Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 
1               5                   10                  15      


Ala Lys Asn Asn Leu Tyr Leu Gln Val Ser Ser Leu Arg Ser Glu Asp 
            20                  25                  30          


Thr Ala Leu Tyr Tyr Cys 
        35              


<210>  680
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of Consensus Cluster #4 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Glycine or Aspartate

<400>  680

Ile Asn Asn Gln Lys Phe Lys Xaa Lys Ala Thr Leu Thr Val Asp Met 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Tyr Cys 
        35              


<210>  681
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S14-24AH as described 
       in Table 2.

<400>  681

Ile Asn Asn Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr Val Asp Met 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Tyr Cys 
        35              


<210>  682
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  682

Ile Asn Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Met 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Tyr Cys 
        35              


<210>  683
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of Consensus Cluster #9 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Lysine, Arginine or Asparagine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Aspartate, Alanine or Asparagine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Proline or Glutamate

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Glutamine or Lysine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Glycine, Aspartate or Serine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Isoleucine or Leucine

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa is Alanine or Valine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Threonine or Lysine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Asparagine, Threonine or Serine

<220>
<221>  misc_feature
<222>  (21)..(21)
<223>  Xaa is Alanine or Valine

<220>
<221>  misc_feature
<222>  (23)..(23)
<223>  Xaa is Leucine or Methionine

<220>
<221>  misc_feature
<222>  (24)..(24)
<223>  Xaa is Glutamine or Aspartate

<220>
<221>  misc_feature
<222>  (27)..(27)
<223>  Xaa is Serine or Arginine

<220>
<221>  misc_feature
<222>  (33)..(33)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (37)..(37)
<223>  Xaa is Tyrosine or Phenylalanine

<400>  683

Xaa Tyr Xaa Xaa Lys Phe Xaa Xaa Lys Ala Thr Xaa Thr Xaa Asp Xaa 
1               5                   10                  15      


Ser Ser Xaa Thr Xaa Tyr Xaa Xaa Leu Ser Xaa Leu Thr Ser Glu Asp 
            20                  25                  30          


Xaa Ala Val Tyr Xaa Cys 
        35              


<210>  684
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S14-2AH as described 
       in Table 2.

<400>  684

Asn Tyr Asn Glu Lys Phe Lys Ser Lys Ala Thr Leu Thr Val Asp Thr 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Tyr Cys 
        35              


<210>  685
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_237H as described in
       Table 2.

<400>  685

Arg Tyr Asn Glu Lys Phe Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys 
1               5                   10                  15      


Ser Ser Thr Thr Val Tyr Met Asp Leu Ser Arg Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Phe Cys 
        35              


<210>  686
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of Consensus Cluster #17 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (26)..(26)
<223>  Xaa is Asparagine or Serine

<220>
<221>  misc_feature
<222>  (29)..(29)
<223>  Xaa is Lysine or Threonine

<220>
<221>  misc_feature
<222>  (30)..(30)
<223>  Xaa is Asparagine or Threonine

<220>
<221>  misc_feature
<222>  (31)..(31)
<223>  Xaa is Aspartate or Glutamate

<220>
<221>  misc_feature
<222>  (33)..(33)
<223>  Xaa is Threonine or Methionine

<400>  686

Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr 
1               5                   10                  15      


Ser Ala Ser Xaa Ala Tyr Leu Gln Ile Xaa Asn Leu Xaa Xaa Xaa Asp 
            20                  25                  30          


Xaa Ala Thr Tyr Phe Cys 
        35              


<210>  687
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-26AH as described 
       in Table 2.

<400>  687

Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr 
1               5                   10                  15      


Ser Ala Ser Ser Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp 
            20                  25                  30          


Met Ala Thr Tyr Phe Cys 
        35              


<210>  688
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_127H as described in
       Table 2.

<400>  688

Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr 
1               5                   10                  15      


Ser Ala Ser Ser Ala Tyr Leu Gln Ile Ser Asn Leu Thr Thr Glu Asp 
            20                  25                  30          


Met Ala Thr Tyr Phe Cys 
        35              


<210>  689
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_128H as described in
       Table 2.

<400>  689

Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr 
1               5                   10                  15      


Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Thr Glu Asp 
            20                  25                  30          


Met Ala Thr Tyr Phe Cys 
        35              


<210>  690
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of Consensus Cluster #7 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Lysine or Aspartate

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Glutamate or Alanine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Lysine or Alanine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Lysine or Isoleucine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Glycine or Serine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Lysine or Arginine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Alanine or Leucine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Leucine or Isoleucine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa is Alanine or Lysine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Threonine or Asparagine

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Serine or Lysine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Threonine or Glutamine

<220>
<221>  misc_feature
<222>  (21)..(21)
<223>  Xaa is Alanine or Valine

<220>
<221>  misc_feature
<222>  (22)..(22)
<223>  Xaa is Tyrosine or Phenylalanine

<220>
<221>  misc_feature
<222>  (23)..(23)
<223>  Xaa is Methionine or Phenylalanine

<220>
<221>  misc_feature
<222>  (24)..(24)
<223>  Xaa is Glutamine or Lysine

<220>
<221>  misc_feature
<222>  (25)..(25)
<223>  Xaa is Leucine or Methionine

<220>
<221>  misc_feature
<222>  (26)..(26)
<223>  Xaa is Serine or Asparagine

<220>
<221>  misc_feature
<222>  (29)..(29)
<223>  Xaa is Threonine or Glutamine

<220>
<221>  misc_feature
<222>  (30)..(30)
<223>  Xaa is Serine or Alanine

<220>
<221>  misc_feature
<222>  (31)..(31)
<223>  Xaa is Glutamate or Aspartate

<220>
<221>  misc_feature
<222>  (33)..(33)
<223>  Xaa is Serine or Threonine

<400>  690

Xaa Tyr Asn Xaa Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa 
1               5                   10                  15      


Ser Xaa Ser Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ser Leu Xaa Xaa Xaa Asp 
            20                  25                  30          


Xaa Ala Ile Tyr Tyr Cys 
        35              


<210>  691
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S15-6AH as described 
       in Table 2.

<400>  691

Lys Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Ile Tyr Tyr Cys 
        35              


<210>  692
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_045H as described in
       Table 2.

<400>  692

Asp Tyr Asn Ala Ala Phe Ile Ser Arg Leu Ser Ile Ser Lys Asp Asn 
1               5                   10                  15      


Ser Lys Ser Gln Val Phe Phe Lys Met Asn Ser Leu Gln Ala Asp Asp 
            20                  25                  30          


Thr Ala Ile Tyr Tyr Cys 
        35              


<210>  693
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_046H as described in
       Table 2.

<400>  693

Asp Tyr Asn Ala Ala Phe Ile Ser Arg Leu Thr Ile Ser Lys Asp Asn 
1               5                   10                  15      


Ser Lys Ser Gln Val Phe Phe Lys Met Asn Ser Leu Gln Ala Asp Asp 
            20                  25                  30          


Thr Ala Ile Tyr Tyr Cys 
        35              


<210>  694
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of Consensus Cluster #13 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Isoleucine, Lysine or Tyrosine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Aspartate or Lysine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Proline or Glutamate

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Glutamine or Lysine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Glycine or Aspartate

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Serine, Threonine or Isoleucine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Isoleucine or Leucine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Threonine or Lysine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Asparagine or Serine

<220>
<221>  misc_feature
<222>  (23)..(23)
<223>  Xaa is Leucine or Methionine

<220>
<221>  misc_feature
<222>  (31)..(31)
<223>  Xaa is Glutamate or Aspartate

<220>
<221>  misc_feature
<222>  (33)..(33)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (37)..(37)
<223>  Xaa is Tyrosine or Phenylalanine

<400>  694

Xaa Tyr Xaa Xaa Lys Phe Xaa Xaa Lys Ala Xaa Xaa Thr Ala Asp Xaa 
1               5                   10                  15      


Ser Ser Xaa Thr Ala Tyr Xaa Gln Leu Ser Ser Leu Thr Ser Xaa Asp 
            20                  25                  30          


Xaa Ala Val Tyr Xaa Cys 
        35              


<210>  695
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S15-29AH as described 
       in Table 2.

<400>  695

Ile Tyr Asp Pro Lys Phe Gln Gly Lys Ala Ser Ile Thr Ala Asp Thr 
1               5                   10                  15      


Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Thr Ala Val Tyr Tyr Cys 
        35              


<210>  696
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S19-24AH as described 
       in Table 2.

<400>  696

Tyr Tyr Lys Glu Lys Phe Lys Asp Lys Ala Ile Leu Thr Ala Asp Lys 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Asp Asp 
            20                  25                  30          


Ser Ala Val Tyr Phe Cys 
        35              


<210>  697
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of Consensus Cluster #18 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (26)..(26)
<223>  Xaa is Asparagine or Serine

<220>
<221>  misc_feature
<222>  (35)..(35)
<223>  Xaa is Methionine or Isoleucine

<400>  697

Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 
1               5                   10                  15      


Ala Lys Asn Thr Leu Tyr Leu Gln Met Xaa Ser Leu Lys Ser Glu Asp 
            20                  25                  30          


Thr Ala Xaa Tyr Tyr Cys 
        35              


<210>  698
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S14-1AH as described 
       in Table 2.

<400>  698

Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 
1               5                   10                  15      


Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp 
            20                  25                  30          


Thr Ala Ile Tyr Tyr Cys 
        35              


<210>  699
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_203H as described in
       Table 2.

<400>  699

Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 
1               5                   10                  15      


Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Ser Glu Asp 
            20                  25                  30          


Thr Ala Met Tyr Tyr Cys 
        35              


<210>  700
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of Consensus Cluster #22 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Asparagine, Serine or Tyrosine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Aspartate, Asparagine or Serine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Glutamate, Proline or Aspartate

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Lysine or Serine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Phenylalanine, Leucine or Valine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Serine or Glycine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Lysine or Arginine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Alanine, Isoleucine or Phenylalanine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Leucine or Isoleucine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa is Valine or Arginine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Threonine or Aspartate

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Serine or Lysine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Serine or Asparagine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Threonine, Glutamine or Serine

<220>
<221>  misc_feature
<222>  (21)..(21)
<223>  Xaa is Alanine, Phenylalanine or Valine

<220>
<221>  misc_feature
<222>  (22)..(22)
<223>  Xaa is Tyrosine or Phenylalanine

<220>
<221>  misc_feature
<222>  (23)..(23)
<223>  Xaa is Methionine or Leucine

<220>
<221>  misc_feature
<222>  (25)..(25)
<223>  Xaa is Leucine or Methionine

<220>
<221>  misc_feature
<222>  (26)..(26)
<223>  Xaa is Serine or Asparagine

<220>
<221>  misc_feature
<222>  (27)..(27)
<223>  Xaa is Serine or Asparagine

<220>
<221>  misc_feature
<222>  (28)..(28)
<223>  Xaa is Leucine or Valine

<220>
<221>  misc_feature
<222>  (29)..(29)
<223>  Xaa is Threonine or Arginine

<220>
<221>  misc_feature
<222>  (30)..(30)
<223>  Xaa is Serine or Alanine

<220>
<221>  misc_feature
<222>  (33)..(33)
<223>  Xaa is Serine, Threonine or Methionine

<220>
<221>  misc_feature
<222>  (34)..(34)
<223>  Xaa is Alanine or Glycine

<220>
<221>  misc_feature
<222>  (35)..(35)
<223>  Xaa is Valine, Threonine or Isoleucine

<220>
<221>  misc_feature
<222>  (37)..(37)
<223>  Xaa is Tyrosine or Phenylalanine

<400>  700

Xaa Tyr Xaa Xaa Xaa Xaa Lys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa 
1               5                   10                  15      


Ser Xaa Xaa Xaa Xaa Xaa Xaa Gln Xaa Xaa Xaa Xaa Xaa Xaa Glu Asp 
            20                  25                  30          


Xaa Xaa Xaa Tyr Xaa Cys 
        35              


<210>  701
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S14-21AH as described 
       in Table 2.

<400>  701

Asn Tyr Asp Glu Lys Phe Lys Ser Lys Ala Thr Leu Thr Val Asp Thr 
1               5                   10                  15      


Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Tyr Cys 
        35              


<210>  702
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S14-27AH as described 
       in Table 2.

<400>  702

Tyr Tyr Ser Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp 
1               5                   10                  15      


Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp 
            20                  25                  30          


Met Gly Ile Tyr Tyr Cys 
        35              


<210>  703
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S14-5AH as described 
       in Table 2.

<400>  703

Ser Tyr Asn Pro Ser Leu Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr 
1               5                   10                  15      


Ser Lys Asn Gln Phe Phe Leu Gln Leu Asn Ser Val Thr Ala Glu Asp 
            20                  25                  30          


Thr Ala Thr Tyr Phe Cys 
        35              


<210>  704
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of Consensus Cluster #16 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Serine or Lysine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Serine or Aspartate

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Serine or Lysine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Leucine or Phenylalanine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Lysine or Glutamine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Serine or Aspartate

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Arginine or Lysine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Isoleucine or Alanine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa is Arginine or Threonine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Threonine or Alanine

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Lysine or Serine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Glutamine or Threonine

<220>
<221>  misc_feature
<222>  (21)..(21)
<223>  Xaa is Phenylalanine or Alanine

<220>
<221>  misc_feature
<222>  (22)..(22)
<223>  Xaa is Phenylalanine or Tyrosine

<220>
<221>  misc_feature
<222>  (26)..(26)
<223>  Xaa is Asparagine or Serine

<220>
<221>  misc_feature
<222>  (28)..(28)
<223>  Xaa is Valine or Leucine

<220>
<221>  misc_feature
<222>  (30)..(30)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (35)..(35)
<223>  Xaa is Threonine or Valine

<400>  704

Xaa Tyr Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ile Thr Xaa Asp Xaa 
1               5                   10                  15      


Ser Xaa Asn Xaa Xaa Xaa Leu Gln Leu Xaa Ser Xaa Thr Xaa Glu Asp 
            20                  25                  30          


Thr Ala Xaa Tyr Tyr Cys 
        35              


<210>  705
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S19-1AH as described 
       in Table 2.

<400>  705

Ser Tyr Ser Pro Ser Leu Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr 
1               5                   10                  15      


Ser Lys Asn Gln Phe Phe Leu Gln Leu Asn Ser Val Thr Thr Glu Asp 
            20                  25                  30          


Thr Ala Thr Tyr Tyr Cys 
        35              


<210>  706
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_023H as described in
       Table 2.

<400>  706

Lys Tyr Asp Pro Lys Phe Gln Asp Lys Ala Thr Ile Thr Thr Asp Ala 
1               5                   10                  15      


Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp 
            20                  25                  30          


Thr Ala Val Tyr Tyr Cys 
        35              


<210>  707
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of Consensus Cluster #2 as 
       described in Table 2.

<400>  707

Val Phe Asn Gln Lys Phe Lys Gly Lys Ala Lys Leu Thr Ala Val Thr 
1               5                   10                  15      


Ser Ala Thr Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr Asn Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Tyr Cys 
        35              


<210>  708
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of Consensus Cluster #3 as 
       described in Table 2.

<400>  708

Thr Tyr Asn Gln Lys Phe Thr Gly Lys Ala Lys Leu Thr Ala Val Thr 
1               5                   10                  15      


Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr Asn Glu Asp 
            20                  25                  30          


Ser Ala Val Tyr Tyr Cys 
        35              


<210>  709
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #11 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Valine, Alanine or Isoleucine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Valine, Methionine or Leucine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Alanine or Aspartate

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Tyrosine, Asparagine, Histidine, Serine or Lysine

<400>  709

Xaa Gly Ala Xaa Xaa Xaa 
1               5       


<210>  710
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  710

Ala Gly Ala Met Asp Tyr 
1               5       


<210>  711
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  711

Ala Gly Ala Met Asp Ser 
1               5       


<210>  712
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  712

Ala Gly Ala Leu Asp Tyr 
1               5       


<210>  713
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S20-24AH as described in Table 2.

<400>  713

Ala Gly Ala Met Asp His 
1               5       


<210>  714
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  714

Ala Gly Ala Met Asp Lys 
1               5       


<210>  715
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S20-33AH as described in Table 2.

<400>  715

Val Gly Ala Val Ala Tyr 
1               5       


<210>  716
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  716

Ala Gly Ala Val Ala Tyr 
1               5       


<210>  717
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S20-54AH as described in Table 2.

<400>  717

Ala Gly Ala Met Asp Asn 
1               5       


<210>  718
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S20-57AH as described in Table 2.

<400>  718

Ile Gly Ala Met Asp Tyr 
1               5       


<210>  719
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S20-60AH as described in Table 2.

<400>  719

Ala Gly Ala Met Ala Tyr 
1               5       


<210>  720
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #20 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Threonine or Alanine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Glycine or Alanine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Tyrosine or Glycine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is no amino acid or Asparagine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is no amino acid, Tyrosine or Phenylalanine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Serine, Phenylalanine or Alanine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Serine or Tryptophan

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Phenylalanine, Histidine or Tyrosine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Valine, Threonine, Alanine or Proline

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Isoleucine, Tyrosine or Phenylalanine

<400>  720

Xaa Arg Gly Xaa Xaa Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10              


<210>  721
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-11AH as described in Table 2.

<400>  721

Ala Arg Gly Gly Gly Gly Asn Tyr Phe Trp Phe Ala Tyr 
1               5                   10              


<210>  722
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-8AH as described in Table 2.

<400>  722

Ala Arg Gly Gly Gly Gly Asn Tyr Phe Trp Phe Thr Tyr 
1               5                   10              


<210>  723
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  723

Ala Arg Gly Ala Tyr Gly Asn Phe Ala Trp Phe Pro Tyr 
1               5                   10              


<210>  724
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-20AH as described in Table 2.

<400>  724

Ala Arg Gly Ala Tyr Gly Asn Phe Ala Trp Phe Ala Phe 
1               5                   10              


<210>  725
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  725

Thr Arg Gly Gly Tyr Gly Ser Ser Tyr Val Ile 
1               5                   10      


<210>  726
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  726

Thr Arg Gly Gly Tyr Gly Ser Ser Phe Val Ile 
1               5                   10      


<210>  727
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  727

Thr Arg Gly Gly Tyr Gly Ser Ser His Val Ile 
1               5                   10      


<210>  728
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S20-6AH as described in Table 2.

<400>  728

Ala Arg Gly Gly Tyr Gly Ser Ser Tyr Val Ile 
1               5                   10      


<210>  729
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #5 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Alanine, Valine or Proline

<400>  729

Ala Arg Asp Trp Glu Arg Asp Ser Ser Gly Pro Phe Xaa Tyr 
1               5                   10                  


<210>  730
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  730

Ala Arg Asp Trp Glu Arg Asp Ser Ser Gly Pro Phe Pro Tyr 
1               5                   10                  


<210>  731
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  731

Ala Arg Asp Trp Glu Arg Asp Ser Ser Gly Pro Phe Ala Tyr 
1               5                   10                  


<210>  732
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  732

Ala Arg Asp Trp Glu Arg Asp Ser Ser Gly Pro Phe Val Tyr 
1               5                   10                  


<210>  733
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #23 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Glutamine, Serine, Arginine, Isoleucine, Threonine or 
       Glycine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Glycine, Serine, Arginine, Methionine, Valine, Tryptophan,
       Asparagine, Tyrosine, Glutamate or Cysteine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Glycine, no amino acid, Proline, Leucine or Tyrosine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Glycine, no amino acid, Leucine, Serine, Asparagine, 
       Arginine or Tyrosine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is no amino acid, Tryptophan or Glycine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Glycine, Serine, no amino acid or Asparagine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Alanine, Serine, no amino acid, Arginine, Leucine, Lysine,
       Tryptophan or Histidine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Methionine, Phenylalanine, Tyrosine, Proline, Isoleucine, 
       Leucine, Valine or Tryptophan

<400>  733

Ala Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Tyr 
1               5                   10      


<210>  734
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-15AH as described in Table 2.

<400>  734

Ala Arg Asn Leu Gly Gly Ser Trp Val Asp Tyr 
1               5                   10      


<210>  735
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-17AH as described in Table 2.

<400>  735

Ala Arg Asn Gly Asn Ser Leu Asp Tyr 
1               5                   


<210>  736
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-25AH as described in Table 2.

<400>  736

Ala Arg Arg Leu Tyr Gly Gly Ala Met Asp Tyr 
1               5                   10      


<210>  737
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-6AH as described in Table 2.

<400>  737

Ala Arg Val Pro Asp Tyr 
1               5       


<210>  738
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-12AH as described in Table 2.

<400>  738

Ala Ser Arg Gly Gly Ser Ser Phe Asp Tyr 
1               5                   10  


<210>  739
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-30AH as described in Table 2.

<400>  739

Ala Arg Glu Tyr Tyr Gly Asn His Phe Asp Tyr 
1               5                   10      


<210>  740
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-38AH as described in Table 2.

<400>  740

Ala Arg Met Tyr Asp Tyr 
1               5       


<210>  741
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  741

Ala Arg Trp Gly Leu Arg Ile Asp Tyr 
1               5                   


<210>  742
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S19-25AH as described in Table 2.

<400>  742

Ala Arg Tyr Pro Arg Trp Gly Lys Ile Asp Tyr 
1               5                   10      


<210>  743
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S19-6AH as described in Table 2.

<400>  743

Ala Arg Gly Gly Ser Leu Phe Asp Tyr 
1               5                   


<210>  744
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S20-15AH as described in Table 2.

<400>  744

Ala Thr Ser Gly Gly Ser Ser Tyr Asp Tyr 
1               5                   10  


<210>  745
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S20-25AH as described in Table 2.

<400>  745

Ala Arg Ser Gly Gly Ser Ser Tyr Asp Tyr 
1               5                   10  


<210>  746
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S20-34AH as described in Table 2.

<400>  746

Ala Ser Ser Gly Gly Ser Ser Phe Asp Tyr 
1               5                   10  


<210>  747
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S20-42AH as described in Table 2.

<400>  747

Ala Gly Ser Gly Gly Ser Ser Tyr Asp Tyr 
1               5                   10  


<210>  748
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S20-8AH as described in Table 2.

<400>  748

Ala Ile Ser Gly Gly Ser Ser Tyr Asp Tyr 
1               5                   10  


<210>  749
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of ITI_021H as described in Table 2.

<400>  749

Ala Arg Cys Tyr Tyr Gly Gly Arg Trp Asp Tyr 
1               5                   10      


<210>  750
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of ITI_200H as described in Table 2.

<400>  750

Ala Gln Gly Gly Gly Gly Ala Met Asp Tyr 
1               5                   10  


<210>  751
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #21 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Alanine or Valine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Isoleucine, Arginine, Proline, Alanine, Glycine, Threonine
       or Asparagine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Tyrosine, Arginine or Proline

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Tyrosine, Glycine or Phenylalanine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Serine, Histidine, Glycine, Asparagine or Alanine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Asparagine, Tyrosine, Serine or Arginine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is no amino acid, Tyrosine, Threonine or Serine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is no amino acid, Glycine, Proline, Tyrosine or Asparagine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Proline, Tyrosine, Alanine or Aspartate

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Valine, Tryptophan or Glycine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Aspartate, Alanine or Valine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Tyrosine or Phenylalanine

<400>  751

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Xaa Xaa 
1               5                   10              


<210>  752
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-11AH as described in Table 2.

<400>  752

Ala Asn Tyr Tyr Ala Ser Ser Tyr Asp Trp Phe Ala Tyr 
1               5                   10              


<210>  753
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-17AH as described in Table 2.

<400>  753

Ala Asn Tyr Tyr Gly Arg Ser Asn Asp Trp Phe Val Tyr 
1               5                   10              


<210>  754
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-1AH as described in Table 2.

<400>  754

Ala Asn Tyr Phe Gly Asn Thr Tyr Asp Trp Phe Ala Phe 
1               5                   10              


<210>  755
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-24AH as described in Table 2.

<400>  755

Ala Asn Tyr Tyr Ala Ser Ser Tyr Asp Trp Phe Val Tyr 
1               5                   10              


<210>  756
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-36AH as described in Table 2.

<400>  756

Ala Arg Pro Tyr Gly Asn Tyr Gly Phe Ala Tyr 
1               5                   10      


<210>  757
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-37AH as described in Table 2.

<400>  757

Ala Ile Tyr Tyr Ser Asn Pro Val Phe Asp Tyr 
1               5                   10      


<210>  758
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-3AH as described in Table 2.

<400>  758

Val Thr Tyr Phe Gly Asn Thr Tyr Asp Trp Phe Ala Tyr 
1               5                   10              


<210>  759
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  759

Ala Gly Tyr Gly Asn Ser Pro Trp Phe Ala Tyr 
1               5                   10      


<210>  760
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S20-49AH as described in Table 2.

<400>  760

Ala Pro Tyr Gly Asn Tyr Pro Ala Trp Phe Ala Tyr 
1               5                   10          


<210>  761
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of ITI_091H as described in Table 2.

<400>  761

Ala Ala Tyr Gly Asn Ser Pro Trp Phe Ala Tyr 
1               5                   10      


<210>  762
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of ITI_122H as described in Table 2.

<400>  762

Ala Arg Arg Gly His Asn Tyr Gly Pro Trp Phe Ala Tyr 
1               5                   10              


<210>  763
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #10 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Alanine, Serine or Threonine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Glycine, Arginine, Leucine, Aspartate or Serine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Isoleucine, Glutamate, Histidine, Valine, Leucine, 
       Glycine, Methionine or Tyrosine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Isoleucine, Arginine, Tyrosine, Aspartate, Asparagine or 
       Glycine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Threonine, Arginine, Glycine, no amino acid, Tyrosine, 
       Serine or Asparagine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Threonine, Glycine, Asparagine, no amino acid, Serine or 
       Lysine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Valine, no amino acid, Tyrosine or Proline

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Valine, Isoleucine or no amino acid

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Glutamate or no amino acid

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Proline or no amino acid

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Isoleucine, no amino acid, Aspartate or Tyrosine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Leucine, Isoleucine, Proline, no amino acid, Asparagine, 
       Tyrosine or Glycine

<400>  763

Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Tyr Ala Met 
1               5                   10                  15      


Asp Tyr 
        


<210>  764
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-10AH as described in Table 2.

<400>  764

Ala Arg Ser Met Tyr Gly Asn Tyr Asn Tyr Ala Met Asp Tyr 
1               5                   10                  


<210>  765
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-16AH as described in Table 2.

<400>  765

Ala Arg Asp Gly Asn Tyr Tyr Ala Met Asp Tyr 
1               5                   10      


<210>  766
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-20AH as described in Table 2.

<400>  766

Thr Arg Gly His Tyr Gly Asn Tyr Asp Pro Tyr Ala Met Asp Tyr 
1               5                   10                  15  


<210>  767
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-22AH as described in Table 2.

<400>  767

Ala Arg Gly Ile Ile Thr Thr Val Ile Glu Pro Ile Leu Tyr Ala Met 
1               5                   10                  15      


Asp Tyr 
        


<210>  768
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-26AH as described in Table 2.

<400>  768

Ala Arg Asp Tyr Gly Ser Ser Tyr Gly Tyr Ala Met Asp Tyr 
1               5                   10                  


<210>  769
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-28AH as described in Table 2.

<400>  769

Ala Arg Arg Val Asp Tyr Ala Met Asp Tyr 
1               5                   10  


<210>  770
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-29AH as described in Table 2.

<400>  770

Ala Arg Gly Ile Ile Thr Thr Val Val Glu Pro Ile Leu Tyr Ala Met 
1               5                   10                  15      


Asp Tyr 
        


<210>  771
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  771

Ala Arg Arg Gly Tyr Asn Lys Gly Tyr Ala Met Asp Tyr 
1               5                   10              


<210>  772
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-40AH as described in Table 2.

<400>  772

Ala Arg Leu Leu Arg Tyr Tyr Ala Met Asp Tyr 
1               5                   10      


<210>  773
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  773

Ala Arg Arg Gly Tyr Gly Ser Pro Tyr Tyr Tyr Ala Met Asp Tyr 
1               5                   10                  15  


<210>  774
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S20-21AH as described in Table 2.

<400>  774

Ser Arg Gly Glu Arg Arg Gly Ile Tyr Ala Met Asp Tyr 
1               5                   10              


<210>  775
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of ITI_130H as described in Table 2.

<400>  775

Ala Arg Arg Gly Tyr Gly Lys Gly Tyr Ala Met Asp Tyr 
1               5                   10              


<210>  776
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #8 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Phenylalanine or Tyrosine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Threonine or Tyrosine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Threonine, Alanine, Glycine or Lysine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Alanine, Asparagine or Serine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Threonine, Asparagine, Tyrosine or Glutamate

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Cysteine or Alanine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Tyrosine or Phenylalanine

<400>  776

Ala Arg Ser Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10  


<210>  777
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  777

Ala Arg Ser Phe Tyr Gly Ser Glu Ala Tyr 
1               5                   10  


<210>  778
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S19-13AH as described in Table 2.

<400>  778

Ala Arg Ser Tyr Tyr Ala Asn Tyr Ala Tyr 
1               5                   10  


<210>  779
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  779

Ala Arg Ser Phe Tyr Lys Asn Tyr Ala Phe 
1               5                   10  


<210>  780
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S19-8AH as described in Table 2.

<400>  780

Ala Arg Ser Tyr Tyr Ala Asn Asn Ala Tyr 
1               5                   10  


<210>  781
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of ITI_035H as described in Table 2.

<400>  781

Ala Arg Ser Tyr Tyr Gly Asn Tyr Ala Tyr 
1               5                   10  


<210>  782
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  782

Ala Arg Ser Phe Thr Thr Ala Thr Cys Tyr 
1               5                   10  


<210>  783
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #15 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Alanine or Valine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Arginine or Lysine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Glutamine, Threonine, Histidine, Alanine, Glycine, 
       Asparagine or Glutamate

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Glycine, Tyrosine or Arginine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Glycine, Tyrosine or Leucine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Histidine, Tyrosine or Arginine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Glycine or Arginine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is no amino acid, Serine, Asparagine, Glycine or Glutamate

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is no amino acid, Serine, Threonine or Asparagine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Asparagine, Serine, Tyrosine, Phenylalanine, Glycine or 
       Aspartate

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Tyrosine, Asparagine, Valine or Leucine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Glycine, Tyrosine or Proline

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Alanine, Serine or Tyrosine

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa is Methionine, Leucine or Phenylalanine

<400>  783

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Tyr 
1               5                   10                  15      


<210>  784
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-18AH as described in Table 2.

<400>  784

Val Arg Glu Gly Gly Tyr Gly Asn Tyr Pro Tyr Phe Asp Tyr 
1               5                   10                  


<210>  785
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-23AH as described in Table 2.

<400>  785

Ala Arg Thr Tyr Tyr Tyr Gly Ser Ser Tyr Gly Ala Met Asp Tyr 
1               5                   10                  15  


<210>  786
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-30AH as described in Table 2.

<400>  786

Ala Arg Gln Gly Gly His Gly Asn Tyr Gly Ala Met Asp Tyr 
1               5                   10                  


<210>  787
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-14AH as described in Table 2.

<400>  787

Ala Lys Ala Arg Gly Tyr Gly Ser Thr Phe Tyr Tyr Ser Met Asp Tyr 
1               5                   10                  15      


<210>  788
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-25AH as described in Table 2.

<400>  788

Ala Lys Ala Arg Gly Tyr Gly Gly Asn Phe Tyr Tyr Ser Met Asp Tyr 
1               5                   10                  15      


<210>  789
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-5AH as described in Table 2.

<400>  789

Ala Lys Ala Arg Gly Tyr Gly Gly Ser Phe Tyr Tyr Ser Met Asp Tyr 
1               5                   10                  15      


<210>  790
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S20-44AH as described in Table 2.

<400>  790

Ala Arg His Arg Gly Tyr Gly Ser Ser Tyr Asn Tyr Ala Met Asp Tyr 
1               5                   10                  15      


<210>  791
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  791

Ala Arg His Arg Gly Tyr Gly Asn Tyr Val Tyr Ala Met Asp Tyr 
1               5                   10                  15  


<210>  792
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S20-51AH as described in Table 2.

<400>  792

Ala Lys Asn Arg Gly Tyr Gly Glu Gly Tyr Tyr Ala Met Asp Tyr 
1               5                   10                  15  


<210>  793
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S20-53AH as described in Table 2.

<400>  793

Ala Arg Glu Gly Leu Arg Arg Asp Tyr Tyr Ala Leu Asp Tyr 
1               5                   10                  


<210>  794
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S20-59AH as described in Table 2.

<400>  794

Ala Lys Gly Arg Gly Tyr Gly Asn Tyr Leu Tyr Ala Met Asp Tyr 
1               5                   10                  15  


<210>  795
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #19 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Alanine or Valine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Aspartate or Serine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Asparagine, Serine, Tyrosine, Leucine or Phenylalanine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Histidine, Arginine or no amino acid

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Threonine or no amino acid

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Valine, Methionine or no amino acid

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Valine, Threonine or Glycine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Glycine, Serine or Arginine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Aspartate or Glycine

<400>  795

Xaa Arg Xaa Xaa Tyr Xaa Xaa Xaa Xaa Asn Xaa Xaa Tyr 
1               5                   10              


<210>  796
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-19AH as described in Table 2.

<400>  796

Ala Arg Asp Asn Tyr His Thr Val Val Asn Gly Asp Tyr 
1               5                   10              


<210>  797
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-32AH as described in Table 2.

<400>  797

Ala Arg Asp Ser Tyr Arg Thr Met Thr Asn Gly Asp Tyr 
1               5                   10              


<210>  798
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  798

Val Arg Ser Tyr Tyr Gly Asn Ser Gly Tyr 
1               5                   10  


<210>  799
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S20-12AH as described in Table 2.

<400>  799

Ala Arg Ser Leu Tyr Gly Asn Arg Asp Tyr 
1               5                   10  


<210>  800
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S20-18AH as described in Table 2.

<400>  800

Ala Arg Ser Phe Tyr Gly Asn Arg Asp Tyr 
1               5                   10  


<210>  801
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #14 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Asparagine, Arginine or Lysine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Tryptophan, Glycine, Threonine, Glutamate or Serine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Alanine, Glycine, Arginine or Leucine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is no amino acid, Threonine, Leucine or Arginine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is no amino acid, Arginine or Alanine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is no amino acid or Serine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is no amino acid, Glycine or Alanine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Glycine, no amino acid, Proline or Tryptophan

<400>  801

Ala Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Ala Tyr 
1               5                   10          


<210>  802
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-13AH as described in Table 2.

<400>  802

Ala Lys Thr Gly Phe Ala Tyr 
1               5           


<210>  803
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-28AH as described in Table 2.

<400>  803

Ala Arg Gly Gly Phe Ala Tyr 
1               5           


<210>  804
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-39AH as described in Table 2.

<400>  804

Ala Asn Trp Ala Gly Phe Ala Tyr 
1               5               


<210>  805
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of ITI_236H as described in Table 2.

<400>  805

Ala Arg Glu Arg Thr Gly Pro Phe Ala Tyr 
1               5                   10  


<210>  806
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of ITI_238H as described in Table 2.

<400>  806

Ala Arg Ser Ala Arg Ala Ala Trp Phe Ala Tyr 
1               5                   10      


<210>  807
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of ITI_240H as described in Table 2.

<400>  807

Ala Arg Glu Leu Leu Arg Ser Ala Trp Phe Ala Tyr 
1               5                   10          


<210>  808
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #6 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Threonine or Serine

<400>  808

Asn Xaa Arg Thr Leu Gly Tyr 
1               5           


<210>  809
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  809

Asn Ser Arg Thr Leu Gly Tyr 
1               5           


<210>  810
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S20-45AH as described in Table 2.

<400>  810

Asn Thr Arg Thr Leu Gly Tyr 
1               5           


<210>  811
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #12 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Isoleucine or Alanine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Tyrosine, Arginine or Serine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Aspartate or Serine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is no amino acid or Tyrosine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Serine or Alanine

<400>  811

Xaa Xaa Xaa Xaa Gly Xaa Tyr 
1               5           


<210>  812
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  812

Ala Ser Ser Gly Ala Tyr 
1               5       


<210>  813
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S19-4AH as described in Table 2.

<400>  813

Ala Arg Ser Tyr Gly Ser Tyr 
1               5           


<210>  814
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S20-56AH as described in Table 2.

<400>  814

Ile Tyr Asp Gly Ser Tyr 
1               5       


<210>  815
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #4 as described in 
       Table 2.

<400>  815

Ala Gly Ser Val Val Asp Arg Tyr Trp Tyr Phe Asp Val 
1               5                   10              


<210>  816
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #9 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Serine or Histidine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Arginine, Phenylalanine, Glutamate or Glycine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Arginine, Glycine, Aspartate or Tyrosine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is no amino acid or Tyrosine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is no amino acid or Glycine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is no amino acid, Asparagine, Glycine or Serine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Phenylalanine or Leucine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Valine or Tyrosine

<400>  816

Ala Arg Xaa Xaa Xaa Xaa Xaa Xaa Tyr Xaa Asp Xaa 
1               5                   10          


<210>  817
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-2AH as described in Table 2.

<400>  817

Ala Arg Ser Gly Tyr Tyr Gly Ser Tyr Leu Asp Tyr 
1               5                   10          


<210>  818
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-27AH as described in Table 2.

<400>  818

Ala Arg Ser Arg Arg Tyr Phe Asp Val 
1               5                   


<210>  819
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S20-22AH as described in Table 2.

<400>  819

Ala Arg Ser Phe Gly Asn Tyr Phe Asp Tyr 
1               5                   10  


<210>  820
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of ITI_237H as described in Table 2.

<400>  820

Ala Arg His Glu Asp Gly Tyr Leu Asp Tyr 
1               5                   10  


<210>  821
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #17 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Isoleucine or Leucine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Asparagine or Tyrosine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is no amino acid, Glycine or Valine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is no amino acid, Asparagine or Aspartate

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Aspartate or Asparagine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Serine or Tyrosine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Aspartate or Glutamate

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Glutamate or Alanine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Lysine, Cysteine or Tyrosine

<400>  821

Ala Arg Ser Xaa Xaa Tyr Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10              


<210>  822
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-21AH as described in Table 2.

<400>  822

Ala Arg Ser Ile Asn Tyr Asp Ser Asp Glu Lys 
1               5                   10      


<210>  823
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S20-26AH as described in Table 2.

<400>  823

Ala Arg Ser Leu Tyr Tyr Gly Asp Asn Tyr Glu Ala Tyr 
1               5                   10              


<210>  824
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of ITI_127H as described in Table 2.

<400>  824

Ala Arg Ser Leu Tyr Tyr Val Asn Asn Tyr Glu Ala Tyr 
1               5                   10              


<210>  825
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of ITI_128H as described in Table 2.

<400>  825

Ala Arg Ser Leu Tyr Tyr Gly Asn Asn Tyr Glu Ala Cys 
1               5                   10              


<210>  826
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #7 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Glycine or Leucine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Arginine or no amino acid

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Aspartate or Tyrosine

<400>  826

Ala Ser Xaa Xaa Xaa Tyr 
1               5       


<210>  827
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-6AH as described in Table 2.

<400>  827

Ala Ser Gly Arg Asp Tyr 
1               5       


<210>  828
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  828

Ala Ser Leu Tyr Tyr 
1               5   


<210>  829
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #13 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Glycine or Valine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Tyrosine or Aspartate

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Serine, Tyrosine or no amino acid

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Serine or Alanine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Serine or Methionine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Proline or Aspartate

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Tyrosine or Phenylalanine

<400>  829

Ala Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   


<210>  830
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-29AH as described in Table 2.

<400>  830

Ala Arg Gly Tyr Ser Ser Ser Pro Tyr 
1               5                   


<210>  831
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-2AH as described in Table 2.

<400>  831

Ala Arg Val Tyr Tyr Ala Met Asp Tyr 
1               5                   


<210>  832
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S19-24AH as described in Table 2.

<400>  832

Ala Arg Gly Asp Ala Met Asp Phe 
1               5               


<210>  833
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #18 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Histidine or Glycine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Glutamate, Aspartate or Glycine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Leucine or Aspartate

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Glycine or no amino acid

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Asparagine or no amino acid

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Arginine or no amino acid

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Serine, Tyrosine or Glycine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Arginine, Glycine or Leucine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Proline or Aspartate

<400>  833

Thr Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Xaa Tyr 
1               5                   10              


<210>  834
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-1AH as described in Table 2.

<400>  834

Thr Arg Gly Gly Asp Gly Leu Phe Asp Tyr 
1               5                   10  


<210>  835
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S19-5AH as described in Table 2.

<400>  835

Thr Arg Gly Asp Asp Tyr Gly Phe Asp Tyr 
1               5                   10  


<210>  836
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of ITI_203H as described in Table 2.

<400>  836

Thr Arg His Glu Leu Gly Asn Arg Ser Arg Phe Pro Tyr 
1               5                   10              


<210>  837
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #22 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Isoleucine, Arginine or Tryptophan

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Tyrosine or Glycine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Aspartate or no amino acid

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Glycine, Methionine or no amino acid

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Tyrosine, Aspartate or Asparagine

<400>  837

Thr Xaa Xaa Xaa Xaa Xaa Tyr 
1               5           


<210>  838
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-21AH as described in Table 2.

<400>  838

Thr Ile Tyr Asp Gly Tyr Tyr 
1               5           


<210>  839
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-27AH as described in Table 2.

<400>  839

Thr Trp Gly Asn Tyr 
1               5   


<210>  840
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-5AH as described in Table 2.

<400>  840

Thr Arg Gly Met Asp Tyr 
1               5       


<210>  841
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #16 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Valine or Threonine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Tyrosine or Lysine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Phenylalanine or Serine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Lysine or Leucine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Tyrosine or Leucine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Glycine or Tryptophan

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is no amino acid or Serine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is no amino acid or Leucine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Alanine or Glycine

<400>  841

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Xaa Phe Ala Tyr 
1               5                   10              


<210>  842
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S19-1AH as described in Table 2.

<400>  842

Val Tyr Phe Lys Tyr Gly Gly Ala Phe Ala Tyr 
1               5                   10      


<210>  843
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of ITI_023H as described in Table 2.

<400>  843

Thr Lys Ser Leu Leu Trp Ser Leu Gly Gly Phe Ala Tyr 
1               5                   10              


<210>  844
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #1 as described in 
       Table 2.

<400>  844

Thr Ser Arg Ser Trp Val Leu 
1               5           


<210>  845
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #2 as described in 
       Table 2.

<400>  845

Thr Lys Glu Pro Arg Thr Ile Glu Gly Ala Trp Phe Thr Tyr 
1               5                   10                  


<210>  846
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #3 as described in 
       Table 2.

<400>  846

Thr Lys Ile Tyr Tyr Asp Tyr Asp Asp Gly Tyr 
1               5                   10      


<210>  847
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of Consensus Cluster #11 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Serine or Alanine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Threonine or Isoleucine

<400>  847

Trp Gly Gln Gly Thr Xaa Val Xaa Val Ser Ser 
1               5                   10      


<210>  848
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  848

Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 
1               5                   10      


<210>  849
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of H5S20-41BH as described 
       in Table 2.

<400>  849

Trp Gly Gln Gly Thr Ser Val Ile Val Ser Ser 
1               5                   10      


<210>  850
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of ITI_047H as described in
       Table 2.

<400>  850

Trp Gly Gln Gly Thr Ala Val Thr Val Ser Ser 
1               5                   10      


<210>  851
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of Consensus Cluster #20 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Threonine or Leucine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Leucine or Valine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Valine or Isoleucine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Serine, Alanine or Threonine

<400>  851

Trp Gly Gln Gly Thr Xaa Xaa Thr Xaa Ser Xaa 
1               5                   10      


<210>  852
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  852

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala 
1               5                   10      


<210>  853
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of H5S14-8AH as described 
       in Table 2.

<400>  853

Trp Gly Gln Gly Thr Leu Val Thr Ile Ser Ala 
1               5                   10      


<210>  854
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of H5S15-16BH as described 
       in Table 2.

<400>  854

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Thr 
1               5                   10      


<210>  855
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of H5S20-11AH as described 
       in Table 2.

<400>  855

Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
1               5                   10      


<210>  856
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  856

Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser 
1               5                   10      


<210>  857
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of Consensus Cluster #23 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Valine or Leucine

<400>  857

Trp Gly Gln Gly Thr Xaa Xaa Thr Val Ser Ser 
1               5                   10      


<210>  858
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of Consensus Cluster #21 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Threonine or Leucine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Leucine or Valine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Serine or Alanine

<400>  858

Trp Gly Gln Gly Thr Xaa Xaa Thr Val Ser Xaa 
1               5                   10      


<210>  859
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of Consensus Cluster #10 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Valine or Phenylalanine

<400>  859

Trp Gly Gln Gly Xaa Ser Xaa Thr Val Ser Ser 
1               5                   10      


<210>  860
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of H5S15-33AH as described 
       in Table 2.

<400>  860

Trp Gly Gln Gly Thr Ser Phe Thr Val Ser Ser 
1               5                   10      


<210>  861
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of H5S20-21AH as described 
       in Table 2.

<400>  861

Trp Gly Gln Gly Ser Ser Val Thr Val Ser Ser 
1               5                   10      


<210>  862
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of Consensus Cluster #8 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Glycine or Serine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Threonine, Leucine or Isoleucine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Leucine or Valine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Serine or Alanine

<400>  862

Trp Gly Gln Xaa Thr Xaa Xaa Thr Val Ser Xaa 
1               5                   10      


<210>  863
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  863

Trp Gly Gln Gly Thr Ile Leu Thr Val Ser Ser 
1               5                   10      


<210>  864
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of ITI_032H as described in
       Table 2.

<400>  864

Trp Gly Gln Ser Thr Ile Leu Thr Val Ser Ser 
1               5                   10      


<210>  865
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of Consensus Cluster #12 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Leucine or Threonine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Valine or Leucine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Alanine or Serine

<400>  865

Trp Gly Gln Gly Thr Xaa Xaa Thr Val Ser Xaa 
1               5                   10      


<210>  866
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of Consensus Cluster #4 as 
       described in Table 2.

<400>  866

Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ser 
1               5                   10      


<210>  867
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of Consensus Cluster #9 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Alanine or Glutamine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Valine or Leucine

<400>  867

Trp Gly Xaa Gly Thr Thr Xaa Thr Val Ser Ser 
1               5                   10      


<210>  868
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of Consensus Cluster #17 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Serine or Leucine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Serine, no amino acid or Alanine

<400>  868

Trp Gly Gln Gly Thr Xaa Val Thr Val Ser Xaa 
1               5                   10      


<210>  869
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of ITI_128H as described in
       Table 2.

<400>  869

Trp Gly Gln Gly Thr Leu Val Thr Val Ser 
1               5                   10  


<210>  870
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of Consensus Cluster #13 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Leucine or Serine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Alanine or Serine

<400>  870

Trp Gly Gln Gly Thr Xaa Val Thr Val Ser Xaa 
1               5                   10      


<210>  871
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of Consensus Cluster #18 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Leucine, Threonine or Alanine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Valine or Leucine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Alanine or Serine

<400>  871

Trp Gly Gln Gly Thr Xaa Xaa Thr Val Ser Xaa 
1               5                   10      


<210>  872
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of H5S14-1AH as described 
       in Table 2.

<400>  872

Trp Gly Gln Gly Thr Ala Leu Thr Val Ser Ser 
1               5                   10      


<210>  873
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of Consensus Cluster #22 as
       described in Table 2.


<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Leucine, Serine or Threonine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Valine or Leucine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Alanine or Serine

<400>  873

Trp Gly Gln Gly Thr Xaa Xaa Thr Val Ser Xaa 
1               5                   10      


<210>  874
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S14-15AL as 
       described in Table 3.

<400>  874

Ser Ile Val Met Thr Gln Thr Pro Lys Phe Leu Leu Val Ser Ala Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Ser Asn Asp 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Glu Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Tyr Gly Thr Asp Phe Thr Phe Thr Ile Ser Thr Val Gln Ala 
65                  70                  75                  80  


Glu Asp Leu Ala Val Tyr Phe Cys Gln Gln Asp Tyr Ser Ser Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  875
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S14-16AL as 
       described in Table 3.

<400>  875

Ser Ile Val Met Thr Gln Thr Pro Lys Phe Leu Leu Val Ser Ala Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Ser Asn Asp 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Tyr Gly Thr Asp Phe Thr Phe Thr Ile Ser Thr Val Gln Ala 
65                  70                  75                  80  


Glu Asp Leu Ala Val Tyr Phe Cys Gln Gln Asp Tyr Ser Ser Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  876
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S14-18AL as 
       described in Table 3.

<400>  876

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met 
            20                  25                  30          


His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr 
        35                  40                  45              


Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu 
65                  70                  75                  80  


Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Phe Thr 
                85                  90                  95      


Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105     


<210>  877
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S14-1AL as described
       in Table 3.

<400>  877

Asp Val Gln Ile Thr Gln Ser Pro Ser Tyr Leu Ala Ala Ser Pro Gly 
1               5                   10                  15      


Glu Thr Ile Thr Ile Asn Cys Arg Ala Ser Lys Ser Ile Ser Lys Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Glu Lys Pro Gly Lys Thr Asn Gln Leu Leu Ile 
        35                  40                  45              


Tyr Ser Gly Ser Thr Leu Gln Ser Gly Ile Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Met Tyr Tyr Cys Gln Gln His Asn Glu Tyr Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  878
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S14-20AL as 
       described in Table 3.

<400>  878

Asn Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr 
            20                  25                  30          


Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 
        35                  40                  45              


Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp 
65                  70                  75                  80  


Pro Val Glu Ala Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Asn Asn 
                85                  90                  95      


Glu Asp Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110     


<210>  879
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S14-24AL as 
       described in Table 3.

<400>  879

Ser Ile Val Met Thr Gln Thr Pro Lys Phe Leu Leu Val Ser Ala Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Ser Asn Asp 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Tyr Gly Thr Asp Phe Thr Phe Thr Ile Ser Thr Val Gln Ala 
65                  70                  75                  80  


Glu Asp Leu Ala Val Tyr Phe Cys Gln Gln Asp Tyr Ser Ser Pro Leu 
                85                  90                  95      


Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105         


<210>  880
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S14-25AL as 
       described in Table 3.

<400>  880

Asp Ile Gln Met Thr Gln Ser Ser Ser Tyr Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Arg Val Thr Ile Thr Cys Lys Ala Ser Asp His Ile Asn Asn Trp 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Ser Gly Ala Thr Ser Leu Glu Thr Gly Val Pro Pro Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Lys Asp Tyr Thr Leu Ser Ile Thr Ser Leu Gln Thr 
65                  70                  75                  80  


Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Trp Ser Thr Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  881
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S14-4AL as described
       in Table 3.

<400>  881

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Ile Ser Cys Ser Ala Ser Ser Ser Val Ser Tyr Met 
            20                  25                  30          


Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr 
        35                  40                  45              


Arg Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu 
65                  70                  75                  80  


Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Tyr His Ser Tyr Pro Leu Thr 
                85                  90                  95      


Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105     


<210>  882
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S14-4BL as described
       in Table 3.

<400>  882

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Ile Ser Cys Ser Ala Ser Ser Ser Val Ser Tyr Met 
            20                  25                  30          


Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr 
        35                  40                  45              


Arg Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Ser Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu 
65                  70                  75                  80  


Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Tyr His Ser Tyr Pro Leu Thr 
                85                  90                  95      


Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105     


<210>  883
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S14-6AL as described
       in Table 3.

<400>  883

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Gln Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Ser Val Thr Ile Thr Cys Leu Ala Ser Gln Thr Ile Gly Thr Trp 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Gln Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Thr Ser Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Lys Phe Ser Phe Lys Ile Ser Ser Leu Gln Ala 
65                  70                  75                  80  


Glu Asp Phe Val Ser Tyr Tyr Cys Gln Gln Leu His Ser Thr Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  884
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-13AL as 
       described in Table 3.

<400>  884

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp 
            20                  25                  30          


Gly Glu Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 
        35                  40                  45              


Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Asp Ser Gly Ile Pro Ala 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 
65                  70                  75                  80  


Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Asn 
                85                  90                  95      


Glu Asp Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105                 110     


<210>  885
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-14AL as 
       described in Table 3.

<400>  885

Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser 
65                  70                  75                  80  


Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Asn Leu Glu Ile Lys 
            100                 105         


<210>  886
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-14BL as 
       described in Table 3.

<400>  886

Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Arg Pro Gly Gln Ser Pro Lys Ser Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser 
65                  70                  75                  80  


Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gly Gly Ala Lys Leu Glu Ile Lys 
            100                 105         


<210>  887
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-14CL as 
       described in Table 3.

<400>  887

Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser 
65                  70                  75                  80  


Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 
            100                 105     


<210>  888
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-15AL as 
       described in Table 3.

<400>  888

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met 
            20                  25                  30          


His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr 
        35                  40                  45              


Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu 
65                  70                  75                  80  


Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Leu Thr 
                85                  90                  95      


Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105     


<210>  889
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-18AL as 
       described in Table 3.

<400>  889

Glu Asn Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Ser Ser 
            20                  25                  30          


Tyr Leu His Trp Tyr Gln Gln Lys Ser Gly Ala Ser Pro Lys Leu Trp 
        35                  40                  45              


Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Val Glu 
65                  70                  75                  80  


Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Gly Tyr Pro 
                85                  90                  95      


Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105             


<210>  890
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-24AL as 
       described in Table 3.

<400>  890

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp 
            20                  25                  30          


Gly Asn Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Arg Gln Pro Pro 
        35                  40                  45              


Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala 
    50                  55                  60                  


Arg Phe Arg Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 
65                  70                  75                  80  


Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Asn 
                85                  90                  95      


Glu Asp Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110     


<210>  891
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-28AL as 
       described in Table 3.

<400>  891

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Ser Leu Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  892
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-29AL as 
       described in Table 3.

<400>  892

Glu Ile Val Leu Thr Gln Ser Pro Ala Leu Met Thr Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Ile Thr Cys Ser Val Ser Ser Thr Ile Ser Ser Arg 
            20                  25                  30          


Asn Leu His Trp Tyr Gln Gln Lys Ser Glu Ala Ser Pro Lys Pro Trp 
        35                  40                  45              


Ile Tyr Gly Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu 
65                  70                  75                  80  


Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Asn Ser Tyr Pro 
                85                  90                  95      


Leu Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105             


<210>  893
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-4AL as described
       in Table 3.

<400>  893

Glu Ile Val Leu Thr Gln Ser Pro Ala Leu Met Ala Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Ile Thr Cys Ser Val Ser Ser Gly Ile Arg Ser Ser 
            20                  25                  30          


Asn Leu His Trp Tyr Gln Gln Lys Ser Glu Thr Ser Pro Lys Pro Trp 
        35                  40                  45              


Ile Tyr Gly Thr Ser Asn Leu Ala Ser Gly Val Pro Ile Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu 
65                  70                  75                  80  


Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Tyr Pro 
                85                  90                  95      


Leu Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105             


<210>  894
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S19-11AL as 
       described in Table 3.

<400>  894

Glu Ile Val Leu Thr Gln Ser Pro Ala Leu Met Ala Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Ile Thr Cys Ser Val Ser Ser Ser Ile Ser Ser Ser 
            20                  25                  30          


Asn Leu His Trp Tyr Gln Gln Lys Ser Glu Thr Ser Pro Lys Pro Trp 
        35                  40                  45              


Ile Tyr Gly Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu 
65                  70                  75                  80  


Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Tyr Pro 
                85                  90                  95      


Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105             


<210>  895
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S19-17AL as 
       described in Table 3.

<400>  895

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly Ile Ser Asn Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Lys Leu Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  896
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S19-17BL as 
       described in Table 3.

<400>  896

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly Ile Ser Asn Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Arg Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Lys Leu Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  897
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S19-17CL as 
       described in Table 3.

<400>  897

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly Ile Ser Asn Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Tyr Ser Lys Leu Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  898
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S19-17DL as 
       described in Table 3.

<400>  898

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly Ile Ser Asn Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Ser Leu Ser Ile Ser Asn Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Lys Leu Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  899
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S19-17EL as 
       described in Table 3.

<400>  899

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly Ile Ser Asn Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Phe Ser Asn Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Lys Leu Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  900
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S19-17FL as 
       described in Table 3.

<400>  900

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly Ile Ser Asn Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Lys Leu Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 
            100                 105     


<210>  901
<211>  110
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S19-1AL as described
       in Table 3.

<400>  901

Asn Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr 
            20                  25                  30          


Gly Asn Ser Leu Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 
        35                  40                  45              


Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp 
65                  70                  75                  80  


Pro Val Glu Ala Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Asn Asn 
                85                  90                  95      


Glu Asp Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 
            100                 105                 110 


<210>  902
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S19-20AL as 
       described in Table 3.

<400>  902

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Thr Ala Ser Gln Gly Ile Ser Asn Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Thr Ser Thr Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Phe Lys Leu Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  903
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S19-23AL as 
       described in Table 3.

<400>  903

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly Ile Asn Asn Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Lys Leu Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  904
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S19-26AL as 
       described in Table 3.

<400>  904

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Thr Ala Ser Gln Gly Ile Asn Asn Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Thr Ser Thr Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Phe Lys Leu Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  905
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S19-28AL as 
       described in Table 3.

<400>  905

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Thr Ala Ser Gln Gly Ile Ser Asn Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Thr Ser Thr Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Lys Leu Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Ala Ile Lys 
            100                 105         


<210>  906
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S19-6AL as described
       in Table 3.

<400>  906

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met 
            20                  25                  30          


Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Arg Leu Leu Ile Tyr 
        35                  40                  45              


Asp Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu 
65                  70                  75                  80  


Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Tyr Pro Phe Thr 
                85                  90                  95      


Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105     


<210>  907
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S19-8AL as described
       in Table 3.

<400>  907

Asp Val Gln Ile Thr Gln Ser Pro Ser Tyr Leu Ala Ala Ser Pro Gly 
1               5                   10                  15      


Glu Thr Ile Thr Ile Asn Cys Arg Thr Ser Lys Asn Ile Ser Lys Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Glu Lys Pro Gly Lys Thr Asn Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ser Gly Ser Thr Leu Gln Ser Gly Ile Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Val Met Tyr His Cys Gln Gln His Asn Glu Tyr Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  908
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-13AL as 
       described in Table 3.

<400>  908

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp 
            20                  25                  30          


Gly Asn Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 
        35                  40                  45              


Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 
65                  70                  75                  80  


Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Asn 
                85                  90                  95      


Glu Asp Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110     


<210>  909
<211>  105
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-16AL as 
       described in Table 3.

<400>  909

Gln Ile Val Leu Thr Gln Ser Pro Ala Leu Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Phe Ile 
            20                  25                  30          


Tyr Trp Tyr Gln Gln Lys Pro Arg Ser Ser Pro Lys Pro Trp Ile Ser 
        35                  40                  45              


Leu Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu 
65                  70                  75                  80  


Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Leu Thr 
                85                  90                  95      


Phe Gly Ala Gly Thr Lys Leu Glu Leu 
            100                 105 


<210>  910
<211>  105
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-16BL as 
       described in Table 3.

<400>  910

Gln Ile Val Leu Thr Gln Ser Pro Ala Leu Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Phe Ile 
            20                  25                  30          


Tyr Trp Tyr Gln Gln Lys Pro Arg Ser Ser Pro Lys Pro Trp Ile Tyr 
        35                  40                  45              


Leu Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu 
65                  70                  75                  80  


Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Leu Thr 
                85                  90                  95      


Phe Gly Ala Gly Thr Lys Leu Glu Leu 
            100                 105 


<210>  911
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-17AL as 
       described in Table 3.

<400>  911

Asp Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Thr Pro Gly 
1               5                   10                  15      


Asp Arg Val Ser Leu Ser Cys Arg Ala Ser Arg Thr Ile Ser Asp Tyr 
            20                  25                  30          


Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu Leu Ile 
        35                  40                  45              


Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Ser Asp Phe Thr Leu Ser Ile Ser Ser Val Glu Pro 
65                  70                  75                  80  


Glu Asp Val Gly Met Tyr Tyr Cys Gln Asn Gly His Ser Phe Pro Leu 
                85                  90                  95      


Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105         


<210>  912
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-18AL as 
       described in Table 3.

<400>  912

Asn Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr 
            20                  25                  30          


Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 
        35                  40                  45              


Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp 
65                  70                  75                  80  


Pro Val Glu Ala Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Asn Tyr 
                85                  90                  95      


Ala Asp Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110     


<210>  913
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-20AL as 
       described in Table 3.

<400>  913

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp 
            20                  25                  30          


Gly Asp Ser Phe Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 
        35                  40                  45              


Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 
65                  70                  75                  80  


Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Asn 
                85                  90                  95      


Glu Asp Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110     


<210>  914
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-23AL as 
       described in Table 3.

<400>  914

Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Thr Val Pro Ala Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser 
            20                  25                  30          


Glu Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Ser 
                85                  90                  95      


Asp Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu 
            100                 105                 110         


Lys 
    


<210>  915
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-32AL as 
       described in Table 3.

<400>  915

Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser 
65                  70                  75                  80  


Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Phe 
                85                  90                  95      


Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  916
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-34AL as 
       described in Table 3.

<400>  916

Gln Ile Val Leu Thr Gln Ser Pro Ala Leu Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Thr Cys Thr Ala Ser Ser Ser Val Ser Tyr Met 
            20                  25                  30          


Tyr Trp Tyr Gln Gln Lys Pro Arg Ser Ser Pro Lys Pro Trp Ile Tyr 
        35                  40                  45              


Leu Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu 
65                  70                  75                  80  


Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Leu Thr 
                85                  90                  95      


Phe Gly Ala Gly Thr Lys Leu Glu Leu Arg 
            100                 105     


<210>  917
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-36AL and 
       H5S20-43AL as described in Table 3.

<400>  917

Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser 
65                  70                  75                  80  


Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  918
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-40AL as 
       described in Table 3.

<400>  918

Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser 
65                  70                  75                  80  


Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Leu 
                85                  90                  95      


Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105         


<210>  919
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-8AL as described
       in Table 3.

<400>  919

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp 
            20                  25                  30          


Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 
        35                  40                  45              


Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 
65                  70                  75                  80  


Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Asn 
                85                  90                  95      


Glu Asp Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110     


<210>  920
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-8BL as described
       in Table 3.

<400>  920

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp 
            20                  25                  30          


Gly Asp Ser Tyr Met Asn Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro 
        35                  40                  45              


Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 
65                  70                  75                  80  


Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Asn 
                85                  90                  95      


Glu Asp Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110     


<210>  921
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_021L as described 
       in Table 3.

<400>  921

Asn Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr 
            20                  25                  30          


Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 
        35                  40                  45              


Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp 
65                  70                  75                  80  


Pro Val Glu Ala Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Asn Asn 
                85                  90                  95      


Glu Asp Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110     


<210>  922
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_040L as described 
       in Table 3.

<400>  922

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Ile Ser Cys Ser Ala Ser Ser Ser Ile Ser Tyr Met 
            20                  25                  30          


Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr 
        35                  40                  45              


Arg Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu 
65                  70                  75                  80  


Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Tyr His Ser Tyr Pro Leu Thr 
                85                  90                  95      


Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105     


<210>  923
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_045L as described 
       in Table 3.

<400>  923

Glu Ile Val Leu Thr Gln Ser Pro Thr Thr Met Ala Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Ile Thr Ile Thr Cys Ser Ala Ser Ser Ser Ile Asn Ser Asn 
            20                  25                  30          


Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Phe Ser Pro Lys Leu Leu 
        35                  40                  45              


Ile Tyr Arg Thr Ser Asn Leu Ala Ser Gly Val Pro Pro Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Gly Thr Met Glu 
65                  70                  75                  80  


Ala Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Gly Ser Thr Ile Pro 
                85                  90                  95      


Tyr Thr Phe Gly Gly Gly Ala Lys Leu Glu Ile Lys 
            100                 105             


<210>  924
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_082L as described 
       in Table 3.

<400>  924

Glu Asn Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Ser Cys Arg Ala Ser Ser Ser Val Asn Tyr Met 
            20                  25                  30          


Tyr Trp Tyr Gln Gln Lys Ser Asp Ala Ser Pro Lys Leu Trp Ile Tyr 
        35                  40                  45              


Tyr Thr Ser Asn Leu Ala Pro Gly Val Pro Ala Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Asn Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Gly Glu 
65                  70                  75                  80  


Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Phe Thr Ser Ser Thr Trp Thr 
                85                  90                  95      


Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105     


<210>  925
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_083L as described 
       in Table 3.

<400>  925

Glu Asn Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Ser Cys Arg Ala Ser Ser Ser Val Asn Tyr Met 
            20                  25                  30          


Phe Trp Tyr Gln Gln Lys Ser Asp Ala Ser Pro Lys Leu Trp Ile Tyr 
        35                  40                  45              


Ser Thr Ser Asn Leu Thr Pro Gly Val Pro Ala Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Asn Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu 
65                  70                  75                  80  


Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Phe Thr Ser Ser Thr Trp Thr 
                85                  90                  95      


Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105     


<210>  926
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_131L as described 
       in Table 3.

<400>  926

Glu Ile Val Leu Thr Gln Ser Pro Ala Leu Met Ala Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Ile Thr Cys Ser Val Ser Ser Ser Ile Ser Ser Ser 
            20                  25                  30          


Asn Leu His Trp Tyr Gln Gln Lys Ser Glu Thr Ser Pro Lys Pro Trp 
        35                  40                  45              


Ile Tyr Gly Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu 
65                  70                  75                  80  


Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Tyr Pro 
                85                  90                  95      


Leu Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105             


<210>  927
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_144L as described 
       in Table 3.

<400>  927

Asp Ile Gln Met Thr Gln Thr Pro Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Asp Ile Asn Asn Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Thr Ser Ser Leu His Ser Gly Ala Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Asp Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Lys Leu Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  928
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_145L as described 
       in Table 3.

<400>  928

Asp Ile Gln Met Thr Gln Thr Pro Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Asp Ile Asn Asn Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 
        35                  40                  45              


Phe Tyr Thr Ser Ser Leu His Ser Gly Ala Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Asp Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Lys Leu Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  929
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_146L as described 
       in Table 3.

<400>  929

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly Ile Arg Asn Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Lys Leu Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  930
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_162L as described 
       in Table 3.

<400>  930

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Thr Ala Ser Gln Gly Ile Ser Asn Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Thr Ser Thr Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Asn Asn Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Lys Leu Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  931
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_166L as described 
       in Table 3.

<400>  931

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Lys Leu Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  932
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_169L as described 
       in Table 3.

<400>  932

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly Ile Thr Lys Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Lys Leu Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  933
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_200L as described 
       in Table 3.

<400>  933

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp 
            20                  25                  30          


Gly Glu Ser Tyr Ile Asn Trp Tyr Gln Gln Arg Pro Gly Gln Pro Ala 
        35                  40                  45              


Lys Leu Leu Ile Phe Ala Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 
65                  70                  75                  80  


Pro Val Glu Glu Glu Asp Ala Ala Ser Tyr Tyr Cys Gln His Cys Tyr 
                85                  90                  95      


Glu Asp Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110     


<210>  934
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_236L as described 
       in Table 3.

<400>  934

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  935
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_237L as described 
       in Table 3.

<400>  935

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly Ile Ser Asn Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Lys Leu Pro Arg 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  936
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S14-11AL as 
       described in Table 3.

<400>  936

Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 
            20                  25                  30          


Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Leu 
                85                  90                  95      


Thr His Phe Pro Gln Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  937
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S14-13AL and 
       H5S19-7AL as described in Table 3.

<400>  937

Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly 
                85                  90                  95      


Ser His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  938
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S14-17AL as 
       described in Table 3.

<400>  938

Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 
            20                  25                  30          


Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Val 
                85                  90                  95      


Thr His Phe Pro Gln Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  939
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S14-2AL as described
       in Table 3.

<400>  939

Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 
            20                  25                  30          


Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Gly 
                85                  90                  95      


Thr His Phe Pro His Ala Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  940
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-12CL as 
       described in Table 3.

<400>  940

Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 
            20                  25                  30          


Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys Trp Gln Gly 
                85                  90                  95      


Thr His Phe Pro Gln Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  941
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-16AL as 
       described in Table 3.

<400>  941

Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 
            20                  25                  30          


Asn Gly Ile Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Glu Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly 
                85                  90                  95      


Ser His Val Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105                 110         


<210>  942
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-17AL as 
       described in Table 3.

<400>  942

Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Val Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 
            20                  25                  30          


Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Arg Asp Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Asn 
                85                  90                  95      


Thr His Phe Pro Gln Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  943
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-1AL as described
       in Table 3.

<400>  943

Glu Asn Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Thr Cys Ser Ala Gly Ser Ser Val Ser Tyr Met 
            20                  25                  30          


His Trp Tyr Gln Gln Lys Ser Ser Thr Ser Pro Lys Leu Trp Ile Tyr 
        35                  40                  45              


Asp Thr Ser Lys Leu Pro Ser Gly Val Pro Gly Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Asn Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu 
65                  70                  75                  80  


Asp Val Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Phe Pro Leu Thr 
                85                  90                  95      


Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105     


<210>  944
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-31AL as 
       described in Table 3.

<400>  944

Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 
            20                  25                  30          


Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Ala 
                85                  90                  95      


Thr His Phe Pro Gln Thr Phe Gly Gly Gly Thr Asn Leu Glu Ile Lys 
            100                 105                 110         


<210>  945
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-3AL as described
       in Table 3.

<400>  945

Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly 
                85                  90                  95      


Ser His Val Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105                 110         


<210>  946
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-3BL as described
       in Table 3.

<400>  946

Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Thr Val Ser Leu Gly 
1               5                   10                  15      


His Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly 
                85                  90                  95      


Ser His Val Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105                 110         


<210>  947
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-6AL as described
       in Table 3.

<400>  947

Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 
            20                  25                  30          


Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Asn 
                85                  90                  95      


Thr His Phe Pro Gln Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  948
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-19AL as 
       described in Table 3.

<400>  948

Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 
            20                  25                  30          


Asp Gly Lys Thr Tyr Leu Ser Trp Leu Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Asn 
                85                  90                  95      


Thr His Phe Pro Gln Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  949
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-19BL as 
       described in Table 3.

<400>  949

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Ile Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 
            20                  25                  30          


Asp Gly Lys Thr Tyr Leu Ser Trp Leu Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Asn 
                85                  90                  95      


Thr His Phe Pro Gln Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  950
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-21AL as 
       described in Table 3.

<400>  950

Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Val Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly 
                85                  90                  95      


Ser His Val Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105                 110         


<210>  951
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-24AL as 
       described in Table 3.

<400>  951

Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 
            20                  25                  30          


Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Asn 
                85                  90                  95      


Thr His Phe Pro Gln Thr Leu Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  952
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-25AL as 
       described in Table 3.

<400>  952

Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 
            20                  25                  30          


Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Gly 
                85                  90                  95      


Thr His Phe Pro Gln Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  953
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-26AL as 
       described in Table 3.

<400>  953

Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 
            20                  25                  30          


Asp Gly Lys Thr Tyr Leu Tyr Trp Leu Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Tyr Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Asn 
                85                  90                  95      


Thr His Phe Pro Gln Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  954
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-31AL as 
       described in Table 3.

<400>  954

Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 
            20                  25                  30          


Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Val Asp Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Asn 
                85                  90                  95      


Thr His Phe Pro Gln Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  955
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-39AL as 
       described in Table 3.

<400>  955

Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile Val His Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly 
                85                  90                  95      


Ser His Val Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105                 110         


<210>  956
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-3BL as described
       in Table 3.

<400>  956

Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 
            20                  25                  30          


Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Ala 
                85                  90                  95      


Thr His Phe Pro Gln Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  957
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-41AL as 
       described in Table 3.

<400>  957

Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser 
            20                  25                  30          


Asn Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Val Gln Gly 
                85                  90                  95      


Thr His Phe Pro Met Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 
            100                 105                 110         


Lys 
    


<210>  958
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-7AL as described
       in Table 3.

<400>  958

Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 
            20                  25                  30          


Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Asn 
                85                  90                  95      


Thr His Phe Pro Gln Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  959
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-7BL as described
       in Table 3.

<400>  959

Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 
            20                  25                  30          


Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys Trp Gln Asn 
                85                  90                  95      


Thr His Phe Pro Gln Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  960
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-7CL as described
       in Table 3.

<400>  960

Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Ile Thr Ile Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 
            20                  25                  30          


Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Asn 
                85                  90                  95      


Thr His Phe Pro Gln Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  961
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-7DL as described
       in Table 3.

<400>  961

Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 
            20                  25                  30          


Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Asn 
                85                  90                  95      


Thr His Phe Pro Gln Thr Phe Gly Gly Gly Thr Glu Leu Glu Ile Lys 
            100                 105                 110         


<210>  962
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-7EL as described
       in Table 3.

<400>  962

Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly 
1               5                   10                  15      


Gln Thr Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 
            20                  25                  30          


Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Asn 
                85                  90                  95      


Thr His Phe Pro Gln Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  963
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-9AL as described
       in Table 3.

<400>  963

Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Asn Leu Gly 
1               5                   10                  15      


Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly 
                85                  90                  95      


Ser His Val Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105                 110         


<210>  964
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-9DL as described
       in Table 3.

<400>  964

Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly 
                85                  90                  95      


Ser His Val Pro Leu Thr Phe Gly Thr Gly Thr Lys Leu Glu Leu Lys 
            100                 105                 110         


<210>  965
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-9EL as described
       in Table 3.

<400>  965

Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Asn Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly 
                85                  90                  95      


Ser His Val Pro Leu Thr Phe Gly Thr Gly Thr Lys Leu Glu Leu Lys 
            100                 105                 110         


<210>  966
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_047L as described 
       in Table 3.

<400>  966

Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 
            20                  25                  30          


Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Thr Gly Asn Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Ala 
                85                  90                  95      


Thr His Phe Pro Gln Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  967
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_091L as described 
       in Table 3.

<400>  967

Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly 
                85                  90                  95      


Ser His Val Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105                 110         


<210>  968
<211>  104
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S14-3AL as described
       in Table 3.

<400>  968

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Glu Ile Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met 
            20                  25                  30          


Gln Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Leu Leu Ile Tyr 
        35                  40                  45              


Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Phe Tyr Ser Leu Thr Ile Ser Ser Val Glu Ala Glu 
65                  70                  75                  80  


Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser Ser Tyr Pro Thr Phe 
                85                  90                  95      


Gly Gly Gly Thr Glu Leu Glu Ile 
            100                 


<210>  969
<211>  105
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S14-5AL as described
       in Table 3.

<400>  969

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Ile Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Glu Val Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met 
            20                  25                  30          


His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Leu Leu Ile Tyr 
        35                  40                  45              


Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Phe Tyr Ser Leu Thr Ile Ser Ser Val Glu Ala Glu 
65                  70                  75                  80  


Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser Ser Tyr Leu Thr Phe 
                85                  90                  95      


Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105 


<210>  970
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-8AL as described
       in Table 3.

<400>  970

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Glu Ile Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Ser Phe Met 
            20                  25                  30          


His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Leu Leu Ile Tyr 
        35                  40                  45              


Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Phe Tyr Ser Leu Thr Ile Ser Ser Val Glu Ala Glu 
65                  70                  75                  80  


Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser Ser Tyr Leu Trp Thr 
                85                  90                  95      


Phe Gly Gly Gly Ala Lys Leu Glu Ile Lys 
            100                 105     


<210>  971
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S19-10AL as 
       described in Table 3.

<400>  971

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Asp Ser Ser 
            20                  25                  30          


Tyr Leu Phe Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp 
        35                  40                  45              


Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu 
65                  70                  75                  80  


Ala Glu Asp Ala Ala Ser Tyr Phe Cys His Gln Trp Ser Ser Tyr Pro 
                85                  90                  95      


Trp Thr Phe Gly Gly Gly Thr Ile Leu Glu Ile Lys 
            100                 105             


<210>  972
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S19-10BL as 
       described in Table 3.

<400>  972

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Asp Ser Ser 
            20                  25                  30          


Tyr Leu Phe Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp 
        35                  40                  45              


Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu 
65                  70                  75                  80  


Ala Glu Asp Ala Ala Ser Tyr Phe Cys His Gln Trp Ser Ser Tyr Pro 
                85                  90                  95      


Trp Thr Phe Gly Gly Gly Thr Ile Leu Glu Ile 
            100                 105         


<210>  973
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S19-14AL as 
       described in Table 3.

<400>  973

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Asp Ser Ser 
            20                  25                  30          


Tyr Leu Phe Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp 
        35                  40                  45              


Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Ser Tyr Tyr Leu Thr Leu Ser Ser Met Glu 
65                  70                  75                  80  


Ala Glu Asp Ala Ala Ser Tyr Phe Cys His Gln Trp Ser Asn Phe Ala 
                85                  90                  95      


Trp Thr Phe Gly Gly Gly Thr Ile Leu Glu Ile Lys 
            100                 105             


<210>  974
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S19-16AL as 
       described in Table 3.

<400>  974

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Asp Ser Ser 
            20                  25                  30          


Tyr Leu Tyr Trp Phe Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp 
        35                  40                  45              


Ile Tyr Gly Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu 
65                  70                  75                  80  


Ala Glu Asp Ala Ala Ser Tyr Phe Cys His Gln Trp Asn Ser Tyr Pro 
                85                  90                  95      


Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105             


<210>  975
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S19-16BL as 
       described in Table 3.

<400>  975

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Asp Ser Ser 
            20                  25                  30          


Tyr Leu Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp 
        35                  40                  45              


Ile Tyr Gly Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu 
65                  70                  75                  80  


Ala Glu Asp Ala Ala Ser Tyr Phe Cys His Gln Trp Asn Ser Tyr Pro 
                85                  90                  95      


Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105             


<210>  976
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S19-18AL as 
       described in Table 3.

<400>  976

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Thr Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Ser Ser Ser 
            20                  25                  30          


Tyr Leu Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp 
        35                  40                  45              


Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu 
65                  70                  75                  80  


Ala Glu Asp Ala Ala Ser Tyr Phe Cys His Gln Trp Ser Thr Tyr Pro 
                85                  90                  95      


Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105             


<210>  977
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S19-19AL as 
       described in Table 3.

<400>  977

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Ser Ser Ser 
            20                  25                  30          


Tyr Leu Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp 
        35                  40                  45              


Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu 
65                  70                  75                  80  


Ala Glu Asp Ala Ala Ser Tyr Phe Cys His Gln Trp Ser Ser Tyr Pro 
                85                  90                  95      


Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105             


<210>  978
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S19-3AL as described
       in Table 3.

<400>  978

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Asp Ser Ser 
            20                  25                  30          


Tyr Leu Phe Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp 
        35                  40                  45              


Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu 
65                  70                  75                  80  


Ala Glu Asp Ala Ala Ser Tyr Phe Cys His Gln Trp Asn Ser Tyr Pro 
                85                  90                  95      


Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105             


<210>  979
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S19-4AL as described
       in Table 3.

<400>  979

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Asp Ser Ser 
            20                  25                  30          


Tyr Leu Phe Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp 
        35                  40                  45              


Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Ser Tyr Tyr Leu Thr Ile Ser Ser Met Glu 
65                  70                  75                  80  


Ala Glu Asp Ala Ala Ser Tyr Phe Cys His Gln Trp Ser Ser Tyr Ala 
                85                  90                  95      


Trp Thr Phe Gly Gly Gly Thr Ile Leu Glu Ile Lys 
            100                 105             


<210>  980
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S19-5AL as described
       in Table 3.

<400>  980

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Asp Ser Ser 
            20                  25                  30          


Tyr Leu Phe Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp 
        35                  40                  45              


Leu Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Ser Tyr Tyr Leu Thr Ile Ser Ser Met Glu 
65                  70                  75                  80  


Ala Glu Asp Ala Ala Ser Tyr Phe Cys His Gln Trp Ser Asn Tyr Ala 
                85                  90                  95      


Trp Thr Phe Gly Gly Gly Thr Ile Leu Glu Ile Lys 
            100                 105             


<210>  981
<211>  105
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-10AL as 
       described in Table 3.

<400>  981

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Glu Ile Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met 
            20                  25                  30          


His Trp Tyr Gln Gln Arg Ser Gly Thr Ser Pro Lys Leu Leu Ile Tyr 
        35                  40                  45              


Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Phe Tyr Ser Leu Thr Ile Ser Ser Val Glu Ala Glu 
65                  70                  75                  80  


Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser Ser Tyr Arg Thr Phe 
                85                  90                  95      


Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105 


<210>  982
<211>  105
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-15AL as 
       described in Table 3.

<400>  982

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Glu Ile Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met 
            20                  25                  30          


His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Leu Leu Ile Tyr 
        35                  40                  45              


Ser Ala Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Phe Tyr Ser Leu Thr Ile Ser Ser Val Glu Ala Glu 
65                  70                  75                  80  


Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser Ser Tyr Arg Thr Phe 
                85                  90                  95      


Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105 


<210>  983
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-22AL as 
       described in Table 3.

<400>  983

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Glu Ile Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met 
            20                  25                  30          


His Trp Tyr Gln Gln Lys Ser Gly Ser Ser Pro Lys Leu Leu Ile Tyr 
        35                  40                  45              


Thr Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Phe Tyr Ser Leu Thr Ile Ser Ser Val Glu Ala Glu 
65                  70                  75                  80  


Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser Ser Tyr Thr Trp Thr 
                85                  90                  95      


Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105     


<210>  984
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_027L as described 
       in Table 3.

<400>  984

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Asp Ser Ser 
            20                  25                  30          


Tyr Leu Phe Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp 
        35                  40                  45              


Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu 
65                  70                  75                  80  


Ala Glu Asp Ala Ala Ser Tyr Phe Cys His Gln Trp Ser Ser Tyr Pro 
                85                  90                  95      


Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105             


<210>  985
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_028L as described 
       in Table 3.

<400>  985

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Asp Ser Ser 
            20                  25                  30          


Tyr Leu Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp 
        35                  40                  45              


Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu 
65                  70                  75                  80  


Ala Glu Asp Ala Ala Ser Tyr Phe Cys His Gln Trp Asn Ser Tyr Pro 
                85                  90                  95      


Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105             


<210>  986
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_029L as described 
       in Table 3.

<400>  986

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Asp Ser Ser 
            20                  25                  30          


Tyr Leu Phe Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp 
        35                  40                  45              


Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu 
65                  70                  75                  80  


Ala Glu Asp Ala Ala Ser Tyr Phe Cys His Gln Trp Ser Ser Tyr Ala 
                85                  90                  95      


Trp Thr Phe Gly Gly Gly Thr Ile Leu Glu Ile Lys 
            100                 105             


<210>  987
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_030L as described 
       in Table 3.

<400>  987

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Asp Ser Ser 
            20                  25                  30          


Tyr Leu Tyr Trp Phe Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp 
        35                  40                  45              


Ile Tyr Gly Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu 
65                  70                  75                  80  


Ala Glu Asp Ala Ala Ser Tyr Phe Cys His Gln Trp Asn Ser Tyr Pro 
                85                  90                  95      


Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105             


<210>  988
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_033L as described 
       in Table 3.

<400>  988

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Asp Ser Ser 
            20                  25                  30          


Tyr Leu Phe Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp 
        35                  40                  45              


Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu 
65                  70                  75                  80  


Ala Glu Asp Ala Ala Ser Tyr Phe Cys His Gln Trp Ser Ser Tyr Pro 
                85                  90                  95      


Trp Thr Phe Gly Gly Gly Thr Met Leu Glu Ile Lys 
            100                 105             


<210>  989
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_038L as described 
       in Table 3.

<400>  989

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Asp Ser Ser 
            20                  25                  30          


Tyr Leu Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp 
        35                  40                  45              


Ile Tyr Gly Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu 
65                  70                  75                  80  


Ala Glu Asp Ala Ala Ser Tyr Phe Cys His Gln Trp Asn Ser Tyr Pro 
                85                  90                  95      


Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105             


<210>  990
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_127L as described 
       in Table 3.

<400>  990

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Glu Ile Thr Leu Thr Cys Ser Ala Arg Ser Ser Val Ser Tyr Met 
            20                  25                  30          


Phe Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Leu Leu Ile Tyr 
        35                  40                  45              


Thr Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Phe Phe Ser Leu Thr Ile Ser Gly Val Glu Ala Glu 
65                  70                  75                  80  


Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser Ser Tyr Thr Trp Thr 
                85                  90                  95      


Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105     


<210>  991
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_128L as described 
       in Table 3.

<400>  991

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Val Ser Ala Ser Leu Gly 
1               5                   10                  15      


Ala Glu Ile Thr Leu Thr Cys Ser Ala Arg Ser Thr Val Ser Tyr Met 
            20                  25                  30          


Phe Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Leu Leu Ile Tyr 
        35                  40                  45              


Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Phe Tyr Ser Leu Thr Ile Ser Gly Val Glu Ala Glu 
65                  70                  75                  80  


Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser Ser Tyr Thr Trp Thr 
                85                  90                  95      


Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105     


<210>  992
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S14-21AL as 
       described in Table 3.

<400>  992

Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser 
            20                  25                  30          


Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln 
                85                  90                  95      


Tyr Tyr Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 
            100                 105                 110         


Lys 
    


<210>  993
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S14-22AL as 
       described in Table 3.

<400>  993

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Arg Val Ser Leu Thr Cys Arg Ala Ser Gln Glu Ile Ser Gly Tyr 
            20                  25                  30          


Leu Ser Trp Leu Gln Gln Lys Pro Asp Gly Thr Ile Lys Arg Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Thr Leu Asp Ser Gly Val Pro Lys Arg Phe Ser Gly 
    50                  55                  60                  


Ser Arg Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser 
65                  70                  75                  80  


Glu Asp Phe Ala Asp Tyr Tyr Cys Leu Gln Tyr Ala Ser Tyr Pro Phe 
                85                  90                  95      


Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  994
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S14-23AL as 
       described in Table 3.

<400>  994

Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly 
1               5                   10                  15      


Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr 
            20                  25                  30          


Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile 
        35                  40                  45              


Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr 
65                  70                  75                  80  


Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  995
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-19AL as 
       described in Table 3.

<400>  995

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Arg Val Thr Leu Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Ser 
            20                  25                  30          


Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp 
        35                  40                  45              


Ile Tyr Asp Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu 
65                  70                  75                  80  


Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Tyr His Arg Ser Gln 
                85                  90                  95      


Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105             


<210>  996
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-21AL as 
       described in Table 3.

<400>  996

Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser 
            20                  25                  30          


Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln 
                85                  90                  95      


Tyr Tyr Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 
            100                 105                 110         


Lys 
    


<210>  997
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-26AL as 
       described in Table 3.

<400>  997

Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser 
            20                  25                  30          


Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln 
                85                  90                  95      


Tyr Tyr Ser Tyr Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 
            100                 105                 110         


Lys 
    


<210>  998
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S19-15AL as 
       described in Table 3.

<400>  998

Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly 
1               5                   10                  15      


Glu Ser Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr 
            20                  25                  30          


Leu Asn Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile 
        35                  40                  45              


Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Phe 
65                  70                  75                  80  


Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Pro Phe 
                85                  90                  95      


Thr Phe Gly Ser Gly Thr Lys Leu Glu Met Lys 
            100                 105         


<210>  999
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S19-9BL as described
       in Table 3.

<400>  999

Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly 
1               5                   10                  15      


Glu Ser Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr 
            20                  25                  30          


Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile 
        35                  40                  45              


Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Phe 
65                  70                  75                  80  


Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Pro Phe 
                85                  90                  95      


Thr Phe Gly Ser Gly Thr Lys Leu Glu Met Lys 
            100                 105         


<210>  1000
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-12AL as 
       described in Table 3.

<400>  1000

Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser 
            20                  25                  30          


Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln 
                85                  90                  95      


Tyr Tyr Ser Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile 
            100                 105                 110         


Lys 
    


<210>  1001
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-12BL as 
       described in Table 3.

<400>  1001

Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser 
            20                  25                  30          


Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln 
        35                  40                  45              


Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln 
                85                  90                  95      


Tyr Tyr Ser Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile 
            100                 105                 110         


Lys 
    


<210>  1002
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-1AL as described
       in Table 3.

<400>  1002

Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser 
            20                  25                  30          


Ser Asp Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln 
                85                  90                  95      


Tyr Tyr Ser Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile 
            100                 105                 110         


Lys 
    


<210>  1003
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-1BL as described
       in Table 3.

<400>  1003

Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Gly Val Ser Val Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser 
            20                  25                  30          


Ser Asp Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln 
                85                  90                  95      


Tyr Tyr Ser Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile 
            100                 105                 110         


Lys 
    


<210>  1004
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-27AL as 
       described in Table 3.

<400>  1004

Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser 
            20                  25                  30          


Ser Asp Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Gly Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln 
                85                  90                  95      


Tyr Tyr Ser Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile 
            100                 105                 110         


Lys 
    


<210>  1005
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-28AL as 
       described in Table 3.

<400>  1005

Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser 
            20                  25                  30          


Ser Asp Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Gly Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln 
                85                  90                  95      


Tyr Tyr Ser Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile 
            100                 105                 110         


Lys 
    


<210>  1006
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-29AL as 
       described in Table 3.

<400>  1006

Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly 
1               5                   10                  15      


Glu Lys Ile Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Phe Ser 
            20                  25                  30          


Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln 
                85                  90                  95      


Tyr Tyr Ser Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile 
            100                 105                 110         


Lys 
    


<210>  1007
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-30AL as 
       described in Table 3.

<400>  1007

Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Pro Val Ser Val Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Thr Cys Lys Ser Ser Gln Ser Leu Leu Tyr Gly 
            20                  25                  30          


Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln 
                85                  90                  95      


Tyr Tyr Ser Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile 
            100                 105                 110         


Lys 
    


<210>  1008
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-33AL as 
       described in Table 3.

<400>  1008

Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly 
1               5                   10                  15      


Glu Lys Ile Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Phe Ser 
            20                  25                  30          


Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln 
                85                  90                  95      


Tyr Tyr Thr Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Met 
            100                 105                 110         


Lys 
    


<210>  1009
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-42AL as 
       described in Table 3.

<400>  1009

Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly 
1               5                   10                  15      


Glu Lys Ile Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Phe Gly 
            20                  25                  30          


Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln 
                85                  90                  95      


Tyr Tyr Thr Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Met 
            100                 105                 110         


Lys 
    


<210>  1010
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-4AL as described
       in Table 3.

<400>  1010

Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly 
1               5                   10                  15      


Glu Lys Ile Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Phe Ser 
            20                  25                  30          


Ser Ile Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Ser Pro Lys Leu Leu Val Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln 
                85                  90                  95      


Tyr Tyr Ser Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile 
            100                 105                 110         


Lys 
    


<210>  1011
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S20-6AL as described
       in Table 3.

<400>  1011

Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser 
            20                  25                  30          


Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Ser Pro Lys Leu Leu Ile Tyr Trp Ser Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln 
                85                  90                  95      


Tyr Tyr Ser Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile 
            100                 105                 110         


Lys 
    


<210>  1012
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_122L as described 
       in Table 3.

<400>  1012

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Arg Val Thr Met Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Ser 
            20                  25                  30          


Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp 
        35                  40                  45              


Ile Tyr Asn Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Ser Phe Ser Leu Thr Ile Ser Ser Met Glu 
65                  70                  75                  80  


Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Tyr His Arg Ser Pro 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  1013
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_173L as described 
       in Table 3.

<400>  1013

Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly 
1               5                   10                  15      


Glu Ser Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr 
            20                  25                  30          


Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile 
        35                  40                  45              


Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Phe 
65                  70                  75                  80  


Glu Asp Met Gly Ile Tyr Phe Cys Leu Gln Tyr Asp Glu Phe Pro Phe 
                85                  90                  95      


Thr Phe Gly Ser Gly Thr Lys Leu Glu Met Lys 
            100                 105         


<210>  1014
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_203L as described 
       in Table 3.

<400>  1014

Asp Ile Leu Met Thr Gln Ser Pro Ser Ser Met Ser Val Ser Leu Gly 
1               5                   10                  15      


Asp Thr Val Asn Ile Thr Cys His Ala Ser Gln Gly Ile Ser Ser Asn 
            20                  25                  30          


Ile Gly Trp Leu Gln Gln Lys Pro Gly Lys Ser Phe Lys Gly Leu Ile 
        35                  40                  45              


Tyr His Gly Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Ala Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Ser 
65                  70                  75                  80  


Glu Asp Phe Ala Asp Tyr Tyr Cys Gly Gln Tyr Gly Gln Phe Pro Pro 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 
            100                 105     


<210>  1015
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S14-10AL as 
       described in Table 3.

<400>  1015

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser 
                85                  90                  95      


Ile His Val Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  1016
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S14-7AL and 
       H5S15-23AL as described in Table 3.

<400>  1016

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser 
                85                  90                  95      


Thr His Val Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  1017
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-10AL as 
       described in Table 3.

<400>  1017

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Thr 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Arg Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser 
                85                  90                  95      


Thr His Val Pro Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110     


<210>  1018
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-11AL as 
       described in Table 3.

<400>  1018

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Ala Ser Val Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ile Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser 
                85                  90                  95      


Thr His Val Pro Thr Phe Gly Ser Gly Thr Lys Leu Glu Val Lys 
            100                 105                 110     


<210>  1019
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-11BL as 
       described in Table 3.

<400>  1019

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser 
                85                  90                  95      


Thr His Val Pro Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110     


<210>  1020
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-11CL as 
       described in Table 3.

<400>  1020

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Leu Met Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Arg Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser 
                85                  90                  95      


Thr His Val Pro Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110     


<210>  1021
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-11DL as 
       described in Table 3.

<400>  1021

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser 
                85                  90                  95      


Thr His Val Pro Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110     


<210>  1022
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-11EL as 
       described in Table 3.

<400>  1022

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Thr Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser 
                85                  90                  95      


Thr His Val Pro Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110     


<210>  1023
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-22AL as 
       described in Table 3.

<400>  1023

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser 
                85                  90                  95      


Thr His Val Pro Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 
            100                 105                 110         


Lys 
    


<210>  1024
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S14-19AL as 
       described in Table 3.

<400>  1024

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Val Ser Val Gly 
1               5                   10                  15      


Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Asn 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val 
        35                  40                  45              


Tyr Ala Ala Thr Asn Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Ser 
65                  70                  75                  80  


Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp Gly Thr Pro Arg 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  1025
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S14-9AL as described
       in Table 3.

<400>  1025

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val 
        35                  40                  45              


Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile Asn Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His His Tyr Gly Thr Met Tyr 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  1026
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-2AL as described
       in Table 3.

<400>  1026

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val 
        35                  40                  45              


Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile Asn Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His His Tyr Gly Thr Tyr Thr 
                85                  90                  95      


Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105     


<210>  1027
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S15-32AL as 
       described in Table 3.

<400>  1027

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Gly Asn Ile His Asn Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val 
        35                  40                  45              


Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp Ser Thr Phe Thr 
                85                  90                  95      


Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105     


<210>  1028
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_023L as described 
       in Table 3.

<400>  1028

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Gly Asn Ile His Asn Tyr 
            20                  25                  30          


Leu Thr Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val 
        35                  40                  45              


Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Asn Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp Ser Thr Phe Thr 
                85                  90                  95      


Phe Gly Ser Gly Thr Lys Leu Glu Val Lys 
            100                 105     


<210>  1029
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of ITI_240L as described 
       in Table 3.

<400>  1029

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Glu Thr Val Thr Ile Thr Cys Arg Pro Ser Glu Asn Ile Tyr Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val 
        35                  40                  45              


Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr His Phe Ser Leu Lys Ile Asn Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Glu Phe Gly Ser Tyr Tyr Cys Gln His His Tyr Gly Thr Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  1030
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S14-12AL as 
       described in Table 3.

<400>  1030

Glu Thr Thr Val Thr Gln Ser Pro Ala Ser Leu Ser Val Ala Thr Gly 
1               5                   10                  15      


Glu Lys Val Thr Ile Arg Cys Ile Thr Ser Thr Asp Ile Asp Asp Asp 
            20                  25                  30          


Met Asn Trp Tyr Gln Gln Lys Pro Gly Glu Pro Pro Lys Leu Leu Ile 
        35                  40                  45              


Ser Glu Gly Asn Thr Leu Arg Pro Gly Val Pro Ser Arg Phe Ser Ser 
    50                  55                  60                  


Ser Gly Tyr Gly Thr Asp Phe Val Phe Thr Ile Glu Asn Thr Leu Ser 
65                  70                  75                  80  


Glu Asp Val Ala Asp Tyr Tyr Cys Leu Gln Ser Asp Asn Met Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  1031
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S19-22AL as 
       described in Table 3.

<400>  1031

Asp Ala Val Met Thr Gln Thr Pro Leu Ser Leu Thr Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Thr Leu Glu Asn Thr 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Arg Val Ser Asn Arg Phe Ser Gly Val Leu 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Leu Gln Val 
                85                  90                  95      


Thr His Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  1032
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-Length sequence of the Light Chain of H5S19-24AL as 
       described in Table 3.

<400>  1032

Asp Ile Val Met Thr Gln Ala Ala Phe Ser Asn Pro Val Thr Leu Gly 
1               5                   10                  15      


Thr Ser Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser 
            20                  25                  30          


Asn Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Ala Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Ser Ser Gly Ser Gly Thr Asp Phe Thr Leu Arg Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn 
                85                  90                  95      


Leu Glu Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  1033
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of Consensus Cluster #6 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Aspartate, Asparagine, Serine, Glutamate or Glutamine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Isoleucine, Asparagine or Valine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Valine or Glutamine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Leucine, Methionine or Isoleucine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Proline, Glutamine, Threonine or Serine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Alanine, Serine, Lysine or Threonine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Serine, Threonine, Phenylalanine, Isoleucine, Tyrosine or 
       Leucine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Leucine, Methionine or Glutamine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Alanine, Serine, Threonine or Leucine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Valine, Alanine or Threonine

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa is Serine, Threonine or Proline

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Leucine, Proline, Alanine or Valine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Glutamine, Aspartate, Glutamate or Glycine

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Arginine, Lysine, Threonine or Serine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Alanine, Valine or Isoleucine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (21)..(21)
<223>  Xaa is Isoleucine, Leucine, Methionine or Valine

<220>
<221>  misc_feature
<222>  (22)..(22)
<223>  Xaa is Serine, Threonine or Asparagine

<220>
<221>  misc_feature
<222>  (24)..(24)
<223>  Xaa is Lysine, Arginine, Serine, Threonine or Leucine

<220>
<221>  misc_feature
<222>  (25)..(25)
<223>  Xaa is Alanine, Serine, Threonine or Valine

<400>  1033

Xaa Xaa Xaa Xaa Thr Gln Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly 
1               5                   10                  15      


Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Ser 
            20                  25      


<210>  1034
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1034

Ser Ile Val Met Thr Gln Thr Pro Lys Phe Leu Leu Val Ser Ala Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser 
            20                  25      


<210>  1035
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1035

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Thr Cys Ser Ala Ser 
            20                  25      


<210>  1036
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S14-1AL as described 
       in Table 2.

<400>  1036

Asp Val Gln Ile Thr Gln Ser Pro Ser Tyr Leu Ala Ala Ser Pro Gly 
1               5                   10                  15      


Glu Thr Ile Thr Ile Asn Cys Arg Ala Ser 
            20                  25      


<210>  1037
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1037

Asn Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser 
            20                  25      


<210>  1038
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S14-25AL as described 
       in Table 2.

<400>  1038

Asp Ile Gln Met Thr Gln Ser Ser Ser Tyr Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Arg Val Thr Ile Thr Cys Lys Ala Ser 
            20                  25      


<210>  1039
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1039

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Ile Ser Cys Ser Ala Ser 
            20                  25      


<210>  1040
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S14-6AL as described 
       in Table 2.

<400>  1040

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Gln Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Ser Val Thr Ile Thr Cys Leu Ala Ser 
            20                  25      


<210>  1041
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1041

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser 
            20                  25      


<210>  1042
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1042

Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Ser Val Thr Cys Lys Ala Ser 
            20                  25      


<210>  1043
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S15-18AL as described 
       in Table 2.

<400>  1043

Glu Asn Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Thr Cys Arg Ala Ser 
            20                  25      


<210>  1044
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S15-28AL as described 
       in Table 2.

<400>  1044

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Arg Ala Ser 
            20                  25      


<210>  1045
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S15-29AL as described 
       in Table 2.

<400>  1045

Glu Ile Val Leu Thr Gln Ser Pro Ala Leu Met Thr Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Ile Thr Cys Ser Val Ser 
            20                  25      


<210>  1046
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1046

Glu Ile Val Leu Thr Gln Ser Pro Ala Leu Met Ala Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Ile Thr Cys Ser Val Ser 
            20                  25      


<210>  1047
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1047

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Ser Ala Ser 
            20                  25      


<210>  1048
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1048

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Thr Ala Ser 
            20                  25      


<210>  1049
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S19-8AL as described 
       in Table 2.

<400>  1049

Asp Val Gln Ile Thr Gln Ser Pro Ser Tyr Leu Ala Ala Ser Pro Gly 
1               5                   10                  15      


Glu Thr Ile Thr Ile Asn Cys Arg Thr Ser 
            20                  25      


<210>  1050
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1050

Gln Ile Val Leu Thr Gln Ser Pro Ala Leu Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Thr Cys Ser Ala Ser 
            20                  25      


<210>  1051
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S20-17AL as described 
       in Table 2.

<400>  1051

Asp Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Thr Pro Gly 
1               5                   10                  15      


Asp Arg Val Ser Leu Ser Cys Arg Ala Ser 
            20                  25      


<210>  1052
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S20-23AL as described 
       in Table 2.

<400>  1052

Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Thr Val Pro Ala Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Ser Cys Lys Ser Ser 
            20                  25      


<210>  1053
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S20-34AL as described 
       in Table 2.

<400>  1053

Gln Ile Val Leu Thr Gln Ser Pro Ala Leu Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Thr Cys Thr Ala Ser 
            20                  25      


<210>  1054
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of ITI_045L as described in
       Table 2.

<400>  1054

Glu Ile Val Leu Thr Gln Ser Pro Thr Thr Met Ala Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Ile Thr Ile Thr Cys Ser Ala Ser 
            20                  25      


<210>  1055
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1055

Glu Asn Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Ser Cys Arg Ala Ser 
            20                  25      


<210>  1056
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1056

Asp Ile Gln Met Thr Gln Thr Pro Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Ser Ala Ser 
            20                  25      


<210>  1057
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of ITI_236L as described in
       Table 2.

<400>  1057

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Arg Ala Ser 
            20                  25      


<210>  1058
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of Consensus Cluster #7 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Aspartate or Glutamate

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Valine or Asparagine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Valine or Leucine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Methionine or Leucine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Leucine or Alanine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Threonine, Isoleucine or Serine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Leucine or Methionine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Serine, Proline or Threonine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Valine, Alanine or Isoleucine

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa is Threonine, Serine or Asparagine

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Isoleucine, Proline, Leucine or Valine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Glutamine, Glutamate, Aspartate or Histidine

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Proline, Lysine, Glutamine or Threonine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Alanine or Valine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (21)..(21)
<223>  Xaa is Isoleucine or Methionine

<220>
<221>  misc_feature
<222>  (22)..(22)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (24)..(24)
<223>  Xaa is Lysine, Serine or Arginine

<220>
<221>  misc_feature
<222>  (25)..(25)
<223>  Xaa is Serine or Alanine

<220>
<221>  misc_feature
<222>  (26)..(26)
<223>  Xaa is Serine or Glycine

<400>  1058

Xaa Xaa Xaa Xaa Thr Gln Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly 
1               5                   10                  15      


Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa 
            20                  25      


<210>  1059
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1059

Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser 
            20                  25      


<210>  1060
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1060

Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser 
            20                  25      


<210>  1061
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S15-17AL as described 
       in Table 2.

<400>  1061

Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Val Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser 
            20                  25      


<210>  1062
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S15-1AL as described 
       in Table 2.

<400>  1062

Glu Asn Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Thr Cys Ser Ala Gly 
            20                  25      


<210>  1063
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S15-3BL as described 
       in Table 2.

<400>  1063

Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Thr Val Ser Leu Gly 
1               5                   10                  15      


His Gln Ala Ser Ile Ser Cys Arg Ser Ser 
            20                  25      


<210>  1064
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S20-19BL as described 
       in Table 2.

<400>  1064

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Ile Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser 
            20                  25      


<210>  1065
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S20-39AL as described 
       in Table 2.

<400>  1065

Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Val Ser Ile Ser Cys Arg Ser Ser 
            20                  25      


<210>  1066
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S20-7CL as described 
       in Table 2.

<400>  1066

Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Ile Thr Ile Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser 
            20                  25      


<210>  1067
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S20-7EL as described 
       in Table 2.

<400>  1067

Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly 
1               5                   10                  15      


Gln Thr Ala Ser Ile Ser Cys Lys Ser Ser 
            20                  25      


<210>  1068
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S20-9AL as described 
       in Table 2.

<400>  1068

Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Asn Leu Gly 
1               5                   10                  15      


Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser 
            20                  25      


<210>  1069
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of Consensus Cluster #3 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Methionine, Valine or Isoleucine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Alanine or Threonine

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Leucine or Proline

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Glutamate or Alanine

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Glutamate or Lysine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Isoleucine or Valine

<220>
<221>  misc_feature
<222>  (26)..(26)
<223>  Xaa is Serine or Arginine

<400>  1069

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Xaa Ser Xaa Ser Xaa Gly 
1               5                   10                  15      


Xaa Xaa Xaa Thr Leu Thr Cys Ser Ala Xaa 
            20                  25      


<210>  1070
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1070

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Glu Ile Thr Leu Thr Cys Ser Ala Ser 
            20                  25      


<210>  1071
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S14-5AL as described 
       in Table 2.

<400>  1071

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Ile Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Glu Val Thr Leu Thr Cys Ser Ala Ser 
            20                  25      


<210>  1072
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1072

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Leu Thr Cys Ser Ala Ser 
            20                  25      


<210>  1073
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S19-18AL as described 
       in Table 2.

<400>  1073

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Thr Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Leu Thr Cys Ser Ala Ser 
            20                  25      


<210>  1074
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of ITI_127L as described in
       Table 2.

<400>  1074

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Glu Ile Thr Leu Thr Cys Ser Ala Arg 
            20                  25      


<210>  1075
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of ITI_128L as described in
       Table 2.

<400>  1075

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Val Ser Ala Ser Leu Gly 
1               5                   10                  15      


Ala Glu Ile Thr Leu Thr Cys Ser Ala Arg 
            20                  25      


<210>  1076
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of Consensus Cluster #5 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Glutamine or Aspartate

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Valine, Glutamine, Leucine or Lysine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Leucine or Methionine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Alanine or Serine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Isoleucine or Serine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Methionine or Leucine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Serine, Alanine, Proline, Glycine or Tyrosine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Alanine or Valine

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Leucine or Valine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Glutamate or Aspartate

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Arginine, Lysine, Threonine or Serine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Valine or Isoleucine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Threonine, Serine or Asparagine

<220>
<221>  misc_feature
<222>  (21)..(21)
<223>  Xaa is Methionine, Leucine or Isoleucine

<220>
<221>  misc_feature
<222>  (22)..(22)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (24)..(24)
<223>  Xaa is Threonine, Arginine, Lysine or Histidine

<220>
<221>  misc_feature
<222>  (25)..(25)
<223>  Xaa is Alanine or Serine

<400>  1076

Xaa Ile Xaa Xaa Xaa Gln Ser Pro Xaa Xaa Xaa Xaa Xaa Ser Xaa Gly 
1               5                   10                  15      


Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Ser 
            20                  25      


<210>  1077
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1077

Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Ser Cys Lys Ser Ser 
            20                  25      


<210>  1078
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S14-22AL as described 
       in Table 2.

<400>  1078

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Arg Val Ser Leu Thr Cys Arg Ala Ser 
            20                  25      


<210>  1079
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S14-23AL as described 
       in Table 2.

<400>  1079

Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly 
1               5                   10                  15      


Glu Arg Val Thr Ile Thr Cys Lys Ala Ser 
            20                  25      


<210>  1080
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S15-19AL as described 
       in Table 2.

<400>  1080

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Arg Val Thr Leu Thr Cys Thr Ala Ser 
            20                  25      


<210>  1081
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1081

Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly 
1               5                   10                  15      


Glu Ser Val Thr Ile Thr Cys Lys Ala Ser 
            20                  25      


<210>  1082
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S20-1BL as described 
       in Table 2.

<400>  1082

Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Gly Val Ser Val Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Ser Cys Lys Ser Ser 
            20                  25      


<210>  1083
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1083

Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly 
1               5                   10                  15      


Glu Lys Ile Thr Met Ser Cys Lys Ser Ser 
            20                  25      


<210>  1084
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S20-30AL as described 
       in Table 2.

<400>  1084

Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Pro Val Ser Val Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Thr Cys Lys Ser Ser 
            20                  25      


<210>  1085
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of ITI_122L as described in
       Table 2.

<400>  1085

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Arg Val Thr Met Thr Cys Thr Ala Ser 
            20                  25      


<210>  1086
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of ITI_203L as described in
       Table 2.

<400>  1086

Asp Ile Leu Met Thr Gln Ser Pro Ser Ser Met Ser Val Ser Leu Gly 
1               5                   10                  15      


Asp Thr Val Asn Ile Thr Cys His Ala Ser 
            20                  25      


<210>  1087
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of Consensus Cluster #1 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Proline or Serine

<220>
<221>  misc_feature
<222>  (21)..(21)
<223>  Xaa is Isoleucine or Valine

<400>  1087

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Xaa Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Ala Ser Xaa Ser Cys Arg Ser Ser 
            20                  25      


<210>  1088
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1088

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser 
            20                  25      


<210>  1089
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S15-11AL as described 
       in Table 2.

<400>  1089

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Ala Ser Val Ser Cys Arg Ser Ser 
            20                  25      


<210>  1090
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S15-11BL as described 
       in Table 2.

<400>  1090

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser 
            20                  25      


<210>  1091
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of Consensus Cluster #4 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Alanine or Valine

<220>
<221>  misc_feature
<222>  (25)..(25)
<223>  Xaa is Alanine or Proline

<400>  1091

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Xaa Ser Val Gly 
1               5                   10                  15      


Glu Thr Val Thr Ile Thr Cys Arg Xaa Ser 
            20                  25      


<210>  1092
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S14-19AL as described 
       in Table 2.

<400>  1092

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Val Ser Val Gly 
1               5                   10                  15      


Glu Thr Val Thr Ile Thr Cys Arg Ala Ser 
            20                  25      


<210>  1093
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1093

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Glu Thr Val Thr Ile Thr Cys Arg Ala Ser 
            20                  25      


<210>  1094
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of ITI_240L as described in
       Table 2.

<400>  1094

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Glu Thr Val Thr Ile Thr Cys Arg Pro Ser 
            20                  25      


<210>  1095
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of Consensus Cluster #2 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Aspartate or Glutamate

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Isoleucine, Threonine or Alanine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Valine or Threonine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Methionine or Valine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Alanine, Serine or Threonine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Alanine or Proline

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Phenylalanine, Alanine or Leucine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Asparagine or Leucine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Proline, Serine or Threonine

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa is Threonine, Alanine or Serine

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Leucine or Threonine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Threonine, Glutamate or Aspartate

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Serine, Lysine or Glutamine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Alanine or Valine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (22)..(22)
<223>  Xaa is Serine or Arginine

<220>
<221>  misc_feature
<222>  (24)..(24)
<223>  Xaa is Arginine or Isoleucine

<220>
<221>  misc_feature
<222>  (25)..(25)
<223>  Xaa is Serine or Threonine

<400>  1095

Xaa Xaa Xaa Xaa Thr Gln Xaa Xaa Xaa Ser Xaa Xaa Val Xaa Xaa Gly 
1               5                   10                  15      


Xaa Xaa Xaa Xaa Ile Xaa Cys Xaa Xaa Ser 
            20                  25      


<210>  1096
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S14-12AL as described 
       in Table 2.

<400>  1096

Glu Thr Thr Val Thr Gln Ser Pro Ala Ser Leu Ser Val Ala Thr Gly 
1               5                   10                  15      


Glu Lys Val Thr Ile Arg Cys Ile Thr Ser 
            20                  25      


<210>  1097
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S19-22AL as described 
       in Table 2.

<400>  1097

Asp Ala Val Met Thr Gln Thr Pro Leu Ser Leu Thr Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser 
            20                  25      


<210>  1098
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 1 of the Heavy Chain of H5S19-24AL as described 
       in Table 2.

<400>  1098

Asp Ile Val Met Thr Gln Ala Ala Phe Ser Asn Pro Val Thr Leu Gly 
1               5                   10                  15      


Thr Ser Ala Ser Ile Ser Cys Arg Ser Ser 
            20                  25      


<210>  1099
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of Consensus Cluster #6 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Glutamine, Glutamate, Arginine, Serine, Lysine or 
       Aspartate

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Serine, Threonine, Asparagine, Aspartate, Glycine or 
       Histidine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Valine, Isoleucine or Leucine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Aspartate, no amino acid, Leucine, Serine, Asparagine or 
       Arginine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Tyrosine, Serine, no amino acid or Asparagine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is no amino acid or Serine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is no amino acid or Glutamate

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Aspartate, Tyrosine, no amino acid or Asparagine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Glycine, no amino acid or Glutamine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Aspartate, Asparagine, Glutamate, Serine, Lysine, no amino
       acid, Glycine, Threonine or Arginine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Serine, Aspartate, Asparagine, Lysine, Arginine or 
       Threonine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Tyrosine, Phenylalanine, Leucine, Aspartate, Asparagine or
       Tryptophan

<400>  1099

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10          


<210>  1100
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1100

Gln Ser Val Ser Asn Asp 
1               5       


<210>  1101
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1101

Ser Ser Val Ser Tyr 
1               5   


<210>  1102
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S14-1AL as described in Table 2.

<400>  1102

Lys Ser Ile Ser Lys Tyr 
1               5       


<210>  1103
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1103

Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe 
1               5                   10  


<210>  1104
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S14-25AL as described in Table 2.

<400>  1104

Asp His Ile Asn Asn Trp 
1               5       


<210>  1105
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S14-6AL as described in Table 2.

<400>  1105

Gln Thr Ile Gly Thr Trp 
1               5       


<210>  1106
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1106

Gln Ser Val Asp Tyr Asp Gly Glu Ser Tyr 
1               5                   10  


<210>  1107
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1107

Gln Asn Val Gly Thr Asn 
1               5       


<210>  1108
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1108

Ser Ser Val Ser Ser Ser Tyr 
1               5           


<210>  1109
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1109

Gln Ser Val Asp Tyr Asp Gly Asn Ser Tyr 
1               5                   10  


<210>  1110
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1110

Gln Asp Ile Ser Asn Tyr 
1               5       


<210>  1111
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S15-29AL as described in Table 2.

<400>  1111

Ser Thr Ile Ser Ser Arg Asn 
1               5           


<210>  1112
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S15-4AL as described in Table 2.

<400>  1112

Ser Gly Ile Arg Ser Ser Asn 
1               5           


<210>  1113
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1113

Ser Ser Ile Ser Ser Ser Asn 
1               5           


<210>  1114
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1114

Gln Gly Ile Ser Asn Tyr 
1               5       


<210>  1115
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S19-1AL as described in Table 2.

<400>  1115

Glu Ser Val Asp Ser Tyr Gly Asn Ser Leu 
1               5                   10  


<210>  1116
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1116

Gln Gly Ile Asn Asn Tyr 
1               5       


<210>  1117
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S19-8AL as described in Table 2.

<400>  1117

Lys Asn Ile Ser Lys Tyr 
1               5       


<210>  1118
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1118

Ser Ser Val Ser Phe 
1               5   


<210>  1119
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S20-17AL as described in Table 2.

<400>  1119

Arg Thr Ile Ser Asp Tyr 
1               5       


<210>  1120
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S20-20AL as described in Table 2.

<400>  1120

Gln Ser Val Asp Tyr Asp Gly Asp Ser Phe 
1               5                   10  


<210>  1121
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S20-23AL as described in Table 2.

<400>  1121

Gln Ser Leu Leu Asn Ser Glu Asn Gln Lys Asn Tyr 
1               5                   10          


<210>  1122
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1122

Gln Ser Val Asp Tyr Asp Gly Asp Ser Tyr 
1               5                   10  


<210>  1123
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of ITI_040L as described in Table 2.

<400>  1123

Ser Ser Ile Ser Tyr 
1               5   


<210>  1124
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of ITI_045L as described in Table 2.

<400>  1124

Ser Ser Ile Asn Ser Asn Tyr 
1               5           


<210>  1125
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1125

Ser Ser Val Asn Tyr 
1               5   


<210>  1126
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1126

Gln Asp Ile Asn Asn Tyr 
1               5       


<210>  1127
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of ITI_146L as described in Table 2.

<400>  1127

Gln Gly Ile Arg Asn Tyr 
1               5       


<210>  1128
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of ITI_169L as described in Table 2.

<400>  1128

Gln Gly Ile Thr Lys Tyr 
1               5       


<210>  1129
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of Consensus Cluster #7 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Glutamine or Serine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Serine or Asparagine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Leucine, Valine or Isoleucine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Leucine, no amino acid or Valine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Tyrosine, no amino acid, Histidine or Aspartate

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Serine or no amino acid

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Asparagine, no amino acid or Aspartate

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Glycine or no amino acid

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Lysine, no amino acid, Asparagine or Isoleucine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Threonine or Serine

<400>  1129

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Tyr 
1               5                   10      


<210>  1130
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1130

Gln Ser Leu Leu Asp Ser Asp Gly Lys Thr Tyr 
1               5                   10      


<210>  1131
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1131

Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr 
1               5                   10      


<210>  1132
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S15-16AL as described in Table 2.

<400>  1132

Gln Ser Ile Val His Ser Asn Gly Ile Thr Tyr 
1               5                   10      


<210>  1133
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S15-1AL as described in Table 2.

<400>  1133

Ser Ser Val Ser Tyr 
1               5   


<210>  1134
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S20-39AL as described in Table 2.

<400>  1134

Gln Asn Ile Val His Ser Asn Gly Asn Thr Tyr 
1               5                   10      


<210>  1135
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S20-41AL as described in Table 2.

<400>  1135

Gln Ser Leu Leu Tyr Ser Asn Gly Lys Thr Tyr 
1               5                   10      


<210>  1136
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of Consensus Cluster #3 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is no amino acid, Aspartate or Serine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is no amino acid or Serine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Tyrosine or Phenylalanine

<400>  1136

Ser Xaa Val Xaa Xaa Ser Xaa 
1               5           


<210>  1137
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1137

Ser Ser Val Ser Tyr 
1               5   


<210>  1138
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S15-8AL as described in Table 2.

<400>  1138

Ser Ser Val Ser Phe 
1               5   


<210>  1139
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1139

Ser Ser Val Asp Ser Ser Tyr 
1               5           


<210>  1140
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1140

Ser Ser Val Ser Ser Ser Tyr 
1               5           


<210>  1141
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of ITI_128L as described in Table 2.

<400>  1141

Ser Thr Val Ser Tyr 
1               5   


<210>  1142
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of Consensus Cluster #5 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Serine or Glutamine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Serine, Glutamate, Glycine or Aspartate

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Valine, Isoleucine or Leucine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Serine, no amino acid or Leucine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is no amino acid, Phenylalanine or Tyrosine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is no amino acid, Glycine or Serine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is no amino acid or Serine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is no amino acid, Asparagine, Aspartate or Isoleucine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is no amino acid or Glutamine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Serine, Lysine or Asparagine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Serine, Glycine or Asparagine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Tyrosine or Asparagine

<400>  1142

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10          


<210>  1143
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1143

Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr 
1               5                   10          


<210>  1144
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S14-22AL as described in Table 2.

<400>  1144

Gln Glu Ile Ser Gly Tyr 
1               5       


<210>  1145
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1145

Gln Asp Ile Asn Ser Tyr 
1               5       


<210>  1146
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1146

Gln Ser Leu Leu Tyr Ser Ser Asp Gln Lys Asn Tyr 
1               5                   10          


<210>  1147
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1147

Gln Ser Leu Leu Phe Ser Ser Asn Gln Lys Asn Tyr 
1               5                   10          


<210>  1148
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S20-30AL as described in Table 2.

<400>  1148

Gln Ser Leu Leu Tyr Gly Ser Asn Gln Lys Asn Tyr 
1               5                   10          


<210>  1149
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S20-42AL as described in Table 2.

<400>  1149

Gln Ser Leu Leu Phe Gly Ser Asn Gln Lys Asn Tyr 
1               5                   10          


<210>  1150
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S20-4AL as described in Table 2.

<400>  1150

Gln Ser Leu Leu Phe Ser Ser Ile Gln Lys Asn Tyr 
1               5                   10          


<210>  1151
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of ITI_203L as described in Table 2.

<400>  1151

Gln Gly Ile Ser Ser Asn 
1               5       


<210>  1152
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of Consensus Cluster #1 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Serine or Threonine

<400>  1152

Gln Ser Leu Val His Xaa Asn Gly Asn Thr Tyr 
1               5                   10      


<210>  1153
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1153

Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr 
1               5                   10      


<210>  1154
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S15-10AL as described in Table 2.

<400>  1154

Gln Ser Leu Val His Thr Asn Gly Asn Thr Tyr 
1               5                   10      


<210>  1155
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of Consensus Cluster #4 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Glutamate or Glycine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Tyrosine or Histidine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Serine or Asparagine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Tyrosine or Asparagine

<400>  1155

Xaa Asn Ile Xaa Xaa Xaa 
1               5       


<210>  1156
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S14-19AL as described in Table 2.

<400>  1156

Glu Asn Ile Tyr Ser Asn 
1               5       


<210>  1157
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1157

Glu Asn Ile Tyr Ser Tyr 
1               5       


<210>  1158
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1158

Gly Asn Ile His Asn Tyr 
1               5       


<210>  1159
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of Consensus Cluster #2 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Lysine, Threonine or Glutamine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Serine, Aspartate or Threonine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Leucine or Isoleucine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Leucine, no amino acid or Glutamate

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Histidine, no amino acid or Asparagine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Serine, no amino acid or Threonine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Asparagine or no amino acid

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Glycine or no amino acid

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Isoleucine, Aspartate or Asparagine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Threonine or Aspartate

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Tyrosine or Aspartate

<400>  1159

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10      


<210>  1160
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S14-12AL as described in Table 2.

<400>  1160

Thr Asp Ile Asp Asp Asp 
1               5       


<210>  1161
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S19-22AL as described in Table 2.

<400>  1161

Gln Thr Leu Glu Asn Thr Asn Gly Asn Thr Tyr 
1               5                   10      


<210>  1162
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of the Heavy Chain of H5S19-24AL as described in Table 2.

<400>  1162

Lys Ser Leu Leu His Ser Asn Gly Ile Thr Tyr 
1               5                   10      


<210>  1163
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of Consensus Cluster #6 as 
       described in Table 2.

<400>  1163

Cys Asp Arg 
1           


<210>  1164
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1164

Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1165
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1165

Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile 
1               5                   10                  15      


Tyr 
    


<210>  1166
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S14-1AL as described 
       in Table 2.

<400>  1166

Leu Ala Trp Tyr Gln Glu Lys Pro Gly Lys Thr Asn Gln Leu Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1167
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1167

Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1168
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S14-25AL as described 
       in Table 2.

<400>  1168

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile 
1               5                   10                  15      


Ser 
    


<210>  1169
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1169

Met Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile 
1               5                   10                  15      


Tyr 
    


<210>  1170
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S14-6AL as described 
       in Table 2.

<400>  1170

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Gln Leu Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1171
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1171

Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1172
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1172

Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1173
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S15-14BL as described 
       in Table 2.

<400>  1173

Val Ala Trp Tyr Gln Gln Arg Pro Gly Gln Ser Pro Lys Ser Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1174
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S15-18AL as described 
       in Table 2.

<400>  1174

Leu His Trp Tyr Gln Gln Lys Ser Gly Ala Ser Pro Lys Leu Trp Ile 
1               5                   10                  15      


Tyr 
    


<210>  1175
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S15-24AL as described 
       in Table 2.

<400>  1175

Met Asn Trp Tyr Gln Gln Lys Pro Arg Gln Pro Pro Lys Leu Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1176
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1176

Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1177
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S15-29AL as described 
       in Table 2.

<400>  1177

Leu His Trp Tyr Gln Gln Lys Ser Glu Ala Ser Pro Lys Pro Trp Ile 
1               5                   10                  15      


Tyr 
    


<210>  1178
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1178

Leu His Trp Tyr Gln Gln Lys Ser Glu Thr Ser Pro Lys Pro Trp Ile 
1               5                   10                  15      


Tyr 
    


<210>  1179
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S19-6AL as described 
       in Table 2.

<400>  1179

Met Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Arg Leu Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1180
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S19-8AL as described 
       in Table 2.

<400>  1180

Leu Ala Trp Tyr Gln Glu Lys Pro Gly Lys Thr Asn Lys Leu Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1181
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S20-16AL as described 
       in Table 2.

<400>  1181

Ile Tyr Trp Tyr Gln Gln Lys Pro Arg Ser Ser Pro Lys Pro Trp Ile 
1               5                   10                  15      


Ser 
    


<210>  1182
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S20-16BL as described 
       in Table 2.

<400>  1182

Ile Tyr Trp Tyr Gln Gln Lys Pro Arg Ser Ser Pro Lys Pro Trp Ile 
1               5                   10                  15      


Tyr 
    


<210>  1183
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S20-17AL as described 
       in Table 2.

<400>  1183

Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu Leu Ile 
1               5                   10                  15      


Lys 
    


<210>  1184
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S20-23AL as described 
       in Table 2.

<400>  1184

Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1185
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S20-34AL as described 
       in Table 2.

<400>  1185

Met Tyr Trp Tyr Gln Gln Lys Pro Arg Ser Ser Pro Lys Pro Trp Ile 
1               5                   10                  15      


Tyr 
    


<210>  1186
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S20-8BL as described 
       in Table 2.

<400>  1186

Met Asn Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1187
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of ITI_045L as described in
       Table 2.

<400>  1187

Leu His Trp Tyr Gln Gln Lys Pro Gly Phe Ser Pro Lys Leu Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1188
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of ITI_082L as described in
       Table 2.

<400>  1188

Met Tyr Trp Tyr Gln Gln Lys Ser Asp Ala Ser Pro Lys Leu Trp Ile 
1               5                   10                  15      


Tyr 
    


<210>  1189
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of ITI_083L as described in
       Table 2.

<400>  1189

Met Phe Trp Tyr Gln Gln Lys Ser Asp Ala Ser Pro Lys Leu Trp Ile 
1               5                   10                  15      


Tyr 
    


<210>  1190
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of ITI_145L as described in
       Table 2.

<400>  1190

Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 
1               5                   10                  15      


Phe 
    


<210>  1191
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of ITI_200L as described in
       Table 2.

<400>  1191

Ile Asn Trp Tyr Gln Gln Arg Pro Gly Gln Pro Ala Lys Leu Leu Ile 
1               5                   10                  15      


Phe 
    


<210>  1192
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of Consensus Cluster #7 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Leucine or Methionine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Asparagine, Histidine, Glutamate, Tyrosine or Serine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Leucine or Tyrosine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Leucine or Glutamine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Arginine or Lysine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Proline or Serine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Glycine or Serine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Glutamine or Threonine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Lysine, Asparagine or Glutamate

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa is Arginine or Leucine

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Leucine or Tryptophan

<400>  1192

Xaa Xaa Trp Xaa Xaa Gln Xaa Xaa Xaa Xaa Ser Pro Xaa Xaa Xaa Ile 
1               5                   10                  15      


Tyr 
    


<210>  1193
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1193

Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser Pro Lys Arg Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1194
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1194

Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1195
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S15-16AL as described 
       in Table 2.

<400>  1195

Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Glu Leu Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1196
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S15-1AL as described 
       in Table 2.

<400>  1196

Met His Trp Tyr Gln Gln Lys Ser Ser Thr Ser Pro Lys Leu Trp Ile 
1               5                   10                  15      


Tyr 
    


<210>  1197
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1197

Leu Ser Trp Leu Leu Gln Arg Pro Gly Gln Ser Pro Lys Arg Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1198
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S20-26AL as described 
       in Table 2.

<400>  1198

Leu Tyr Trp Leu Leu Gln Arg Pro Gly Gln Ser Pro Lys Arg Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1199
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S20-9EL as described 
       in Table 2.

<400>  1199

Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Asn Leu Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1200
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of Consensus Cluster #3 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Methionine or Leucine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Histidine, Phenylalanine, Tyrosine or Glutamine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Tyrosine or Phenylalanine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Lysine or Arginine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Serine or Proline

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Leucine or Tryptophan

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Isoleucine or Leucine

<400>  1200

Xaa Xaa Trp Xaa Gln Gln Xaa Xaa Gly Xaa Ser Pro Lys Leu Xaa Xaa 
1               5                   10                  15      


Tyr 
    


<210>  1201
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S14-3AL as described 
       in Table 2.

<400>  1201

Met Gln Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Leu Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1202
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1202

Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Leu Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1203
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1203

Leu Phe Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp Ile 
1               5                   10                  15      


Tyr 
    


<210>  1204
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1204

Leu Tyr Trp Phe Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp Ile 
1               5                   10                  15      


Tyr 
    


<210>  1205
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1205

Leu Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp Ile 
1               5                   10                  15      


Tyr 
    


<210>  1206
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S19-5AL as described 
       in Table 2.

<400>  1206

Leu Phe Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp Leu 
1               5                   10                  15      


Tyr 
    


<210>  1207
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S20-10AL as described 
       in Table 2.

<400>  1207

Met His Trp Tyr Gln Gln Arg Ser Gly Thr Ser Pro Lys Leu Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1208
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S20-22AL as described 
       in Table 2.

<400>  1208

Met His Trp Tyr Gln Gln Lys Ser Gly Ser Ser Pro Lys Leu Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1209
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1209

Met Phe Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Leu Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1210
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of Consensus Cluster #5 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Leucine or Isoleucine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Histidine, Serine, Alanine, Glycine or Asparagine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Tyrosine, Leucine or Phenylalanine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Lysine or Arginine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Glycine or Aspartate

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Serine, Glycine, Glutamine or Lysine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Proline, Isoleucine or Phenylalanine

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa is Leucine, Arginine, Glycine or Threonine

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Tryptophan or Leucine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Isoleucine or Valine

<400>  1210

Xaa Xaa Trp Xaa Gln Gln Xaa Pro Xaa Xaa Xaa Xaa Lys Xaa Xaa Xaa 
1               5                   10                  15      


Tyr 
    


<210>  1211
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1211

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1212
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S14-22AL as described 
       in Table 2.

<400>  1212

Leu Ser Trp Leu Gln Gln Lys Pro Asp Gly Thr Ile Lys Arg Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1213
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1213

Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1214
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1214

Leu His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp Ile 
1               5                   10                  15      


Tyr 
    


<210>  1215
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S19-15AL as described 
       in Table 2.

<400>  1215

Leu Asn Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1216
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S20-12BL as described 
       in Table 2.

<400>  1216

Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln Ser Pro Lys Leu Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1217
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S20-4AL as described 
       in Table 2.

<400>  1217

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Val 
1               5                   10                  15      


Tyr 
    


<210>  1218
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of ITI_203L as described in
       Table 2.

<400>  1218

Ile Gly Trp Leu Gln Gln Lys Pro Gly Lys Ser Phe Lys Gly Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1219
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of Consensus Cluster #1 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Lysine or Arginine

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Leucine or Methionine

<400>  1219

Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Xaa Leu Xaa Ile 
1               5                   10                  15      


Tyr 
    


<210>  1220
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1220

Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1221
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S15-10AL as described 
       in Table 2.

<400>  1221

Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1222
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S15-11CL as described 
       in Table 2.

<400>  1222

Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Met Ile 
1               5                   10                  15      


Tyr 
    


<210>  1223
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of Consensus Cluster #4 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Alanine or Threonine

<400>  1223

Leu Xaa Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val 
1               5                   10                  15      


Tyr 
    


<210>  1224
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1224

Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val 
1               5                   10                  15      


Tyr 
    


<210>  1225
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of ITI_023L as described in
       Table 2.

<400>  1225

Leu Thr Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val 
1               5                   10                  15      


Tyr 
    


<210>  1226
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of Consensus Cluster #2 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Leucine or Methionine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Tyrosine or Asparagine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Leucine or Glutamine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Glutamine or Glutamate

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Serine or Proline

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Glutamine or Lysine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Tyrosine or Serine

<400>  1226

Xaa Xaa Trp Tyr Xaa Gln Lys Pro Gly Xaa Xaa Pro Xaa Leu Leu Ile 
1               5                   10                  15      


Xaa 
    


<210>  1227
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S14-12AL as described 
       in Table 2.

<400>  1227

Met Asn Trp Tyr Gln Gln Lys Pro Gly Glu Pro Pro Lys Leu Leu Ile 
1               5                   10                  15      


Ser 
    


<210>  1228
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S19-22AL as described 
       in Table 2.

<400>  1228

Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1229
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 2 of the Heavy Chain of H5S19-24AL as described 
       in Table 2.

<400>  1229

Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile 
1               5                   10                  15      


Tyr 
    


<210>  1230
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of Consensus Cluster #6 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Alanine, Leucine, Tyrosine, Tryptophan, Serine, Glycine, 
       Arginine or Aspartate

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Alanine, Glutamate, Threonine or Glycine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Serine or Threonine

<400>  1230

Xaa Xaa Xaa 
1           


<210>  1231
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S14-15AL as described in Table 2.

<400>  1231

Tyr Glu Ser 
1           


<210>  1232
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1232

Tyr Ala Ser 
1           


<210>  1233
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1233

Asp Thr Ser 
1           


<210>  1234
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1234

Ser Gly Ser 
1           


<210>  1235
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1235

Leu Ala Ser 
1           


<210>  1236
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S14-25AL as described in Table 2.

<400>  1236

Gly Ala Thr 
1           


<210>  1237
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1237

Arg Thr Ser 
1           


<210>  1238
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1238

Ala Ala Thr 
1           


<210>  1239
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1239

Ala Ala Ser 
1           


<210>  1240
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1240

Ser Ala Ser 
1           


<210>  1241
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1241

Ser Thr Ser 
1           


<210>  1242
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1242

Tyr Thr Ser 
1           


<210>  1243
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1243

Gly Thr Ser 
1           


<210>  1244
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1244

Leu Thr Ser 
1           


<210>  1245
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1245

Trp Ala Ser 
1           


<210>  1246
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of Consensus Cluster #7 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Leucine, Aspartate or Lysine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Valine or Threonine

<400>  1246

Xaa Xaa Ser 
1           


<210>  1247
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1247

Leu Val Ser 
1           


<210>  1248
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1248

Lys Val Ser 
1           


<210>  1249
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of Consensus Cluster #3 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Threonine, Serine or Glycine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Threonine or Alanine

<400>  1249

Xaa Xaa Ser 
1           


<210>  1250
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1250

Thr Thr Ser 
1           


<210>  1251
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of Consensus Cluster #5 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Asparagine, Aspartate, Alanine, Tryptophan, Histidine or 
       Arginine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Threonine, Alanine, Serine or Glycine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Serine, Threonine or Asparagine

<400>  1251

Xaa Xaa Xaa 
1           


<210>  1252
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1252

Arg Ala Asn 
1           


<210>  1253
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S20-6AL as described in Table 2.

<400>  1253

Trp Ser Ser 
1           


<210>  1254
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of ITI_122L as described in Table 2.

<400>  1254

Asn Thr Ser 
1           


<210>  1255
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of ITI_203L as described in Table 2.

<400>  1255

His Gly Thr 
1           


<210>  1256
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of Consensus Cluster #4 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Asparagine or Alanine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Lysine or Threonine

<400>  1256

Xaa Ala Xaa 
1           


<210>  1257
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1257

Asn Ala Lys 
1           


<210>  1258
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of Consensus Cluster #2 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Glutamine, Glutamate or Arginine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Methionine, Glycine or Valine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Serine or Asparagine

<400>  1258

Xaa Xaa Xaa 
1           


<210>  1259
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S14-12AL as described in Table 2.

<400>  1259

Glu Gly Asn 
1           


<210>  1260
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S19-22AL as described in Table 2.

<400>  1260

Arg Val Ser 
1           


<210>  1261
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of the Heavy Chain of H5S19-24AL as described in Table 2.

<400>  1261

Gln Met Ser 
1           


<210>  1262
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of Consensus Cluster #6 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Asparagine, Glutamine, Threonine, Tyrosine, Arginine, 
       Serine or Lysine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Leucine, Serine or Arginine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Glutamate, Aspartate, Isoleucine, Tyrosine, Threonine, 
       Alanine, Glutamine or Histidine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Serine, Threonine, Proline or Aspartate

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Isoleucine, Valine or Alanine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Alanine, Serine, Aspartate, Valine, Proline or Isoleucine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Serine, Arginine or Threonine

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Serine or Tyrosine

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa is Glycine or Arginine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Threonine, Serine, Asparagine or Lysine

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Aspartate, Serine or Lysine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Phenylalanine or Tyrosine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (21)..(21)
<223>  Xaa is Leucine or Phenylalanine

<220>
<221>  misc_feature
<222>  (22)..(22)
<223>  Xaa is Asparagine, Threonine, Serine or Lysine

<220>
<221>  misc_feature
<222>  (23)..(23)
<223>  Xaa is Isoleucine or Phenylalanine

<220>
<221>  misc_feature
<222>  (24)..(24)
<223>  Xaa is Histidine, Aspartate, Serine, Asparagine, Glycine or 
       Threonine

<220>
<221>  misc_feature
<222>  (25)..(25)
<223>  Xaa is Proline, Serine, Threonine, Asparagine or Arginine

<220>
<221>  misc_feature
<222>  (26)..(26)
<223>  Xaa is Valine, Methionine or Leucine

<220>
<221>  misc_feature
<222>  (27)..(27)
<223>  Xaa is Glutamate, Glutamine or Aspartate

<220>
<221>  misc_feature
<222>  (28)..(28)
<223>  Xaa is Glutamate, Alanine, Proline, Glycine, Serine, Glutamine or
       Threonine

<220>
<221>  misc_feature
<222>  (29)..(29)
<223>  Xaa is Glutamate or Aspartate

<220>
<221>  misc_feature
<222>  (31)..(31)
<223>  Xaa is Alanine, Valine, Leucine, Phenylalanine or Isoleucine

<220>
<221>  misc_feature
<222>  (32)..(32)
<223>  Xaa is Alanine, Glycine or Valine

<220>
<221>  misc_feature
<222>  (33)..(33)
<223>  Xaa is Threonine, Serine, Methionine, Valine, Glutamate or 
       Aspartate

<220>
<221>  misc_feature
<222>  (35)..(35)
<223>  Xaa is Tyrosine, Phenylalanine or Histidine

<400>  1262

Xaa Xaa Xaa Xaa Gly Xaa Pro Xaa Arg Phe Xaa Gly Ser Gly Xaa Xaa 
1               5                   10                  15      


Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa 
            20                  25                  30          


Xaa Tyr Xaa Cys 
        35      


<210>  1263
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1263

Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Tyr Gly 
1               5                   10                  15      


Thr Asp Phe Thr Phe Thr Ile Ser Thr Val Gln Ala Glu Asp Leu Ala 
            20                  25                  30          


Val Tyr Phe Cys 
        35      


<210>  1264
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1264

Lys Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala 
            20                  25                  30          


Thr Tyr Tyr Cys 
        35      


<210>  1265
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S14-1AL as described 
       in Table 2.

<400>  1265

Thr Leu Gln Ser Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala 
            20                  25                  30          


Met Tyr Tyr Cys 
        35      


<210>  1266
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1266

Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg 
1               5                   10                  15      


Thr Asp Phe Thr Leu Thr Ile Asp Pro Val Glu Ala Asp Asp Ala Ala 
            20                  25                  30          


Thr Tyr Tyr Cys 
        35      


<210>  1267
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S14-25AL as described 
       in Table 2.

<400>  1267

Ser Leu Glu Thr Gly Val Pro Pro Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Lys Asp Tyr Thr Leu Ser Ile Thr Ser Leu Gln Thr Glu Asp Val Ala 
            20                  25                  30          


Thr Tyr Tyr Cys 
        35      


<210>  1268
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1268

Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala 
            20                  25                  30          


Thr Tyr Tyr Cys 
        35      


<210>  1269
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S14-4BL as described 
       in Table 2.

<400>  1269

Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Ser Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala 
            20                  25                  30          


Thr Tyr Tyr Cys 
        35      


<210>  1270
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S14-6AL as described 
       in Table 2.

<400>  1270

Ser Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Lys Phe Ser Phe Lys Ile Ser Ser Leu Gln Ala Glu Asp Phe Val 
            20                  25                  30          


Ser Tyr Tyr Cys 
        35      


<210>  1271
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S15-13AL as described 
       in Table 2.

<400>  1271

Asn Leu Asp Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala 
            20                  25                  30          


Thr Tyr Tyr Cys 
        35      


<210>  1272
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1272

Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala 
            20                  25                  30          


Glu Tyr Phe Cys 
        35      


<210>  1273
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S15-14BL as described 
       in Table 2.

<400>  1273

Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala 
            20                  25                  30          


Asp Tyr Phe Cys 
        35      


<210>  1274
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S15-18AL as described 
       in Table 2.

<400>  1274

Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Ser Tyr Ser Leu Thr Ile Ser Ser Val Glu Ala Glu Asp Ala Ala 
            20                  25                  30          


Thr Tyr Tyr Cys 
        35      


<210>  1275
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S15-24AL as described 
       in Table 2.

<400>  1275

Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Arg Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala 
            20                  25                  30          


Thr Tyr Tyr Cys 
        35      


<210>  1276
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S15-28AL as described 
       in Table 2.

<400>  1276

Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Ser Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln Glu Asp Ile Ala 
            20                  25                  30          


Thr Tyr Phe Cys 
        35      


<210>  1277
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1277

Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala 
            20                  25                  30          


Thr Tyr Tyr Cys 
        35      


<210>  1278
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S15-4AL as described 
       in Table 2.

<400>  1278

Asn Leu Ala Ser Gly Val Pro Ile Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala 
            20                  25                  30          


Thr Tyr Tyr Cys 
        35      


<210>  1279
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1279

Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro Glu Asp Ile Ala 
            20                  25                  30          


Thr Tyr Tyr Cys 
        35      


<210>  1280
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S19-17BL as described 
       in Table 2.

<400>  1280

Ser Leu His Ser Gly Val Pro Ser Arg Phe Arg Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro Glu Asp Ile Ala 
            20                  25                  30          


Thr Tyr Tyr Cys 
        35      


<210>  1281
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S19-17CL as described 
       in Table 2.

<400>  1281

Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro Glu Asp Ile Ala 
            20                  25                  30          


Thr Tyr Phe Cys 
        35      


<210>  1282
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S19-17DL as described 
       in Table 2.

<400>  1282

Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Tyr Ser Leu Ser Ile Ser Asn Leu Glu Pro Glu Asp Ile Ala 
            20                  25                  30          


Thr Tyr Tyr Cys 
        35      


<210>  1283
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S19-17EL as described 
       in Table 2.

<400>  1283

Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Tyr Ser Leu Thr Phe Ser Asn Leu Glu Pro Glu Asp Ile Ala 
            20                  25                  30          


Thr Tyr Tyr Cys 
        35      


<210>  1284
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1284

Thr Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro Glu Asp Ile Ala 
            20                  25                  30          


Thr Tyr Tyr Cys 
        35      


<210>  1285
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S19-6AL as described 
       in Table 2.

<400>  1285

Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu Asp Ala Ala 
            20                  25                  30          


Thr Tyr Tyr Cys 
        35      


<210>  1286
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S19-8AL as described 
       in Table 2.

<400>  1286

Thr Leu Gln Ser Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Val 
            20                  25                  30          


Met Tyr His Cys 
        35      


<210>  1287
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1287

Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala 
            20                  25                  30          


Thr Tyr Tyr Cys 
        35      


<210>  1288
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-17AL as described 
       in Table 2.

<400>  1288

Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Ser Asp Phe Thr Leu Ser Ile Ser Ser Val Glu Pro Glu Asp Val Gly 
            20                  25                  30          


Met Tyr Tyr Cys 
        35      


<210>  1289
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-23AL as described 
       in Table 2.

<400>  1289

Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala 
            20                  25                  30          


Val Tyr Tyr Cys 
        35      


<210>  1290
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_045L as described in
       Table 2.

<400>  1290

Asn Leu Ala Ser Gly Val Pro Pro Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Ser Tyr Ser Leu Thr Ile Gly Thr Met Glu Ala Glu Asp Val Ala 
            20                  25                  30          


Thr Tyr Tyr Cys 
        35      


<210>  1291
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_082L as described in
       Table 2.

<400>  1291

Asn Leu Ala Pro Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Asn Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Gly Glu Asp Ala Ala 
            20                  25                  30          


Thr Tyr Tyr Cys 
        35      


<210>  1292
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_083L as described in
       Table 2.

<400>  1292

Asn Leu Thr Pro Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Asn Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala 
            20                  25                  30          


Thr Tyr Tyr Cys 
        35      


<210>  1293
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1293

Ser Leu His Ser Gly Ala Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Asp Pro Glu Asp Ile Ala 
            20                  25                  30          


Thr Tyr Tyr Cys 
        35      


<210>  1294
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_162L as described in
       Table 2.

<400>  1294

Thr Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Tyr Ser Leu Thr Ile Asn Asn Leu Glu Pro Glu Asp Ile Ala 
            20                  25                  30          


Thr Tyr Tyr Cys 
        35      


<210>  1295
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_200L as described in
       Table 2.

<400>  1295

Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala 
            20                  25                  30          


Ser Tyr Tyr Cys 
        35      


<210>  1296
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_236L as described in
       Table 2.

<400>  1296

Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln Glu Asp Ile Ala 
            20                  25                  30          


Thr Tyr Phe Cys 
        35      


<210>  1297
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of Consensus Cluster #7 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Lysine or Asparagine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Leucine, Arginine or Valine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Aspartate, Proline, Phenylalanine or Valine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Aspartate or Glycine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Serine or Asparagine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Threonine or Asparagine

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Aspartate, Serine, Tyrosine or Glutamate

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Phenylalanine or Tyrosine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (22)..(22)
<223>  Xaa is Lysine, Threonine or Asparagine

<220>
<221>  misc_feature
<222>  (25)..(25)
<223>  Xaa is Arginine or Serine

<220>
<221>  misc_feature
<222>  (26)..(26)
<223>  Xaa is Valine or Methionine

<220>
<221>  misc_feature
<222>  (31)..(31)
<223>  Xaa is Leucine or Valine

<220>
<221>  misc_feature
<222>  (32)..(32)
<223>  Xaa is Glycine or Alanine

<220>
<221>  misc_feature
<222>  (33)..(33)
<223>  Xaa is Valine, Threonine or Isoleucine

<400>  1297

Xaa Xaa Xaa Ser Gly Val Pro Xaa Arg Phe Xaa Gly Xaa Gly Ser Gly 
1               5                   10                  15      


Xaa Xaa Xaa Xaa Leu Xaa Ile Ser Xaa Xaa Glu Ala Glu Asp Xaa Xaa 
            20                  25                  30          


Xaa Tyr Tyr Cys 
        35      


<210>  1298
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1298

Lys Leu Asp Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly 
            20                  25                  30          


Val Tyr Tyr Cys 
        35      


<210>  1299
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1299

Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly 
            20                  25                  30          


Val Tyr Tyr Cys 
        35      


<210>  1300
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1300

Lys Leu Asp Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly 
            20                  25                  30          


Ile Tyr Tyr Cys 
        35      


<210>  1301
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S15-17AL as described 
       in Table 2.

<400>  1301

Lys Arg Asp Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly 
            20                  25                  30          


Val Tyr Tyr Cys 
        35      


<210>  1302
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S15-1AL as described 
       in Table 2.

<400>  1302

Lys Leu Pro Ser Gly Val Pro Gly Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Asn Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Val Ala 
            20                  25                  30          


Thr Tyr Tyr Cys 
        35      


<210>  1303
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S15-6AL as described 
       in Table 2.

<400>  1303

Lys Leu Asp Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Glu Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly 
            20                  25                  30          


Val Tyr Tyr Cys 
        35      


<210>  1304
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-21AL as described 
       in Table 2.

<400>  1304

Asn Arg Val Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly 
            20                  25                  30          


Val Tyr Tyr Cys 
        35      


<210>  1305
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-26AL as described 
       in Table 2.

<400>  1305

Lys Leu Asp Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Tyr Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly 
            20                  25                  30          


Val Tyr Tyr Cys 
        35      


<210>  1306
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-31AL as described 
       in Table 2.

<400>  1306

Lys Val Asp Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly 
            20                  25                  30          


Val Tyr Tyr Cys 
        35      


<210>  1307
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_047L as described in
       Table 2.

<400>  1307

Lys Leu Asp Ser Gly Val Pro Asp Arg Phe Thr Gly Asn Gly Ser Gly 
1               5                   10                  15      


Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly 
            20                  25                  30          


Val Tyr Tyr Cys 
        35      


<210>  1308
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_091L as described in
       Table 2.

<400>  1308

Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Phe Thr Leu Asn Ile Ser Arg Val Glu Ala Glu Asp Leu Gly 
            20                  25                  30          


Val Tyr Tyr Cys 
        35      


<210>  1309
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of Consensus Cluster #3 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Serine, Alanine or Valine

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Phenylalanine or Serine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Tyrosine or Phenylalanine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Serine or Tyrosine

<220>
<221>  misc_feature
<222>  (23)..(23)
<223>  Xaa is Isoleucine or Leucine

<220>
<221>  misc_feature
<222>  (25)..(25)
<223>  Xaa is Serine or Glycine

<220>
<221>  misc_feature
<222>  (26)..(26)
<223>  Xaa is Valine or Methionine

<220>
<221>  misc_feature
<222>  (33)..(33)
<223>  Xaa is Aspartate or Serine

<220>
<221>  misc_feature
<222>  (35)..(35)
<223>  Xaa is Tyrosine or Phenylalanine

<400>  1309

Asn Leu Ala Ser Gly Val Pro Xaa Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Xaa Xaa Xaa Leu Thr Xaa Ser Xaa Xaa Glu Ala Glu Asp Ala Ala 
            20                  25                  30          


Xaa Tyr Xaa Cys 
        35      


<210>  1310
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1310

Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Phe Tyr Ser Leu Thr Ile Ser Ser Val Glu Ala Glu Asp Ala Ala 
            20                  25                  30          


Asp Tyr Tyr Cys 
        35      


<210>  1311
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1311

Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala 
            20                  25                  30          


Ser Tyr Phe Cys 
        35      


<210>  1312
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S19-14AL as described 
       in Table 2.

<400>  1312

Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Ser Tyr Tyr Leu Thr Leu Ser Ser Met Glu Ala Glu Asp Ala Ala 
            20                  25                  30          


Ser Tyr Phe Cys 
        35      


<210>  1313
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1313

Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Ser Tyr Tyr Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala 
            20                  25                  30          


Ser Tyr Phe Cys 
        35      


<210>  1314
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1314

Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala 
            20                  25                  30          


Ser Tyr Phe Cys 
        35      


<210>  1315
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_127L as described in
       Table 2.

<400>  1315

Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Phe Phe Ser Leu Thr Ile Ser Gly Val Glu Ala Glu Asp Ala Ala 
            20                  25                  30          


Asp Tyr Tyr Cys 
        35      


<210>  1316
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_128L as described in
       Table 2.

<400>  1316

Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Phe Tyr Ser Leu Thr Ile Ser Gly Val Glu Ala Glu Asp Ala Ala 
            20                  25                  30          


Asp Tyr Tyr Cys 
        35      


<210>  1317
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of Consensus Cluster #5 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Asparagine, Threonine or Arginine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Leucine, Arginine or Glycine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Alanine, Aspartate, Glutamate, Glycine or Valine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Serine or Aspartate

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Alanine, Lysine, Aspartate or Serine

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa is Glycine or Arginine

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa is Threonine, Serine, Alanine or Glutamine

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Serine or Aspartate

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Phenylalanine or Tyrosine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Serine or Threonine

<220>
<221>  misc_feature
<222>  (25)..(25)
<223>  Xaa is Serine or Asparagine

<220>
<221>  misc_feature
<222>  (26)..(26)
<223>  Xaa is Methionine, Leucine or Valine

<220>
<221>  misc_feature
<222>  (27)..(27)
<223>  Xaa is Glutamate or Lysine

<220>
<221>  misc_feature
<222>  (28)..(28)
<223>  Xaa is Alanine, Serine, Tyrosine or Phenylalanine

<220>
<221>  misc_feature
<222>  (31)..(31)
<223>  Xaa is Alanine, Phenylalanine, Leucine or Methionine

<220>
<221>  misc_feature
<222>  (32)..(32)
<223>  Xaa is Alanine or Glycine

<220>
<221>  misc_feature
<222>  (33)..(33)
<223>  Xaa is Threonine, Aspartate, Valine or Isoleucine

<220>
<221>  misc_feature
<222>  (35)..(35)
<223>  Xaa is Tyrosine or Phenylalanine

<400>  1317

Xaa Xaa Xaa Xaa Gly Val Pro Xaa Arg Phe Xaa Gly Ser Xaa Ser Gly 
1               5                   10                  15      


Xaa Xaa Xaa Xaa Leu Thr Ile Ser Xaa Xaa Xaa Xaa Glu Asp Xaa Xaa 
            20                  25                  30          


Xaa Tyr Xaa Cys 
        35      


<210>  1318
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1318

Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Lys Ala Glu Asp Leu Ala 
            20                  25                  30          


Val Tyr Tyr Cys 
        35      


<210>  1319
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S14-22AL as described 
       in Table 2.

<400>  1319

Thr Leu Asp Ser Gly Val Pro Lys Arg Phe Ser Gly Ser Arg Ser Gly 
1               5                   10                  15      


Ser Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser Glu Asp Phe Ala 
            20                  25                  30          


Asp Tyr Tyr Cys 
        35      


<210>  1320
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S14-23AL as described 
       in Table 2.

<400>  1320

Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr Glu Asp Met Gly 
            20                  25                  30          


Ile Tyr Tyr Cys 
        35      


<210>  1321
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1321

Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Phe Glu Asp Met Gly 
            20                  25                  30          


Ile Tyr Tyr Cys 
        35      


<210>  1322
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-27AL as described 
       in Table 2.

<400>  1322

Thr Gly Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Lys Ala Glu Asp Leu Ala 
            20                  25                  30          


Val Tyr Tyr Cys 
        35      


<210>  1323
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S20-28AL as described 
       in Table 2.

<400>  1323

Thr Arg Gly Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Lys Ala Glu Asp Leu Ala 
            20                  25                  30          


Val Tyr Tyr Cys 
        35      


<210>  1324
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_122L as described in
       Table 2.

<400>  1324

Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Ser Phe Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala 
            20                  25                  30          


Thr Tyr Tyr Cys 
        35      


<210>  1325
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_173L as described in
       Table 2.

<400>  1325

Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Phe Glu Asp Met Gly 
            20                  25                  30          


Ile Tyr Phe Cys 
        35      


<210>  1326
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_203L as described in
       Table 2.

<400>  1326

Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Ala Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Ser Glu Asp Phe Ala 
            20                  25                  30          


Asp Tyr Tyr Cys 
        35      


<210>  1327
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of Consensus Cluster #1 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa is Serine or Isoleucine

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa is Serine or Glycine

<220>
<221>  misc_feature
<222>  (22)..(22)
<223>  Xaa is Lysine or Arginine

<220>
<221>  misc_feature
<222>  (28)..(28)
<223>  Xaa is Threonine or Alanine

<400>  1327

Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Xaa Gly Xaa Gly Ser Gly 
1               5                   10                  15      


Thr Asp Phe Thr Leu Xaa Ile Ser Arg Val Glu Xaa Glu Asp Leu Gly 
            20                  25                  30          


Val Tyr Phe Cys 
        35      


<210>  1328
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1328

Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly 
            20                  25                  30          


Val Tyr Phe Cys 
        35      


<210>  1329
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S15-10AL as described 
       in Table 2.

<400>  1329

Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Gly Gly Ser Gly 
1               5                   10                  15      


Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly 
            20                  25                  30          


Val Tyr Phe Cys 
        35      


<210>  1330
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S15-11AL as described 
       in Table 2.

<400>  1330

Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ile Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly 
            20                  25                  30          


Val Tyr Phe Cys 
        35      


<210>  1331
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S15-11CL as described 
       in Table 2.

<400>  1331

Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Phe Thr Leu Arg Ile Ser Arg Val Glu Ala Glu Asp Leu Gly 
            20                  25                  30          


Val Tyr Phe Cys 
        35      


<210>  1332
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S15-11EL as described 
       in Table 2.

<400>  1332

Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Thr Glu Asp Leu Gly 
            20                  25                  30          


Val Tyr Phe Cys 
        35      


<210>  1333
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of Consensus Cluster #4 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Threonine or Asparagine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Glutamate or Aspartate

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa is Glutamine or Histidine

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa is Phenylalanine or Tyrosine

<220>
<221>  misc_feature
<222>  (25)..(25)
<223>  Xaa is Serine or Asparagine

<220>
<221>  misc_feature
<222>  (28)..(28)
<223>  Xaa is Proline or Serine

<220>
<221>  misc_feature
<222>  (30)..(30)
<223>  Xaa is Aspartate or Glutamate

<400>  1333

Xaa Leu Ala Xaa Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Xaa Xaa Ser Leu Lys Ile Asn Xaa Leu Gln Xaa Glu Xaa Phe Gly 
            20                  25                  30          


Ser Tyr Tyr Cys 
        35      


<210>  1334
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S14-19AL as described 
       in Table 2.

<400>  1334

Asn Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Ser Glu Asp Phe Gly 
            20                  25                  30          


Ser Tyr Tyr Cys 
        35      


<210>  1335
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1335

Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Gln Phe Ser Leu Lys Ile Asn Ser Leu Gln Pro Glu Asp Phe Gly 
            20                  25                  30          


Ser Tyr Tyr Cys 
        35      


<210>  1336
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S15-32AL as described 
       in Table 2.

<400>  1336

Thr Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Pro Glu Asp Phe Gly 
            20                  25                  30          


Ser Tyr Tyr Cys 
        35      


<210>  1337
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_023L as described in
       Table 2.

<400>  1337

Thr Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Gln Tyr Ser Leu Lys Ile Asn Asn Leu Gln Pro Glu Asp Phe Gly 
            20                  25                  30          


Ser Tyr Tyr Cys 
        35      


<210>  1338
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of ITI_240L as described in
       Table 2.

<400>  1338

Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr His Phe Ser Leu Lys Ile Asn Ser Leu Gln Pro Glu Glu Phe Gly 
            20                  25                  30          


Ser Tyr Tyr Cys 
        35      


<210>  1339
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of Consensus Cluster #2 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Asparagine or Threonine

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Leucine or Arginine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Alanine, Arginine or Phenylalanine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Serine or Proline

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Proline or Leucine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Aspartate or Serine

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa is Serine or Glycine

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa is Serine or Tyrosine

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa is Threonine or Valine

<220>
<221>  misc_feature
<222>  (21)..(21)
<223>  Xaa is Leucine or Phenylalanine

<220>
<221>  misc_feature
<222>  (22)..(22)
<223>  Xaa is Arginine, Threonine or Lysine

<220>
<221>  misc_feature
<222>  (24)..(24)
<223>  Xaa is Serine or Glutamate

<220>
<221>  misc_feature
<222>  (25)..(25)
<223>  Xaa is Arginine or Asparagine

<220>
<221>  misc_feature
<222>  (26)..(26)
<223>  Xaa is Valine or Threonine

<220>
<221>  misc_feature
<222>  (27)..(27)
<223>  Xaa is Glutamate or Leucine

<220>
<221>  misc_feature
<222>  (28)..(28)
<223>  Xaa is Alanine or Serine

<220>
<221>  misc_feature
<222>  (31)..(31)
<223>  Xaa is Valine or Leucine

<220>
<221>  misc_feature
<222>  (32)..(32)
<223>  Xaa is Glycine or Alanine

<220>
<221>  misc_feature
<222>  (33)..(33)
<223>  Xaa is Valine or Aspartate

<220>
<221>  misc_feature
<222>  (35)..(35)
<223>  Xaa is Tyrosine or Phenylalanine

<400>  1339

Xaa Xaa Xaa Xaa Gly Val Xaa Xaa Arg Phe Ser Xaa Ser Gly Xaa Gly 
1               5                   10                  15      


Thr Asp Phe Xaa Xaa Xaa Ile Xaa Xaa Xaa Xaa Xaa Glu Asp Xaa Xaa 
            20                  25                  30          


Xaa Tyr Xaa Cys 
        35      


<210>  1340
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S14-12AL as described 
       in Table 2.

<400>  1340

Thr Leu Arg Pro Gly Val Pro Ser Arg Phe Ser Ser Ser Gly Tyr Gly 
1               5                   10                  15      


Thr Asp Phe Val Phe Thr Ile Glu Asn Thr Leu Ser Glu Asp Val Ala 
            20                  25                  30          


Asp Tyr Tyr Cys 
        35      


<210>  1341
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S19-22AL as described 
       in Table 2.

<400>  1341

Asn Arg Phe Ser Gly Val Leu Asp Arg Phe Ser Gly Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly 
            20                  25                  30          


Val Tyr Phe Cys 
        35      


<210>  1342
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 3 of the Heavy Chain of H5S19-24AL as described 
       in Table 2.

<400>  1342

Asn Leu Ala Ser Gly Val Pro Asp Arg Phe Ser Ser Ser Gly Ser Gly 
1               5                   10                  15      


Thr Asp Phe Thr Leu Arg Ile Ser Arg Val Glu Ala Glu Asp Val Gly 
            20                  25                  30          


Val Tyr Tyr Cys 
        35      


<210>  1343
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #6 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa is Glutamine, Histidine, Asparagine or Serine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Serine, Asparagine, Cysteine, Glycine, Aspartate, 
       Phenylalanine, Histidine, Tryptophan, Tyrosine or Leucine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Asparagine, Tyrosine, Histidine, Threonine, Phenylalanine,
       Serine or Tryptophan

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Glutamate, Alanine, Serine, Threonine, Lysine or Glycine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Aspartate, Phenylalanine, Tyrosine, Serine, Leucine, 
       Isoleucine, Threonine or Asparagine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Proline or Threonine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Tryptophan, Leucine, Phenylalanine, Tyrosine, Proline or 
       Arginine

<400>  1343

Gln Xaa Xaa Xaa Xaa Xaa Xaa Xaa Thr 
1               5                   


<210>  1344
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1344

Gln Gln Asp Tyr Ser Ser Pro Trp Thr 
1               5                   


<210>  1345
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-18AL as described in Table 2.

<400>  1345

Gln Gln Trp Ser Ser Asn Pro Phe Thr 
1               5                   


<210>  1346
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1346

Gln Gln His Asn Glu Tyr Pro Trp Thr 
1               5                   


<210>  1347
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-20AL as described in Table 2.

<400>  1347

Gln Gln Asn Asn Glu Asp Pro Tyr Thr 
1               5                   


<210>  1348
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-24AL as described in Table 2.

<400>  1348

Gln Gln Asp Tyr Ser Ser Pro Leu Thr 
1               5                   


<210>  1349
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-25AL as described in Table 2.

<400>  1349

Gln Gln Tyr Trp Ser Thr Pro Tyr Thr 
1               5                   


<210>  1350
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1350

Gln Gln Tyr His Ser Tyr Pro Leu Thr 
1               5                   


<210>  1351
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-6AL as described in Table 2.

<400>  1351

Gln Gln Leu His Ser Thr Pro Tyr Thr 
1               5                   


<210>  1352
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-13AL as described in Table 2.

<400>  1352

Gln Gln Ser Asn Glu Asp Pro Leu Thr 
1               5                   


<210>  1353
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1353

Gln Gln Tyr Asn Ser Tyr Pro Tyr Thr 
1               5                   


<210>  1354
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1354

Gln Gln Trp Ser Ser Asn Pro Leu Thr 
1               5                   


<210>  1355
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-18AL as described in Table 2.

<400>  1355

Gln Gln Tyr Ser Gly Tyr Pro Leu Thr 
1               5                   


<210>  1356
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-24AL as described in Table 2.

<400>  1356

Gln Gln Ser Asn Glu Asp Pro Phe Thr 
1               5                   


<210>  1357
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-28AL as described in Table 2.

<400>  1357

Gln Gln Gly Asn Ser Leu Pro Trp Thr 
1               5                   


<210>  1358
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-29AL as described in Table 2.

<400>  1358

Gln Gln Trp Asn Ser Tyr Pro Leu Thr 
1               5                   


<210>  1359
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1359

Gln Gln Trp Ser Ser Tyr Pro Leu Thr 
1               5                   


<210>  1360
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1360

Gln Gln Tyr Ser Lys Leu Pro Trp Thr 
1               5                   


<210>  1361
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S19-1AL as described in Table 2.

<400>  1361

Gln Gln Asn Asn Glu Asp Pro Pro Thr 
1               5                   


<210>  1362
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1362

Gln Gln Tyr Phe Lys Leu Pro Trp Thr 
1               5                   


<210>  1363
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S19-6AL as described in Table 2.

<400>  1363

Gln Gln Trp Ser Ser Tyr Pro Phe Thr 
1               5                   


<210>  1364
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1364

Gln Gln Ser Asn Glu Asp Pro Trp Thr 
1               5                   


<210>  1365
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S20-17AL as described in Table 2.

<400>  1365

Gln Asn Gly His Ser Phe Pro Leu Thr 
1               5                   


<210>  1366
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S20-18AL as described in Table 2.

<400>  1366

Gln Gln Asn Tyr Ala Asp Pro Trp Thr 
1               5                   


<210>  1367
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S20-23AL as described in Table 2.

<400>  1367

Gln Ser Asp Tyr Ser Tyr Pro Leu Thr 
1               5                   


<210>  1368
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S20-32AL as described in Table 2.

<400>  1368

Gln Gln Tyr Asn Ser Tyr Pro Phe Thr 
1               5                   


<210>  1369
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1369

Gln Gln Tyr Asn Ser Tyr Pro Leu Thr 
1               5                   


<210>  1370
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of ITI_021L as described in Table 2.

<400>  1370

Gln Gln Asn Asn Glu Asp Pro Leu Thr 
1               5                   


<210>  1371
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of ITI_045L as described in Table 2.

<400>  1371

Gln Gln Gly Ser Thr Ile Pro Tyr Thr 
1               5                   


<210>  1372
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1372

Gln Gln Phe Thr Ser Ser Thr Trp Thr 
1               5                   


<210>  1373
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of ITI_200L as described in Table 2.

<400>  1373

Gln His Cys Tyr Glu Asp Pro Trp Thr 
1               5                   


<210>  1374
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of ITI_236L as described in Table 2.

<400>  1374

Gln Gln Gly Asn Thr Leu Pro Tyr Thr 
1               5                   


<210>  1375
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of ITI_237L as described in Table 2.

<400>  1375

Gln Gln Tyr Ser Lys Leu Pro Arg Thr 
1               5                   


<210>  1376
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #7 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Valine, Phenylalanine or Tryptophan

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Glycine, Alanine, Asparagine, Leucine or Valine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Threonine or Serine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Histidine or Glycine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Phenylalanine or no amino acid

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Proline, Phenylalanine or Valine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Methionine or Proline

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Tyrosine, Leucine, Tryptophan, Histidine or Glutamine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Threonine or Alanine

<400>  1376

Xaa Gln Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10  


<210>  1377
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-11AL as described in Table 2.

<400>  1377

Trp Gln Leu Thr His Phe Pro Gln Thr 
1               5                   


<210>  1378
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-13AL and H5S19-7AL as described 
       in Table 2.

<400>  1378

Phe Gln Gly Ser His Val Pro Trp Thr 
1               5                   


<210>  1379
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-17AL as described in Table 2.

<400>  1379

Trp Gln Val Thr His Phe Pro Gln Thr 
1               5                   


<210>  1380
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-2AL as described in Table 2.

<400>  1380

Trp Gln Gly Thr His Phe Pro His Ala 
1               5                   


<210>  1381
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1381

Trp Gln Gly Thr His Phe Pro Gln Thr 
1               5                   


<210>  1382
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1382

Phe Gln Gly Ser His Val Pro Leu Thr 
1               5                   


<210>  1383
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1383

Trp Gln Asn Thr His Phe Pro Gln Thr 
1               5                   


<210>  1384
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-1AL as described in Table 2.

<400>  1384

Phe Gln Gly Ser Gly Phe Pro Leu Thr 
1               5                   


<210>  1385
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1385

Trp Gln Ala Thr His Phe Pro Gln Thr 
1               5                   


<210>  1386
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S20-41AL as described in Table 2.

<400>  1386

Val Gln Gly Thr His Phe Pro Met Tyr Thr 
1               5                   10  


<210>  1387
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #3 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Serine or Asparagine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Serine, Threonine, Asparagine or no amino acid

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Tyrosine, Phenylalanine or Serine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Threonine, Leucine, Alanine, Proline or Tyrosine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Tryptophan, Arginine, Leucine or Proline

<400>  1387

His Gln Trp Xaa Xaa Xaa Xaa Xaa Thr 
1               5                   


<210>  1388
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-3AL as described in Table 2.

<400>  1388

His Gln Trp Ser Ser Tyr Pro Thr 
1               5               


<210>  1389
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-5AL as described in Table 2.

<400>  1389

His Gln Trp Ser Ser Tyr Leu Thr 
1               5               


<210>  1390
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-8AL as described in Table 2.

<400>  1390

His Gln Trp Ser Ser Tyr Leu Trp Thr 
1               5                   


<210>  1391
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1391

His Gln Trp Ser Ser Tyr Pro Trp Thr 
1               5                   


<210>  1392
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S19-14AL as described in Table 2.

<400>  1392

His Gln Trp Ser Asn Phe Ala Trp Thr 
1               5                   


<210>  1393
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1393

His Gln Trp Asn Ser Tyr Pro Trp Thr 
1               5                   


<210>  1394
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S19-18AL as described in Table 2.

<400>  1394

His Gln Trp Ser Thr Tyr Pro Trp Thr 
1               5                   


<210>  1395
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1395

His Gln Trp Ser Ser Tyr Ala Trp Thr 
1               5                   


<210>  1396
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S19-5AL as described in Table 2.

<400>  1396

His Gln Trp Ser Asn Tyr Ala Trp Thr 
1               5                   


<210>  1397
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1397

His Gln Trp Ser Ser Tyr Arg Thr 
1               5               


<210>  1398
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1398

His Gln Trp Ser Ser Tyr Thr Trp Thr 
1               5                   


<210>  1399
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #5 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Histidine, Leucine, Glutamine or Glycine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Histidine, Alanine, Tyrosine, Glycine or Aspartate

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is no amino acid, Arginine, Serine, Threonine, Glutamine or 
       Glutamate

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Arginine, Serine, Tyrosine or Phenylalanine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Serine, Glutamine or Proline

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Proline, Tryptophan, Phenylalanine, Arginine or Tyrosine

<400>  1399

Xaa Gln Tyr Xaa Xaa Xaa Xaa Xaa Thr 
1               5                   


<210>  1400
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-21AL as described in Table 2.

<400>  1400

Gln Gln Tyr Tyr Ser Tyr Pro Trp Thr 
1               5                   


<210>  1401
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-22AL as described in Table 2.

<400>  1401

Leu Gln Tyr Ala Ser Tyr Pro Phe Thr 
1               5                   


<210>  1402
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-23AL as described in Table 2.

<400>  1402

Leu Gln Tyr Asp Glu Phe Pro Trp Thr 
1               5                   


<210>  1403
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-19AL as described in Table 2.

<400>  1403

His Gln Tyr His Arg Ser Gln Trp Thr 
1               5                   


<210>  1404
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-21AL as described in Table 2.

<400>  1404

Gln Gln Tyr Tyr Ser Tyr Pro Tyr Thr 
1               5                   


<210>  1405
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-26AL as described in Table 2.

<400>  1405

Gln Gln Tyr Tyr Ser Tyr Pro Arg Thr 
1               5                   


<210>  1406
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1406

Leu Gln Tyr Asp Glu Phe Pro Phe Thr 
1               5                   


<210>  1407
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1407

Gln Gln Tyr Tyr Ser Tyr Pro Phe Thr 
1               5                   


<210>  1408
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1408

Gln Gln Tyr Tyr Thr Tyr Pro Phe Thr 
1               5                   


<210>  1409
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of ITI_122L as described in Table 2.

<400>  1409

His Gln Tyr His Arg Ser Pro Thr 
1               5               


<210>  1410
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of ITI_203L as described in Table 2.

<400>  1410

Gly Gln Tyr Gly Gln Phe Pro Pro Thr 
1               5                   


<210>  1411
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #1 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Threonine or Isoleucine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is no amino acid or Histidine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is no amino acid or Valine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Histidine, Proline or Valine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Valine or Proline

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Proline, Tryptophan or Phenylalanine

<400>  1411

Ser Gln Ser Xaa Xaa Xaa Xaa Xaa Xaa Thr 
1               5                   10  


<210>  1412
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-10AL as described in Table 2.

<400>  1412

Ser Gln Ser Ile His Val Pro Phe Thr 
1               5                   


<210>  1413
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-7AL and H5S15-23AL as described 
       in Table 2.

<400>  1413

Ser Gln Ser Thr His Val Pro Phe Thr 
1               5                   


<210>  1414
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1414

Ser Gln Ser Thr His Val Pro Thr 
1               5               


<210>  1415
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-22AL as described in Table 2.

<400>  1415

Ser Gln Ser Thr His Val Pro Pro Trp Thr 
1               5                   10  


<210>  1416
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #4 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Histidine or Phenylalanine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Tyrosine or Tryptophan

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is no amino acid or Glycine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Glycine, Threonine or Serine

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa is Threonine, Proline or Methionine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Tyrosine, Arginine or Phenylalanine

<400>  1416

Gln His Xaa Xaa Xaa Xaa Xaa Xaa Thr 
1               5                   


<210>  1417
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-19AL as described in Table 2.

<400>  1417

Gln His Phe Trp Gly Thr Pro Arg Thr 
1               5                   


<210>  1418
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-9AL as described in Table 2.

<400>  1418

Gln His His Tyr Gly Thr Met Tyr Thr 
1               5                   


<210>  1419
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S15-2AL as described in Table 2.

<400>  1419

Gln His His Tyr Gly Thr Tyr Thr 
1               5               


<210>  1420
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of multiple antibodies as described in 
       Table 2.

<400>  1420

Gln His Phe Trp Ser Thr Phe Thr 
1               5               


<210>  1421
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of ITI_240L as described in Table 2.

<400>  1421

Gln His His Tyr Gly Thr Pro Tyr Thr 
1               5                   


<210>  1422
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of Consensus Cluster #2 as described in 
       Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Alanine or Leucine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Asparagine, Serine or Valine

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa is Leucine, Aspartate or Threonine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Glutamate, Asparagine or Histidine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Leucine, Methionine or Valine

<400>  1422

Xaa Gln Xaa Xaa Xaa Xaa Pro Tyr Thr 
1               5                   


<210>  1423
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S14-12AL as described in Table 2.

<400>  1423

Leu Gln Ser Asp Asn Met Pro Tyr Thr 
1               5                   


<210>  1424
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S19-22AL as described in Table 2.

<400>  1424

Leu Gln Val Thr His Val Pro Tyr Thr 
1               5                   


<210>  1425
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of the Heavy Chain of H5S19-24AL as described in Table 2.

<400>  1425

Ala Gln Asn Leu Glu Leu Pro Tyr Thr 
1               5                   


<210>  1426
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of Consensus Cluster #6 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Glycine, Alanine or Serine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Threonine or Alanine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Lysine or Asparagine

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa is Glutamate or Alanine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Isoleucine or Leucine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Lysine, no amino acid or Arginine

<400>  1426

Phe Gly Xaa Gly Xaa Xaa Leu Xaa Xaa Xaa 
1               5                   10  


<210>  1427
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1427

Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
1               5                   10  


<210>  1428
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1428

Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
1               5                   10  


<210>  1429
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1429

Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
1               5                   10  


<210>  1430
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1430

Phe Gly Gly Gly Thr Asn Leu Glu Ile Lys 
1               5                   10  


<210>  1431
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1431

Phe Gly Gly Gly Ala Lys Leu Glu Ile Lys 
1               5                   10  


<210>  1432
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1432

Phe Gly Gly Gly Thr Lys Leu Glu Ile 
1               5                   


<210>  1433
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of H5S19-28AL as described 
       in Table 2.

<400>  1433

Phe Gly Gly Gly Thr Lys Leu Ala Ile Lys 
1               5                   10  


<210>  1434
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1434

Phe Gly Ala Gly Thr Lys Leu Glu Leu 
1               5                   


<210>  1435
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of H5S20-34AL as described 
       in Table 2.

<400>  1435

Phe Gly Ala Gly Thr Lys Leu Glu Leu Arg 
1               5                   10  


<210>  1436
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of Consensus Cluster #7 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa is Phenylalanine or Leucine

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Glycine, Serine, Alanine or Threonine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Lysine, Asparagine or Glutamate

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Isoleucine or Leucine

<400>  1436

Xaa Gly Xaa Gly Thr Xaa Leu Glu Xaa Lys 
1               5                   10  


<210>  1437
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of H5S20-24AL as described 
       in Table 2.

<400>  1437

Leu Gly Gly Gly Thr Lys Leu Glu Ile Lys 
1               5                   10  


<210>  1438
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of H5S20-7DL as described 
       in Table 2.

<400>  1438

Phe Gly Gly Gly Thr Glu Leu Glu Ile Lys 
1               5                   10  


<210>  1439
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1439

Phe Gly Thr Gly Thr Lys Leu Glu Leu Lys 
1               5                   10  


<210>  1440
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of Consensus Cluster #3 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Glycine or Alanine

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa is Threonine or Alanine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa is Lysine, Isoleucine, Methionine or Glutamate

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Isoleucine or Leucine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Lysine or no amino acid

<400>  1440

Phe Gly Xaa Gly Xaa Xaa Leu Glu Xaa Xaa 
1               5                   10  


<210>  1441
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of H5S14-3AL as described 
       in Table 2.

<400>  1441

Phe Gly Gly Gly Thr Glu Leu Glu Ile 
1               5                   


<210>  1442
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1442

Phe Gly Gly Gly Thr Ile Leu Glu Ile Lys 
1               5                   10  


<210>  1443
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of H5S19-10BL as described 
       in Table 2.

<400>  1443

Phe Gly Gly Gly Thr Ile Leu Glu Ile 
1               5                   


<210>  1444
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of ITI_033L as described in
       Table 2.

<400>  1444

Phe Gly Gly Gly Thr Met Leu Glu Ile Lys 
1               5                   10  


<210>  1445
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of Consensus Cluster #5 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Glycine or Serine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Isoleucine or Methionine

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa is Lysine or no amino acid

<400>  1445

Phe Gly Xaa Gly Thr Lys Leu Glu Xaa Xaa 
1               5                   10  


<210>  1446
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1446

Phe Gly Ser Gly Thr Lys Leu Glu Met Lys 
1               5                   10  


<210>  1447
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of Consensus Cluster #1 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Serine or Glycine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Isoleucine or Valine

<400>  1447

Phe Gly Xaa Gly Thr Lys Leu Glu Xaa Lys 
1               5                   10  


<210>  1448
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of multiple antibodies as 
       described in Table 2.

<400>  1448

Phe Gly Ser Gly Thr Lys Leu Glu Val Lys 
1               5                   10  


<210>  1449
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Framework Region 4 of the Heavy Chain of Consensus Cluster #4 as 
       described in Table 2.


<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa is Glycine or Serine

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is Isoleucine or Valine

<400>  1449

Phe Gly Xaa Gly Thr Lys Leu Glu Xaa Lys 
1               5                   10  


